

FILE 'REGISTRY' ENTERED AT 11:12:46 ON 21 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1
DICTIONARY FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1


New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:
<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10524577.str



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

Web Page for STN Seminar Schedule - N. America

NEWS 1 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format

NEWS 2 MAR 16 CASREACT coverage extended

NEWS 3 MAR 16 CASREACT coverage extended

NEWS 4 MAR 20 MARPAT now updated daily

NEWS 5 MAR 22 LWPI reloaded

NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements

NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field

NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records

NEWS 10 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records

NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN

NEWS 12 MAY 01 New CAS web site launched

NEWS 13 MAY 08 CA/CAPLUS Indian patent publication number format defined

NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields

NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data

NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload

NEWS 17 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents

NEWS 18 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents

NEWS 19 JUN 18 CA/CAPLUS to be enhanced with pre-1967 CAS Registry Numbers

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01C, CURRENT
MACINTOSH VERSION IS V6.0C(ENG) AND V6.0JC(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IFC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:12:37 ON 21 JUN 2007

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY
TOTAL SESSION
0.21 0.21


chain nodes :
 11 12 14
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 8-11 9-12
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 8-11 9-12
 exact bonds :
 6-9 8-9
 isolated ring systems :
 containing 1 :

Gl:C,H,X,Cy,S

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
 12:Atom 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
 L1 HAS NO ANSWERS
 L1 STR



Gl C,H,X,Cy,S

Structure attributes must be viewed using STN Express query preparation.

=>
 Uploading C:\Program Files\Stnexp\Queries\10524577a.str




chain nodes :
 11 13
 ring nodes :
 1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
 chain bonds :
 8-15 9-11
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19
 19-20
 exact/norm bonds :
 1-6 4-5 5-6 5-7 7-8 9-11
 exact bonds :
 6-9 8-9 8-15
 normalized bonds :
 1-2 2-3 3-4 15-16 15-20 16-17 17-18 18-19 19-20
 isolated ring systems :
 containing 1 :

Gl:C,H,X,Cy,S

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L2 STRUCTURE UPLOADED

=> d 12
L2 HAS NO ANSWERS
L2 STR



G1 C,H,X,Cy,S

Structure attributes must be viewed using STN Express query preparation.

=> s 11 full
FULL SEARCH INITIATED 11:13:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 65646 TO ITERATE

100.0% PROCESSED 65646 ITERATIONS
SEARCH TIME: 00:00.01

L3 2214 SEA SSS FUL L1

2214 ANSWERS

=> s 12 full
FULL SEARCH INITIATED 11:13:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 24312 TO ITERATE

100.0% PROCESSED 24312 ITERATIONS
SEARCH TIME: 00:00.01

L4 0 SEA SSS FUL L2

0 ANSWERS

=> file caplus
COST IN U.S. DOLLARS
SINCE FILE ENTRY TOTAL
344.65 344.86

FILE 'CAPLUS' ENTERED AT 11:14:28 ON 21 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 20 Jun 2007 (20070620/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13 full
L5 88 L3

=> d 1b1b abs hitstr tot

L5 ANSWER 1 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:35679 CAPLUS
DOCUMENT NUMBER: 146:330260

TITLE: FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice

AUTHOR(S):

Ohori, Makoto; Takeuchi, Mikio; Maruki, Riyo;

Nakajima, Hidenori; Miyake, Hiroshi

CORPORATE SOURCE: Lead Discovery Research Labs, Astellas Pharma Inc.,

Source: Tsukuba, 305-8585, Japan

Naunyn-Schmiedeberg's Archives of Pharmacology (2007), 374(4), 311-316

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER:

Springer

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Extracellular signal-regulated kinase (ERK), a serine/threonine protein kinase of the mitogen-activated protein kinase superfamily, is activated by various stimuli in inflammatory cells. We recently described FR180204 (5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine), a novel selective ERK inhibitor. In this paper, we investigated the effect of FR180204 on collagen-induced arthritis (CIA) in DBA/1 mice, an animal model of rheumatoid arthritis (RA) mediated by type II collagen (CII)-reactive T cells and anti-CII antibodies. Preventive administration of FR180204 (100 mg/kg, i.p., b.i.d.) significantly ameliorated the CIA arthritis and body weight loss occurring in the CIA mice. Furthermore, FR180204-treated mice showed a significant decrease in plasma anti-CII antibody levels (62%). FR180204 also attenuated delayed-type hypersensitivity in CII-immunized DBA/1 mice, an inflammatory response elicited by CII-reactive T cells, in a dose-dependent manner (52 and 62% inhibition at 32 and 100 mg/kg, resp.). Moreover, FR180204 inhibited in vitro CII-induced proliferation of lymph node cells prepared from CII-immunized mice, in which CII-specific T cells are known to undergo specific proliferation. In conclusion, our results suggest that ERK regulates both the cell-mediated and humoral immune responses in the development of CIA. ERK inhibitors may be useful as therapeutic reagents for the treatment of RA.


IT 865362-74-9, FR 180204

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice)

RN 865362-74-9 CAPLUS


CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2-OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:952415 CAPLUS
DOCUMENT NUMBER: 145:342443
TITLE: Compositions comprising NEP inhibitors, endogenous endothelin inhibitors and diuretics for treatment of cardiovascular disease
INVENTOR(S): Fischer, Yvan
PATENT ASSIGNEE(S): Straub, Matthias; Witte, Klaus; Ziegler, Dieter;
SOURCE: Solvay Pharmaceuticals GmbH, Germany
U.S. Pat. Appl., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
US 2006205625 A1 20060914 US 2006-356088 20060217
PRIORITY APPL. INFO.: US 2005-639956P P 20050218
OTHER SOURCE(S): MARPAT 145:342443
AB A novel combination therapy for cardiovascular diseases or conditions, including administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist. For example, capsule was formulated containing daglutril calcium 250 mg and hydrochlorothiazide 50 mg.
IT 131185-37-0, FK-838 171050-45-6, FR-166124
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) and diuretics for treatment of cardiovascular disease
RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 3 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:847629 CAPLUS
DOCUMENT NUMBER: 145:278270
TITLE: Pharmaceutical compositions comprising inhibitors of neutral endopeptidase and inhibitors of the endogenous endothelin and diuretics for the treatment of cardiovascular diseases

INVENTOR(S): Fischer, Yvan
PATENT ASSIGNEE(S): Solvay Pharmaceuticals GmbH, Germany
SOURCE: PCT Int. Appl., 39pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2006087371 A1 20060824 WO 2006-EP60057 20060217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPL. INFO.: MARPAT 145:278270 EP 2005-101235 A 20050218
OTHER SOURCE(S):
AB A novel combination therapy is described for cardiovascular diseases or conditions, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist. For example, capsules contained daglutril calcium, and hydrochlorothiazide, corn starch, lactose and Et acetate.
IT 131185-37-0, FR 838 171050-45-6, FR 166124
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) and inhibitors of the endogenous endothelin and diuretics for the treatment of cardiovascular diseases
RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 4 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:634999 CAPLUS
 DOCUMENT NUMBER: 145:103711


TITLE: Preparation of 2-pyrimidinyl pyrazolopyridines as Erbb kinase inhibitors for treating neoplasm
 INVENTOR(S): Uehling, David Edward; Stevens, Kirk Lawrence; Dickerson, Scott Howard; Waterson, Alex Gregory; Harris, Philip Anthony; Sammond, Douglas McCord; Hubbard, Robert Dale; Emerson, Holly Kathleen; Wilson, Joseph W.

PATENT ASSIGNEE(S): Smithline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 255 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006068826	A2	20060629	WO 2005-US44166	20051206
WO 2006068826	A3	20061005		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2004-637928P	P 20041221
OTHER SOURCE(S):			US 2005-709079P	P 20050817
GI			MARPAT 145:103711	







IT 895636-34-7P 895636-35-8P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (drug candidate: Preparation of 2-pyrimidinyl pyrazolopyridines as ErbB
 kinase inhibitors for treating neoplasms)
 RN 895636-34-7 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-{3-[2-({3-[1-(methylsulfonyl)ethyl]phenyl}am
 no)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-, (+)-(9CI) (CA
 INDEX NAME)

Rotation (+).

PAGE 1-A




PAGE 2-A




RN 895636-35-8 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-{3-[2-({3-[1-(methylsulfonyl)ethyl]phenyl}am
 no)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-, (-)-(9CI) (CA
 INDEX NAME)

Rotation (-).

PAGE 1-A




PAGE 2-A




IT 895634-90-9P, 1-Methyl-1H-pyrrole-2-carboxylic acid
 N-[3-{3-[2-({2,3-dihydrobenzo[1,4]dioxin-6-yl}amino)pyrimidin-4-
 yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amide 895634-92-1P,
 N-[3-{3-[2-({2,3-dihydrobenzo[1,4]dioxin-6-yl}amino)pyrimidin-4-
 yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895634-94-3P,
 N-[3-{3-[2-({2,3-dihydrobenzo[1,4]dioxin-6-yl}amino)pyrimidin-4-
 yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxybenzamide
 895634-96-5P 895635-68-4P, N-[3-{3-[2-({1,2,3,4-
 Tetrahydro-7-isoquinolinyl}amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-

yl]phenyl]benzamide 895635-95-7P, N-[3-[3-[2-[(3-chloro-4-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-68-7P, N-[3-[3-[2-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl-1H-pyrrole-2-carboxamide 895636-76-7P 895637-12-4P, 2,6-difluoro-N-[3-[3-[2-[(3-hydroxy-4-(methyloxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-83-9P, 4-[2-(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)-2-pyrimidinamine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasms)


RN 895634-90-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895634-92-1 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-94-3 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 895634-96-5 CAPLUS
 CN Benzamide, 2-chloro-N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-68-4 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-95-7 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(3-chloro-4-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-68-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-[(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895636-76-7 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(7-(trifluoromethyl)-3-[(2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-12-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(3-(2-[(3-hydroxy-4-methoxyphenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-83-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 895634-81-8P, 1-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-phenylurea (9CI)
895634-89-6P, 1-(2-Chlorophenyl)-3-[(3-[(2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]urea (9CI)
895634-97-6P, N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]thiobenzamide (9CI)
895634-98-7P, 2-Chloro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]thiobenzamide (9CI)
895634-99-8P, N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxythiobenzamide (9CI)
895635-00-4P, 1-Methyl-1H-pyrrole-2-carboxylic acid N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amide (9CI)
895635-01-5P, 2-Chloro-5-fluoro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide (9CI)
895635-06-0P, 2-Fluoro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide (9CI)
895635-07-1P, 2-Fluoro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-6-trifluoromethylbenzamide (9CI)
895635-08-2P, 2,3-Difluoro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide (9CI)
895635-09-3P, 4-Fluoro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide (9CI)
895635-10-6P, N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide (9CI)
895635-11-7P, 3-Fluoro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide (9CI)
895635-12-8P, N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methylbenzamide (9CI)
895635-13-9P, 2,4-Difluoro-N-[3-[(2-[(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methylbenzamide (9CI)




RN 895634-89-6 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-97-6 CAPLUS
CN Benzenecarbothioamide, 2-chloro-N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-98-7 CAPLUS
CN Benzenecarbothioamide, 2-chloro-N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-99-8 CAPLUS
CN Benzenecarbothioamide, N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 895635-00-4 CAPLUS
CN 1H-Pyrrole-2-carbothioamide, N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895635-01-5 CAPLUS
CN Benzamide, 2-chloro-5-fluoro-N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-06-0 CAPLUS
CN Benzamide, 2-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-07-1 CAPLUS
CN Benzamide, 2-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-6-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 895635-08-2 CAPLUS
CN Benzamide, 2,3-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-09-3 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-10-6 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 895635-11-7 CAPLUS
CN Benzamide, 3-fluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-12-8 CAPLUS
CN Benzamide, N-[3-([2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-3-methyl]- (9CI) (CA INDEX NAME)




RN 895635-13-9 CAPLUS
CN Benzamide, 2,4-difluoro-N-[3-([2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 895635-14-0 CAPLUS
CN Benzamide, 2-chloro-4-fluoro-N-[3-([2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)



RN 895635-15-1 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[3-([2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 895635-16-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[3-([2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 895635-17-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[3-([2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)

RN 895635-21-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)





RN 895635-23-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-[[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A


RN 895635-18-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-19-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-20-8 CAPLUS
CN 1H-Benzotriazole-5-carboxamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,3-dihydro-1-methyl- (9CI) (CA INDEX NAME)







RN 895635-26-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3-{2-[(3-methoxyphenyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 895635-27-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3-{2-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 895635-28-6 CAPLUS
CN Benzamide, N-[(3-{2-[(3-cyanophenyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895635-29-7 CAPLUS
CN Benzamide, N-[(3-{2-[(1H-benzotriazol-5-ylamino)-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-30-0 CAPLUS
CN Benzamide, N-[(3-{2-[(4-(aminosulfonyl)phenyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-31-1 CAPLUS


CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-32-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-33-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-(5-oxazolyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-34-4 CAPLUS
CN Benzamide, N-[3-[2-[(3-(acetylamino)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895635-35-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-37-7 CAPLUS
CN 4-isoxazolecarboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 895635-38-8 CAPLUS


CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-39-9 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-41-3 CAPLUS
CN Benzamide, N-[3-[3-[2-[[4-[(3-(dimethylamino)propyl)amino]-3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-43-5 CAPLUS


CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-45-7 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-48-0 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[3-(5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-49-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-50-4 CAPIUS
CN Benzamide, 2,5-difluoro-N-[3-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-51-5 CAPIUS
CN Benzamide, N-[3-[(3-[(3-(acetylamino)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-52-6 CAPIUS


CN Benzamide, N-[3-[(3-[(3-(cyanophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-53-7 CAPIUS
CN Benzamide, 2,5-difluoro-N-[3-[(3-[(3-(2-oxo-1-pyrrolidinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-54-8 CAPIUS
CN Benzamide, 2,5-difluoro-N-[3-[(3-[(3-(2-oxo-1-pyrrolidinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-55-9 CAPLUS
CN Benzamide, N-[3-[2-[[4-[(ethylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-56-0 CAPLUS
CN Benzamide, N-[3-[2-[[3-[(aminosulfonyl)-4-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-57-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-58-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[2-[(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-59-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[2-[(4-morpholinyl)propyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-62-8 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[4-[(2-(4-morpholinyl)ethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


o]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-63-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-64-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(2-hydroxyethyl)sulfonyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-65-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-66-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-67-3 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-[2-[(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-72-0 CAPLUS
CN Benzamide, N-[3-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-73-1 CAPIUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-75-3 CAPIUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(6-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-76-4 CAPIUS
CN 3-Pyridinecarboxamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-77-5 CAPIUS
CN 5-Isoxazolecarboxamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-78-6 CAPIUS
CN Benzamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 895635-79-7 CAPIUS
CN Benzamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 895635-80-0 CAPLUS
CN Benzamide, 2-chloro-N-[3-[3-[2-((3-fluorophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 895635-81-1 CAPLUS
CN Benzamide, 3-fluoro-N-[3-[3-[2-((3-fluorophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 895635-82-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-((3-fluorophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 895635-83-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[3-[3-[2-((3-fluorophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-84-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[3-[2-((3-fluorophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-85-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[3-[3-[2-((3-fluorophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-86-6 CAPLUS
CN 2-Thiophenecarboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 895635-87-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-88-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-bromo-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-89-9 CAPLUS
CN 3-Thiophenecarboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-90-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895635-91-3 CAPIUS
CN Benzamide, 5-fluoro-N-[3-{2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-92-4 CAPIUS
CN 1H-Imidazole-5-carboxamide, N-[3-{2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-93-5 CAPIUS
CN Benzamide, 2,6-difluoro-N-[3-{2-[(3-((3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 895635-96-8 CAPIUS
CN Benzamide, N-[3-{2-[(3-chloro-4-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-97-9 CAPLUS
CN Benzamide, N-[3-[3-[(3-cyano-4-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-98-0 CAPLUS
CN Benzamide, N-[3-[3-[(4-chloro-3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-99-1 CAPLUS
CN Benzamide, N-[3-[3-[(3-cyano-4-(1H-pyrazol-1-yl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895636-00-7 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-01-8 CAPLUS
CN Benzamide, N-[3-[3-[(2-[(4-chlorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-02-9 CAPLUS
CN Benzamide, N-[3-[3-[(2-[(4'-cyano[1,1'-biphenyl]-4-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)


RN 895636-05-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[[2-[[4-(phenylamino)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-06-3 CAPLUS
CN Benzamide, N-[3-[[3-[[2-[[2,3-dimethyl-6-quinoxaliny]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-07-4 CAPLUS
CN Benzamide, N-[3-[[3-[[2-[[4-benzoylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-03-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[[2-[[4-(4-pyridinylmethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-04-1 CAPLUS
CN Benzamide, N-[3-[[3-[[2-[[4-cyano-3-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-11-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(phenylacetyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-12-1 CAPLUS
CN Benzamide, N-[3-[3-[2-[[4-((cyclopropylamino)carbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-10-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(1H-pyrazol-3-yl)phenyl]amino]-4-




RN 895636-08-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-09-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(4-morpholinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-13-2 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-14-3 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-15-4 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-16-5 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-17-6 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-18-7 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-19-8 CAPLUS
 CN Benzamide, N-[3-[2-[[3-[2-[[3-[[[(dimethylamino)acetyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-20-1 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[2-[[3-(4-methoxy-3-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895636-21-2 CAPLUS
 CN Benzamide, N-[3-[2-[[3-[2-[[3-(dimethylamino)propyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-22-3 CAPLUS
 CN Benzamide, N-[3-[2-[[3-[2-[[3-[[[(dimethylamino)acetyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-23-4 CAPLUS


CN Benzamide, N-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-24-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-25-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-26-7 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-[(aminosulfonyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-27-8 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-[(aminosulfonyl)ethyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-29-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-30-3 CAPLUS
CN Benzamide, N-[3-[3-[(5-(ethylsulfonyl)-2-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-31-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[(2-methoxy-4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-36-9 CAPLUS
CN Benzamide, N-[3-[3-[(2-[(3-chloro-4-(2-methoxyethoxy)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-37-0 CAPLUS
CN Benzamide, N-[3-[3-[(2-[(3-chloro-4-[3-(dimethylamino)propoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-38-1 CAPLUS
CN Benzamide, N-[3-[3-[(2-[(4-morpholinyl)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-39-2 CAPLUS
CN Benzamide, N-[3-{3-[(2-{2-[(3-chloro-4-[(2-(dimethylamino)ethoxy)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-41-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[(2-{2-[(3-fluoro-4-[(2-methoxyethoxy)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-42-7 CAPLUS
CN Benzamide, N-[3-{3-[(2-{2-[(4-amino-2-fluorophenoxy)propyl]methylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-43-8 CAPLUS
CN Benzamide, N-[3-{3-[(2-{2-[(3-(diethylamino)propoxy)-3-fluorophenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-45-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[(2-{2-[(3-fluoro-4-[(2-oxo-1-pyrrolidinyl)ethoxy]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-47-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[(2-{2-[(3-fluoro-4-[(2-(1-piperidinyl)ethoxy]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-48-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-{(methylsulfonyl)methyl}phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-49-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-{(1-pyrrolidinyl)ethoxy}phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-52-9 CAPLUS
CN 2-Furancarboxamide, N-[3-[3-[2-[(3-{(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-54-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-[2-[(3-{(2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895636-55-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[3-[3-[2-[(3-{(2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-56-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[3-[3-[2-[(3-{(2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-57-4 CAPLUS
CN Benzamide, 3-methyl-N-[3-[3-[2-[(3-{(2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-58-5 CAPLUS
CN Benzamide, 4-chloro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-59-6 CAPLUS
CN Benzamide, 3-amino-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-60-9 CAPLUS
CN Benzamide, 4-amino-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-61-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-methyl-N-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-62-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-64-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-(1-pyrrolidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-65-4 CAPLUS
CN 1H-Pyrrolo-2-carboxamide, 1-methyl-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-69-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-{3-[2-[(3-cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895636-82-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-(phenylamino)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-83-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895636-84-7 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-85-8 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-methyl-3-[2-[(3-trifluoromethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-87-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-88-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-89-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(7-methoxy-3-[(2-[(3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-91-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[2-methoxy-5-[3-[(2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-99-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[2-fluoro-5-[3-[(2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-06-6 CAPLUS
CN 1-Propanesulfonic acid, 3-[2-chloro-4-[(4-[2-[(3-(2,6-difluorobenzoyl)amino]phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 895637-07-7 CAPLUS
 CN Butanoic acid, 4-[[2-chloro-4-[[4-[2-[3-[[2,6-difluorobenzoyl]amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 895637-08-8 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[3-chloro-4-[2-[(methylsulfonyl)amino]ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-09-9 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[3-chloro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895637-11-3 CAPLUS
 CN Formic acid, compd. with N-[3-[3-[2-[[3-[3-(dimethylamino)propoxy]-4-

methoxyphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide (9CI) (CA INDEX NAME)


CM 1
 CRN 895637-10-2
 CMF C36 H33 F2 N7 O3



CM 2
 CRN 64-18-6
 CMF C H2 O2




RN 895637-13-5 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[3-[2-[[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-14-6 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)


pyrimidinyl]-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-
(9CI) (CA INDEX NAME)




RN 895637-25-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[6-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-
pyrrolidinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-
yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-26-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[6-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-
7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 895637-27-1 CAPLUS



RN 895637-20-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[4-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-
7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 895637-21-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[4-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-
pyrrolidinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-
yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-22-6 CAPLUS
CN Benzamide, N-[3-[3-[2-[(2-(dimethylamino)ethoxy]phenyl)amino]-4-

CN Benzamide, N-[3-[3-[2-[(7-amino-5,6,7,8-tetrahydro-2-naphthalenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-30-6 CAPLUS
CN Benzamide, N-[3-[7-(dimethylamino)-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1
CRN 895637-29-3
CMF C32 H24 F3 N7 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 895637-33-9 CAPLUS
CN Benzamide, N-[3-[3-[2-[(2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895637-36-2 CAPLUS
CN Benzamide, N-[3-[3-[2-[(2-amino-2,3-dihydro-1H-inden-5-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-38-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-(4-methyl-5-oxazolyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-41-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(1,2,3,4-tetrahydro-2,4,4-trimethyl-7-isouquinoliny)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


CM 1
 CRN 895637-46-4
 CMF C35 H28 F3 N7 O




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 895637-50-0 CAPLUS
 CN Benzamide, N-[5-[3-([2-([3-(2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl)-2,6-difluoro-(9CI) (CA INDEX NAME)




RN 895637-53-3 CAPLUS



RN 895637-42-0 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-([2-([1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2,6-difluoro-(9CI) (CA INDEX NAME)




RN 895637-43-1 CAPLUS
 CN Benzamide, N-[3-([2-([3-(aminomethyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2,6-difluoro-(9CI) (CA INDEX NAME)




RN 895637-47-5 CAPLUS
 CN Benzamide, N-[5-[3-([2-([2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl)-2,6-difluoro-mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-[2-(methylsulfonyl)ethyl]amino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-72-6 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-75-9 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl- (9CI) (CA INDEX NAME)




RN 895637-76-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-(3-fluorophenyl)amino)-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-84-0 CAPLUS
CN Benzamide, N-[5-[3-[2-[(3-[2-[(3-[2-(dimethylamino)methyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-85-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-[2-(3-fluorophenyl)amino)-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-90-8 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-92-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-[2-(methyl-2-propenylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-93-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[(3-[2-(methyl-2-propenylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895637-95-3 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-96-4 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-(dimethylamino)propoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-98-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(2-methyl-5-benzothiazolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


pyrimidinylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)





RN 895638-09-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[(1,2,3,4-tetrahydro-2-methyl-7-isouinoliny]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895638-10-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluoro-4-[(1-methyl-2-pyrrolidiny]methoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895637-99-7 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895638-00-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895638-01-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[(3-fluorophenyl)amino]-4-

[illegible]


895638-07-0P, 2,2,2-Trifluoro-N-[3-(3-(2-Chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]acetamide
 895638-08-1P, 2,2,2-Trifluoro-N-[3-(3-(5-fluoro-2-((2-methyl-1,2,3,4-tetrahydro-7-isoquinolyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]acetamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Intermediate; preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)
 RN 895634-85-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(2-(methylthio)-4-pyrimidinyl)-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 895634-86-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(2-(methylsulfinyl)-4-pyrimidinyl)-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 895634-87-4 CAPLUS
 CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(2-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 895634-88-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,3-


dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 895635-03-7 CAPLUS
 CN Acetamide, N-[3-(3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895635-04-8 CAPLUS
 CN Acetamide, N-[3-(3-(2-trifluoro-N-[3-(3-(2-(3-(3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 895635-05-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 895635-25-3 CAPLUS
CN Benzamide, N-[3-{3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-46-8 CAPLUS
CN Benzamide, N-[3-{3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-69-5 CAPLUS
CN Benzamide, N-[3-{3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-71-9 CAPLUS
CN Benzamide, N-[3-{3-(2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-74-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895636-50-7 CAPLUS
CN Acetamide, N-[3-{3-[2-[[3-(2-chloroethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895636-51-8 CAPLUS
CN 2-Pyrimidine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(2-(1-pyrrolidinylethoxy)phenyl)]- (9CI) (CA INDEX NAME)




RN 895636-70-1 CAPLUS
CN Benzamide, N-[3-[5-(hydroxymethyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-71-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)]- (9CI) (CA INDEX NAME)




RN 895636-72-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 895636-73-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-3-[2-(methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)]- (9CI) (CA INDEX NAME)




RN 895636-74-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-2-(3-nitrophenyl)-3-(4-pyrimidinyl)]- (9CI) (CA INDEX NAME)




RN 895636-75-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-methanol, 2-(3-aminophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 895636-80-3 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[3-(2-(methylthio)-4-pyrimidinyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-81-4 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[3-(2-(methylsulfinyl)-4-pyrimidinyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-86-9 CAPLUS
 CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-90-5 CAPLUS
 CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-7-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-95-0 CAPLUS
 CN Acetamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895636-96-1 CAPLUS
 CN Benzamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-97-2 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[2-methoxy-5-[3-[2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isquinolyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-03-3 CAPLUS
CN Acetamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895637-04-4 CAPLUS
CN Benzamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-05-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[2-fluoro-5-[3-[2-[(1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-16-8 CAPLUS
CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895637-18-0 CAPLUS
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 895637-19-1 CAPLUS
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-23-7 CAPLUS
CN Benzamide, N-[3-[(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-28-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(2-[[5,6,7,8-tetrahydro-7-(trifluoroacetyl)amino]-2-naphthalenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-31-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[(3-bromophenyl)-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-N,N-dimethyl]- (9CI) (CA INDEX NAME)



RN 895637-37-3 CAPLUS
CN Benzamide, N-[3-[(2-[(2,3-dihydro-2-[(trifluoroacetyl)amino]-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-45-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(2-[(3-[(trifluoroacetyl)amino]methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-48-6 CAPLUS
CN Acetamide, N-[5-[(2-[(2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)





RN 895637-55-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{2-[[3-[[methyl(trifluoroacetyl)amino]meth-
yl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA
INDEX NAME)




RN 895637-57-7 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-{2-[[3-[[[trifluoroacetyl]amino]methyl]phe-
nyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA
INDEX NAME)




RN 895637-69-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-{2-[[3-[[[2-(methylsulfonyl)ethyl](trifluo-
roacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-
yl]phenyl]- (9CI) (CA INDEX NAME)







NRN	895638-03-6	CAPLUS	
CN	Pyrazolo[1,5-a]pyridine, 2-(3-bromophenyl)-3-(2-chloro-5-fluoro-4-pyrimidinyl)- (9CI)	(CA INDEX NAME)	




ERN	895638-04-7	CAPLUS
CN	2-Pyrimidinamine, 4-{2-(3-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl}-5-fluoro-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)	




NRN	895638-05-8	CAPLUS
CN	7-Isoquinolinamine, N-{4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-2-pyrimidinyl}-1,2,3,4-tetrahydro-2-methyl-	(9CI) (CA INDEX NAME)



RN	895638-07-0	CAPLUS
CN	Acetamide, N-[3-[3-(2-chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)	



895638-08-1 CAPLUS
Acetamide, 2,2,2-trifluoro-N-[3-(3-[5-fluoro-2-[(1,2,3,4-tetrahydro-2-methyl-7-isquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




995635-36-6, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-1-(3-fluorophenyl)-2-pyrimidinamine 995635-40-2, 995635-70-8
[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amine 995636-53-0, N-[4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]phenylamine 995636-63-2, 3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-N-(2,6-difluorophenyl)benzamide 995637-24-8, 3-[3-(2-Chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-


a)pyridin-2-yl]aniline 895637-63-5, N-[3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methylbenzamide

RL: RCT (Reactant): RACT (Reactant or reagent)
for treating neoplasm


RN 895635-36-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-1-(3-fluorophenyl)-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 895635-40-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 895635-70-8 CAPLUS
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 895636-53-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 895636-63-2 CAPLUS
CN Benzenamide, 3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 895637-24-8 CAPLUS
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 895637-63-5 CAPLUS
CN Benzenamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl- (9CI) (CA INDEX NAME)



IT 895637-17-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors
 for treating neoplasms)
 RN 895637-17-9 CAPLUS
 CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:496072 CAPLUS
 DOCUMENT NUMBER: 145:8184
 TITLE: Process for preparing pyrazolopyridine compounds
 INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006055245	A2	20060526	WO 2005-US39571	20051101
WO 2006055245	A3	20060817		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GM, GW, GQ, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MM, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPL. INFO.: US 2004-628820P P 20041117				
OTHER SOURCE(S): MARPAT 145:8184				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The present invention provides a process for preparing pyrazolopyridine compounds. I [R1 = (hetero)aryl; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, cycloalkyl, etc.; p = 0-3; R6 = halo, alkyl, cycloalkyl, etc.] comprising the steps of

(a) reacting II with a hindered amide base to produce an anion and reacting the anion with 9-methoxy-9-borabicyclo[3.3.1]nonane; (b) adding a compound R1X (wherein X = halo or triflate) in the presence of a palladium catalyst to prepare a compound of formula I wherein R2 = SMe; (c) optionally converting I into its pharmaceutically acceptable salt or solvate; and (d) optionally converting I or a pharmaceutically acceptable salt into a different compound I. Thus, treating 2-(4-fluorophenyl)-3-(2-(methylthio)pyrimidin-4-yl)pyrazolo[1,5-a]pyridine (2-step synthesis given) with lithium diisopropylamide in THF followed by addition of 9-methoxy-9-borabicyclo[3.3.1]nonane, and after 1 h K3PO4, DMF, 4-iodotoluene and PdCl2(dppf):CH2Cl2 afforded 67% III.


IT 401816-34-0P 888021-52-1P 888021-53-2P
 888021-54-3P 888021-55-4P 888021-59-0P
 888021-71-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (process for preparing pyrazolopyridine compds.)


RN 401816-34-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 888021-52-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(4-methoxyphenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 888021-53-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(3-methoxyphenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 888021-54-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 888021-55-4 CAPLUS
CN Ethanone, 1-{4-[2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-7-yl]phenyl}- (9CI) (CA INDEX NAME)



RN 888021-69-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-58-7 CAPLUS
CN Benzenamine, 4-[2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 888021-71-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-(cyclopropylmethoxy)phenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


IT 888021-56-5P 888021-57-6P 888021-58-7P
888021-59-8P 888021-60-1P 888021-61-2P
888021-62-3P 888021-63-4P 888021-64-5P
888021-65-6P 888021-66-7P 888021-67-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing pyrazolopyridine compds.)
RN 888021-56-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(4-fluorophenyl)-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-57-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(3-methoxyphenyl)-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-59-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(3-thienyl)]- (9CI) (CA INDEX NAME)




RN 888021-60-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(4-methylphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-61-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 888021-62-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 888021-63-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(cyclopropylmethoxy)phenyl]-7-(3-methylphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 888021-64-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

15 ANSWER 6 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:440458 CAPLUS

2006:440458 CAPLUS

2006: 440456
144: 468186

TITLE:
Preparation of (halopyrazolopyridinyl)pyridazinones
and their use as phosphodiesterase (PDE) inhibitors
and pharmaceuticals

INVENTOR(S):
Kono, Yasushi; Ando, Naoki; Iwase, Kazuhiko; Yasue,
Tokutaro; Kishi, Tetsuya; Nagasawa, Michiaki; Hori,
Wataru

PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 66 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006117647	A	20060511	JP 2005-271518	20050920
PRIORITY APPLN. INFO. :			JP 2004-274779	A 20040922
OTHER SOURCE(S) :		MARPAT 144:468186		




Title compds. I [R1 = halo, Cl-4 alkoxy; R2 = H, halo, OH, Cl-4 alkoxy; R3 = H, halo, (un)substituted Cl-4 alkyl, C3-8 cycloalkyl, C2-4 alkenyl, Cl-4 alkoxy, CO₂H; etc.; R4 = H, R6(CH₂)_m, R6 = C3-8 cycloalkyl, aromatic or saturated heterocyclyl; m = 1, 2; the broken line may be single or double bond] are prepared. They are useful for treatment of angina pectoris, heart failure, hypertension, asthma, COPD, atopic dermatitis, multiple sclerosis, Alzheimer's disease, schizophrania, etc. Thus, refluxing NH₂NH₂·H₂O with 4-(6-chloro-2-methylpyrazolo[1,5-a]pyridin-3-yl)-3-methyl-4-oxobutyrac acid in EtOH gave I (R1 = Cl, R2 = R5 = H, R3 = R4 = Me, the broken line is single bond), which inhibited human PDE3, PDE4, PDE5, and PDE10 with IC₅₀ values of 1.46, 16.5, 55.7, and 8.44 μmol/L, resp.

IT 886222-87-3P

RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(uses)
 (preparation of (halopyrazolopyridinyl)pyridazinones as phosphodiesterase inhibitors for treatment of diseases)

886222-87-3 CAPLUS
3(2H)-Pyridazinone, 6-(6-chloro-2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-
4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




888021-65-6 CAPLUS

CA INDEX NAME	(CA INDEX NAME)	(9CI)	fluorophenylpyrazolo[1,5-a]pyridin-7-ylphenyl-	1-[4-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-ethanone, 1-[4-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-ylphenyl]-
000221-03-0	CA 000221-03-0	000221-03-0	000221-03-0	000221-03-0




888021-66-7 CAPLUS


2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



URN 888021-67-8 CAPLUS

000021-07-0 CARLOS
2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






L5 ANSWER 7 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:386432 CAPLUS
 DOCUMENT NUMBER: 144:425692
 TITLE: Methods using TGF- β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries
 INVENTOR(S): Ling, Leona E.; Fu, Kai; Gill, Alan; Gotwals, Philip J.
 PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA
 SOURCE: PCT Int. Appl., 228 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044509	A2	20060427	WO 2005-US36770	20051013
WO 2006044509	A3	20060817		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005295734	A1	20060427	AU 2005-295734	20051013
US 2004-619116P	P			20041015
WO 2005-US36770	W			20051013


OTHER SOURCE(S): MARPAT 144:425692
 AB The invention discloses the use of TGF- β type I receptor inhibitors and Alk4 inhibitors and implantable devices including these compounds in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).

IT 672932-46-6 672932-50-2 672932-51-3
 RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TGF- β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries)


RN 672932-46-6 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 672932-50-2 CAPLUS
 CN 2-Pyrimidinamine, 4-(2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 672932-51-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:342780 CAPLUS
 DOCUMENT NUMBER: 144:390930
 TITLE: Preparation of pyridazinone derivatives as inhibitors of the production and transduction of cytokines

INVENTOR(S): Yamazaki, Hitoshi; Kasahara, Chiyoashi; Shigenaga, Shinji; Higuchi, Koichi; Mizuhara, Hidekazu; Yasuda, Minoru; Yokomoto, Masaharu; Misumi, Keiji; Kinoshita, Tomohiko; Katayama, Kimiko
 PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan; Wakunaga Pharmaceutical Co., Ltd.
 SOURCE: PCT Int. Appl., 124 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006038734	A1	20060413	WO 2005-JP18901	20051007
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ,			

LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PI, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, XU, ZA, ZB, ZM, ZW


RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GA, GG, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: AU 2004-905844 A 20041008
OTHER SOURCE(S): MARPAT 144:390930

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I and II [R1 = (un)substituted lower alkyl, aryl; R2 = (un)substituted aryl or thienyl; R3 = H, lower alkyl; A = O, S; R4 = H, (un)substituted amino, piperazin-1-yl, etc.; R5 = H, lower alkyl, hydroxy(lower)alkyl; R6 = H, (un)substituted amino, N-lower alkoxy(carbonyl)piperazinyl; or R5R6 = -Y-CH-CH-, -Z-(CH2)3-, Y = CH, N; Z = CH2, NH; with provisos; and their salts] were prepared as inhibitors of the production and transduction of cytokines. Thus, reacting 6-[2-amino-4-(4-fluorophenyl)-1,3-thiazol-5-yl]-3(2H)-pyridazinone (preparation given) with 1-oxaspiro[2.5]octane in dioxane in the presence of NaOH gave pyridazinone III. Pyridazinone III inhibited TNF- α production in THP-1 cells at 100 nM. I and II are useful for treating cytokines mediated diseases, such as pain, rheumatoid arthritis, inflammation, psoriasis, etc.

IT 882975-01-1P, 2-[(1-hydroxycyclohexyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone
RN 882975-01-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-hydroxycyclohexyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 882974-78-9P, 2-(2,6-dichlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone 882975-12-4P, 2-(2-chlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone 882975-13-5P, 2-(2-methylphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone
RN: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyridazinones as inhibitors of the production and transduction of cytokines)
RN 882974-78-9 CAPLUS


CN 3(2H)-Pyridazinone, 2-(2,6-dichlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 882975-12-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-chlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 882975-13-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methylphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 131185-06-3, 6-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone
RN: RCT (Reactant); RACT (Reactant or reagent)
CN 3(2H)-Pyridazinone, 2-(2-methylphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
15 ANSWER 9 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2006:19715 CAPLUS
 DOCUMENT NUMBER: 144:163524
 TITLE: Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses
 AUTHOR(S): Allen, Scott H.; Johns, Brian A.; Gudmundsson, Kristjan S.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie H.; Selleseth, Dean W.; Creech, Katrina L.; Moniri, Kelly R.
 CORPORATE SOURCE: Department of Medicinal Chemistry, GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(4), 944-954
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:163524

AB A novel series of potent C-6 substituted pyrazolo[1,5-a]pyridine inhibitors of herpes simplex viruses has been identified. A synthetic methodol. was developed involving functionalization of a C-6 trifluoromethyl pyrazolo[1,5-a]pyridine to allow facile access to a diverse set of analogs from common late stage intermediates. The expansion of the SAR of this series at the 6 position allows for modifications to developability parameters such as clog P, while maintaining potency comparable to acyclovir.
 IT 468062-75-1P 473712-17-3P 474304-08-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 468062-75-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473712-17-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 474304-08-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 874668-24-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 468062-82-0P 468062-84-2P 468063-30-1P
 473711-98-7P 473711-99-8P 474303-58-7P
 474303-60-1P 474303-61-2P 474303-82-3P
 474303-63-4P 474303-64-5P 474303-65-6P
 474303-66-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 468062-82-0 CAPIUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-84-2 CAPIUS
 CN Pyrazolo[1,5-a]pyridine-6-methanamine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468063-30-1 CAPIUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 473711-98-7 CAPIUS
 CN Pyrazolo[1,5-a]pyridin-6-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473711-99-8 CAPIUS
 CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 474303-58-7 CAPIUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 474303-60-1 CAPIUS
 CN Pyrazolo[1,5-a]pyridine, 1-[[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 474303-61-2 CAPLUS

Pyrazolo(1,5-a)pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl-
(CA INDEX NAME)




RN 474303-62-3 CAPLUS

INDEX NAME	CA
Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-hydroxy-	(9CI)




URN 474303-63-4 CAPLUS

4/4303-63-4 CAPLUS
Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-{2-(cyclopentylamino)-4-pyrimidinyl}-2-(4-fluorophenyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




NRN 474303-64-5 CAPLUS

Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




NRN 474303-65-6 CAPLUS

474303-63-6 CAFLUOS
Pyrazol[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)




NRN 474303-66-7 CAPLUS


NAME	CA INDEX
Pyrazolo[1,5-a]pyridine-6-methanol, 7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)- (9CI)	474303-66-7 CAPLUS




IT 437611-97-7, GW 3733
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 437611-97-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)]- (9CI) (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-81-9P
 468062-83-1P 468063-25-4P 468063-27-6P
 468063-28-7P 468063-29-8P 473712-18-4P
 474304-03-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 468062-79-5 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 468062-81-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)]-, ethyl ester (9CI) (CA INDEX NAME)



RN 468062-83-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[[6-(bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)]-, ethyl ester (9CI) (CA INDEX NAME)




RN 468063-27-6 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 468063-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)



RN 473712-18-4 CAPLUS
CN Carbamic acid, [3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474304-05-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 88 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2005:1241434 CAPLUS
DOCUMENT NUMBER: 144:63899
TITLE: Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative

AUTHOR(S): Kinoshita, Takayoshi; Warizaya, Masaichi; Ohori, Makoto; Sato, Kentaro; Neya, Masahiro; Fujii, Takashi
CORPORATE SOURCE: Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, Tsukuba, Ibaraki, 300-2698, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(11), 55-58


CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


GI



AB A series of pyrazolopyridazine compds. were briefly investigated as ERK2 inhibitors. The crystal structure of ERK2 complexed with the allyl derivative (I) was determined. The compound induces structural change including movement of the glycine-rich loop and peptide flip between Met108-Glu109. As a result, the newly formed subsite can recognize small hydrophobic substituents but not hydrophilic ones.


IT 871568-25-1 CAPLUS
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative)

RN 871568-25-1 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-d]pyridin-3-yl)-1-(2-propenyl)- (9CI) (CA INDEX NAME)




IT 865362-74-9 871568-24-0 871568-26-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative)

RN 865362-74-9 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-d]pyridin-3-yl)- (CA INDEX NAME)




RN 871568-24-0 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 1-methyl-5-(2-phenylpyrazolo[1,5-d]pyridin-3-yl)- (9CI) (CA INDEX NAME)

alpyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 871568-26-2 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 1-methyl-5-(2-phenylpyrazolo[1,5-d]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 11 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1162315 CAPLUS
 DOCUMENT NUMBER: 144:345937

TITLE: Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain

AUTHOR(S): Matsuya, Takahiro; Takamatsu, Hiroyuki; Murakami, Yoshihiro; Noda, Akihiro; Ichise, Rikuya; Awaga, Yuji; Nishimura, Shintaro

CORPORATE SOURCE: Basic Research Division, The Medical and Pharmacological Research Center Foundation, Ishikawa, 925-0613, Japan

SOURCE: Nuclear Medicine and Biology (2005), 32(8), 837-844
 CODEN: NMBIO; ISSN: 0969-8051

PUBLISHER: Elsevier Inc.
 DOCUMENT TYPE: Journal


LANGUAGE: English
 AB This report describes the synthesis of [11C]2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-d]pyridin-3-yl)-3(2H)-pyridazinone ([11C]FR194921), a highly selective, nonxanthine-type adenosine A1 receptor antagonist, used in brain imaging in rats and conscious monkeys as a potential novel PET tracer. [11C]FR194921 was successfully synthesized in 19 min after [11C]CH3I formation. The radiochem. yield was 38±3%; and radioactivity was 4.1±0.4 GBq, calculated from end of synthesis; radiochem. purity was higher than 99%; and the specific radioactivity was 25.0±8.1 GBq/μmol-1 (n=5). In a rat experiment, the distribution of [11C]FR194921 was higher in the hippocampus, striatum and cerebellum regions. This accumulation was significantly decreased by approx. 50% by pretreatment with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), an adenosine A1 receptor antagonist, which indicated specific binding of the radioligand to adenosine A1 receptors. In conscious monkey PET expts., [11C]FR194921 accumulated in several regions of the brain, especially in the occipital cortex.

thalamus and striatum. These results suggest that [11C]FR194921 can be used as an agent for imaging adenosine A1 receptors in vivo by positron emission tomog. (PET).

IT 881030-50-8P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis and evaluation of [11C]FR194921 as nonxanthine-type PET tracer for adenosine A1 receptors in brain)


RN 881030-50-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[1-(methyl-11C)-4-piperidinyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 202646-90-0, Desmethyl-FR194921

RL: RCT (Reactant); RACT (Reactant or reagent) (synthesis and evaluation of [11C]FR194921 as nonxanthine-type PET tracer for adenosine A1 receptors in brain)

RN 202646-90-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1024651 CAPLUS
DOCUMENT NUMBER: 143:460071

TITLE: Pyrazolo[1,5-a]pyridines as p38 Kinase Inhibitors
AUTHOR(S): Stevens, Kirk L.; Jung, David K.; Alberti, Michael J.; Badiang, Jennifer G.; Peckham, Gregory E.; Veal, Jim M.; Cheung, Mui; Harris, Philip A.; Chamberlain, Stanley D.; Feel, Michael R.

CORPORATE SOURCE: Research and Development, Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA

SOURCE: Organic Letters (2005), 7(21), 4753-4756


PUBLISHER: CODEN: ORLEF7; ISSN: 1523-7060

DOCUMENT TYPE: American Chemical Society

LANGUAGE: Journal

OTHER SOURCE(S): CASREACT 143:460071

GI



I


AB A convergent synthesis of substituted pyrazolo[1,5-a]pyridines, e.g., I, has been achieved either via a regioselective [3 + 2]-cycloaddn. of N-aminopyridines with alkynes or by thermal cyclization of disubstituted azirines. Subsequent palladium-catalyzed introduction of pyridines or de novo synthesis of pyrimidines afforded inhibitors of p38 kinase.

IT 401816-10-2P 401816-13-5P 401816-14-6P
401816-32-8P 401816-41-9P 401816-44-2P
401816-51-1P 401816-54-4P 401816-57-7P
401816-61-3P 401816-62-4P 401816-67-9P
401816-68-0P 401816-79-3P 401816-80-6P
401816-89-5P 468062-94-4P 468062-95-5P
468062-99-9P 468063-20-9P 468063-23-2P
468063-44-7P 869334-80-5P 869334-81-6P
869334-82-7P 869334-83-8P 869334-84-9P
869334-85-0P 869334-86-1P 869334-87-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (regioselective preparation, p38 kinase inhibitory activity, and structure-activity relationship of pyrazolopyridines using a [3 + 2]-cycloaddn. or thermal cyclization as the key reaction)


RN 401816-10-2 CAPLUS

CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 401816-13-5 CAPLUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-14-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 401816-32-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-41-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-44-2 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-51-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-54-4 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-57-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-61-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 401816-62-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-67-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-68-0 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 401816-79-3 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-80-6 CAPLUS
CN 1,3-Propanediamine, N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-89-5 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 468063-23-2 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-(2-(cyclopropylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 869334-80-5 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[4-fluoro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-94-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)-
(9CI) (CA INDEX NAME)



RN 468062-95-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-99-9 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-20-9 CAPLUS


CN 2-Pyrimidinamine, N-[3-(4-methyl-1-piperazinyl)propyl]-4-(6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 869334-85-0 CAPLUS
CN 1-Propanol, 3-[[4-[6-(trifluoromethyl)-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 869334-86-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N,N-dimethyl-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 869334-87-2 CAPLUS
CN 1-Propanol, 3-[[4-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)





RN 869334-84-9 CAPLUS


RN 869334-81-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 869334-82-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(1-methylethyl)amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 869334-83-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 869334-84-9 CAPLUS




IT 401815-97-2P 401816-29-3P 401816-55-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (regioselective preparation, p38 kinase inhibitory activity, and
 structure-activity relationship of pyrazolopyridines using a [3 +
 2]-cycloaddn. or thermal cyclization as the key reaction)
 RN 401815-97-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-
 (9CI) (CA INDEX NAME)



RN 401816-29-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(2-fluoro-4-
 pyridinyl)- (9CI) (CA INDEX NAME)



RN 401816-55-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
 a]pyridin-3-yl]-N-[3-[(4-methoxyphenyl)methoxy]propyl]- (9CI) (CA INDEX
 NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

15 ANSWER 13 OF 88 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005:993256 CAPLUS
 DOCUMENT NUMBER: 143:318600
 TITLE: Identification of a selective ERK inhibitor and
 structural determination of the inhibitor-ERK2 complex
 AUTHOR(S): Otori, Makoto; Kinoshita, Takayoshi; Okubo, Mitsuru;
 Sato, Kentaro; Yamazaki, Akiko; Arakawa, Hiroyuki;
 Nishimura, Shintaro; Inamura, Noriaki; Nakajima,
 Hidenori; Neya, Masahiro; Miyake, Hiroshi; Fujii,
 Takashi
 CORPORATE SOURCE: Lead Discovery Research Laboratories, Astellas Pharma
 Inc., Tsukuba, Ibaraki, 300-8585, Japan
 SOURCE: Biochemical and Biophysical Research Communications
 (2005), 336(1), 357-363
 CODEN: BRC9; ISSN: 0006-291X


PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Selective inhibition of extracellular signal-regulated kinase (ERK)
 represents a potential approach for the treatment of cancer and other
 diseases; however, no selective inhibitors are currently available. Here,
 the authors describe an ERK-selective inhibitor, FR180204, and determine the
 structural basis of its selectivity. FR180204 inhibited the kinase
 activity of ERK1 and ERK2, with Ki values 0.31 and 0.14 μM, resp.
 Lineweaver-Burk anal. of the binding interaction revealed that FR180204
 acted as competitive inhibitor of ATP. In mink lung epithelial Mv1Lu
 cells, FR180204 inhibited TGFβ-induced luciferase-expression. X-ray
 crystal structure anal. of the human ERK2/FR180204 complex revealed that
 Q105, D106, I156, and C166, which form the ATP-binding pocket on ERK, play
 important roles in the drug/protein interaction. These results suggest
 that FR180204 is an ERK-selective and cell-permeable inhibitor, and could
 be useful for elucidating the roles of ERK as well as for drug
 development.

IT 865362-74-9, FR 180204
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (identification of a selective ERK inhibitor and structural determination of
 inhibitor-ERK2 complex)
 RN 865362-74-9 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)- (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 14 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:777994 CAPLUS
 DOCUMENT NUMBER: 143:367266
 TITLE: Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses
 AUTHOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.; Wang, Zhicheng; Turner, Elizabeth M.; Allen, Scott H.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie J.; Selleseth, Dean W.; Moniri, Kelly R.; Creech, Katrina L.
 CORPORATE SOURCE: GlaxoSmithKline Research and Development, Department of Medicinal Chemistry, Research Triangle Park, NC, 27709-3398, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(18), 5346-5361
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:367266
 AB Herpesviruses are a significant source of human disease; amongst these herpes simplex virus 1 (HSV-1) and HSV-2 are very prevalent and cause recurrent infections. A pyrazolo[1,5-a]pyridine scaffold that showed promising activity against HSV-1 and HSV-2 in Vero cell antiviral assays was recently reported. Here, the synthesis and anti-herpetic activity of several 3-pyrimidinyl-2-(phenyl)pyrazolo[1,5-a]pyridine derivs. with differing 2-Ph substitution patterns is described. Approaches to rapidly access a number of analogs with different 2-Ph substitution patterns are outlined. Several of the compds. described have comparable activity to acyclovir against HSV-1 and HSV-2.
 IT 437611-97-7
 RL: PAC (Pharmacological activity); BIOL (Biological study) (preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and study of antiviral activity of N-cyclopentyl[(cyclopentylamino)pyrimidinyl](fluorophenyl)pyrazolo[1,3-a]pyridinamine)
 RN 437611-97-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 437611-98-8P 460078-20-0P 460078-26-8P
 460078-37-9P 460078-45-9P 460078-46-0P
 460078-55-1P 460078-60-8P 460078-71-1P
 460078-74-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and study of their activity against herpesvirus)
 RN 437611-98-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-20-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-26-6 CAPLUS
 CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-37-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-aminophenyl)-N-cyclopentyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-45-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(2-bromophenyl)-N-cyclopentyl-3-[2-(N-butyrylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-46-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(N-cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-aminophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-60-8 CAPLUS
CN Benzonitrile, 3-[7-(cyclopentylamino)-3-(2-(pyrimidin-2-yl)-pyrazolo[1,5-a]pyridin-2-yl)]- (9CI) (CA INDEX NAME)




RN 460078-71-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-74-4 CAPLUS
CN Phenol, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




IT 437611-99-9P 437612-02-7P 437612-76-5P
460078-29-9P 460078-30-2P 460078-31-3P
460078-33-5P 460078-34-6P 460078-35-7P
460078-36-8P 460078-38-0P 460078-44-8P
460078-50-6P 460078-56-2P 460078-57-3P
460078-59-5P 460078-61-9P 460078-62-0P
460078-66-4P 460078-75-5P 460078-76-6P
460078-77-7P 460079-24-7P 866393-63-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (pyrimidinyl) (phenyl) pyrazolo[1,5-a]pyridine derivs. and study of their activity against herpesvirus)
RN 437611-99-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-76-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-29-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-30-2 CAPLUS
CN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460078-31-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 460078-33-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-(cyclopropylmethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 460078-34-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-(cyclobutylmethoxy)phenyl)-N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 460078-35-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-36-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(1,1'-biphenyl)-4-yl-N-butyl-3-(2-(butylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 460078-38-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-(2-(butylamino)-4-pyrimidinyl)-2-(4-(cyclohexylamino)phenyl)- (9CI) (CA INDEX NAME)




RN 460078-44-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-(dimethylamino)phenyl)- (9CI) (CA INDEX NAME)




RN 460078-50-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[1,1'-biphenyl-3-yl]-N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 460078-56-2 CAPLUS
CN Acetamide, N-[3-(7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-57-3 CAPLUS
CN Methanesulfonamide, N-[3-(7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-59-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 460078-61-9 CAPLUS
CN Benzamide, 3-[7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-62-0 CAPLUS
CN Benzoic acid, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-66-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460078-75-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-76-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 460078-77-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460079-24-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 866393-63-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(4-(1-methylpropoxy)phenyl)]- (9CI) (CA INDEX NAME)




IT 460078-70-0P 460079-65-6P 866393-64-8P
866393-65-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyrimidinyl)phenyl)pyrazolo[1,5-a]pyridine derivs. and study of their activity against herpesvirus)
RN 460078-70-0 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-65-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 866393-64-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[(4-(1-methylpropoxy)phenyl)]- (9CI) (CA INDEX NAME)



RN 866393-65-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-[(diphenylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

15 ANSWER 15 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:202833 CAPLUS
DOCUMENT NUMBER: 142:430228
TITLE: Pyrazolopyridine antitherapeutics: SAR of C2' and C7 amine substituents
AUTHOR(S): Johns, Brian A.; Gudmundsson, Kristjan S.; Turner,

Elizabeth M.; Allen, Scott H.; Samano, Vicente A.; Ray, John A.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie J.; Selleseth, Dean W.; Creech, Katrina L.; Moniri, Kelly R.

GlaxoSmithKline Research and Development, Department of Medicinal Chemistry, Research Triangle Park, NC, 27709-3398, USA

Bioorganic & Medicinal Chemistry (2005), 13(7), 2397-2411

CODEN: BMCEP; ISSN: 0968-0896 Elsevier Ltd.

Journal English

CASREACT 142:430228

CORPORATE SOURCE:

SOURCE:


PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

GI




AB A series of potent pyrimidinylpyrazolo[1,5-a]pyridine inhibitors, e.g., I, of herpes simplex virus 1 replication have been identified. Several complementary synthetic methods were developed to allow facile access to a diverse set of analogs from common late stage intermediates. Detailed examination of the amine substituents at the C2' position of the pyrimidine and C7 position of the core pyrazolopyridine is described. The antiviral data suggested that non-polar amines were preferred for optimal activity. Adnl., the 2' position has been shown to require an NH group to retain activity levels similar to that of the gold standard acyclovir.

IT 437384-04-8P 437384-12-8P 437384-13-9P
437611-97-7P 437611-99-9P 437612-00-5P
437612-01-6P 437612-02-7P 437612-07-2P
437612-08-3P 437612-09-4P 437612-17-4P
437612-19-6P 437612-27-6P 437612-28-7P
437612-29-8P 437612-30-1P 437612-31-2P
437612-32-3P 437612-34-5P 437612-36-7P
437612-39-0P 437612-40-3P 437612-41-4P
437612-43-6P 437612-44-7P 437612-45-8P
437612-50-5P 850999-17-6P 850999-18-7P
850999-30-3P 850999-31-4P 850999-44-9P
850999-51-8P 850999-52-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation, antitherapeutic activity, and structure-activity relationship of (aminopyrimidinyl)aminopyrazolopyridines)


RN 437384-04-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437384-12-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-(4-methoxyphenyl)amino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 437384-13-9 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-(4-fluorophenyl)amino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437611-97-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


RN 437612-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-07-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-08-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-09-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(1-(4-morpholinyl)propylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437611-99-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-00-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-01-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)







RN 437612-17-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-19-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 437612-27-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[(2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyrimidin-3-yl)]- (9CI) (CA INDEX NAME)




RN 437612-28-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 437612-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 437612-31-2 CAPLUS


CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 437612-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-34-5 CAPLUS
CN 1-Propanol, 3-[[[4-(7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 437612-36-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 437612-39-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(2-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-40-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-41-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


RN 437612-43-6 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 437612-44-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 437612-45-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 437612-50-5 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 850999-17-6 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-1-pyrrolidinyl- (9CI) (CA INDEX NAME)




RN 850999-18-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 850999-30-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N,2-bis(4-fluorophenyl)-3-[2-(4-fluorophenyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 850999-31-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-(cyclopentylamino)-4-pyrimidinyl)-N,2-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 850999-44-9 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-(2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 850999-51-8 CAPLUS
CN 1-Piperazineethanol, 4-[[4-(7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 850999-52-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[[4-(2-methoxyethyl)-1-piperazinyl]amino]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




IT 401816-34-0P 401816-35-1P 437612-22-1P
437612-33-4P 437613-05-3P 437613-07-5P
437613-08-6P 468062-98-8P 850999-40-3P
850999-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, antihypertensive activity, and structure-activity relationship of (aminopyrimidinyl)aminopyrazolopyridines)
RN 401816-34-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-22-1 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 437612-33-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437613-07-5 CAPLUS
CN 2(1H)-Pyrimidinethione, 4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 437613-08-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468062-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850999-40-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 850999-41-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1068075 CAPLUS
DOCUMENT NUMBER: 142:168975
TITLE: "Lead Hopping". Validation of Topomer Similarity as a Superior Predictor of Similar Biological Activities
AUTHOR(S): Cramer, Richard D.; Jilek, Robert J.; Guesseggen, Stefan; Clark, Stephanie J.; Wendt, Bernd; Clark, Robert D.
CORPORATE SOURCE: Tripos Discovery Research, Cornwall, EX23 8LY, UK
SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6777-6791
CODEN: JMCWAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Two extensive studies quantifying the ability of topomer shape similarity to forecast a variety of biol. similarities are described. In a prospective trial of "lead hopping", using topomer similarity for virtual screening and queries from the patent literature, biol. assays of 308 selected compds. (representing 0.03% of those available, per assay type) yielded 11 successful "lead hops" in the 13 assays attempted. The hit rate averaged over all assays was 39% ("activity" defined as inhibition 220% at $10\ \mu\text{M}$), significantly greater than an unexpectedly high neg. control hit rate of 13%. The average "Tanimoto 2D fingerprint similarity" between query and "lead hop" structures (0.36) was little more than the Tanimoto similarity between random drug-like structures. Topomer shape and Tanimoto 2D fingerprint similarities were also compared retrospectively, in their tendencies to concentrate together potential and actual drugs reported to belong to the same "activity class", for twenty

classes. Among the most similar 3% of structures (corresponding to "20.85 Tanimoto" for these structures), an average of 62% of the topomer similar selection possessed a near neighbor belonging to the same activity class, roughly a one-third superiority over the "Tanimoto ≥ 0.85 " selection containing 48% actives in avoiding false positives. Conversely, the least similar 75% of structures contained 0.3% actives for topomer similarity vs. 1.0% actives for Tanimoto 2D fingerprint similarity, a 3-fold superiority for topomers in avoiding false negatives.

IT 202646-80-8
RL: PAC (Pharmacological activity); BIOL (Biological study) (validation of topomer similarity as a superior predictor of similar biol. activities of "Lead hopping")
RN 202646-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:798011 CAPLUS
DOCUMENT NUMBER: 142:148488
TITLE: Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors
AUTHOR(S): Mamoto, Takuya; Tada, Miho; Mihara, Takuma; Ueyama, Noriko; Matsuoka, Hideaki; Harada, Katsuya; Yamaji, Takayuki; Shirakawa, Kiyoharu; Kuroda, Satoru; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya; Mutoh, Seitaro
CORPORATE SOURCE: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
SOURCE: Journal of Pharmacological Sciences (Tokyo, Japan) (2004), 96(1), 42-52
CODEN: JESTGJ; ISSN: 1347-8613
PUBLISHER: Japanese Pharmacological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Adenosine A1 receptors in the brain are believed to play an important role in brain functioning. We have discovered a novel adenosine A1 receptor antagonist, FR194921 (2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone), and characterized the pharmacol. activity in the present study. FR194921 showed potent and selective affinity for the adenosine A1 receptor without affinity for A2A and A3 receptors and did not show any species differences in binding affinity profile among human, rat, and mouse. Pharmacokinetic study in rats revealed that FR194921 was orally active and highly brain penetrable. Oral administration of FR194921 dose-dependently ameliorated the hypolocomotion induced by the A1 receptor agonist N6-cyclopentyladenosine in rats, indicating this compound exerts A1-antagonistic action in vivo. In the passive avoidance test, scopolamine (1 mg/kg)-induced memory deficits were significantly ameliorated by FR194921 (0.32, 1 mg/kg). In two animal models of anxiety, the social interaction test and elevated plus maze, FR194921 showed specific anxiolytic activity without significantly influencing general behavior. In contrast, FR194921 did not show

antidepressant activity even at a dose of 32 mg/kg in the rat forced swimming test. These results indicate that the novel, potent, and selective adenosine A1 receptor antagonist FR194921 exerts both cognitive-enhancing and anxiolytic activity, suggesting the therapeutic potential of this compound for dementia and anxiety disorders.

IT 202646-80-8, FR 194921
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Pharmacol. characterization of FR194921)
RN 202646-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:343857 CAPLUS
DOCUMENT NUMBER: 141:405831
TITLE: Effects of the adenosine A1 receptor inhibitor FK 838 on proximal tubular fluid output in rats
AUTHOR(S): Bak, Martin; Thomsen, Klaus
CORPORATE SOURCE: Institute for Basic Psychiatric Research, Department of Biological Psychiatry, Aarhus University Hospital, Risskov, DK-8240, Den.
SOURCE: Nephrology, Dialysis, Transplantation (2004), 19(5), 1077-1082
CODEN: NDTREA; ISSN: 0931-0509
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background. Adenosine A1 receptor blockade has been suggested as a treatment in conditions with sodium and fluid retention because it increases urinary Na⁺ excretion and increases proximal tubular fluid output. In the present study, we examine the time course for the renal responses to adenosine A1 receptor blockade in order to investigate whether the effects may be prolonged and not just temporary. Methods. The acute effects of the adenosine A1 receptor inhibitor FK 838 on segmental tubular Na⁺ handling were examined by a renal clearance technique in conscious chronically instrumented rats. Lithium clearance (CLi) was used as a clearance marker of proximal tubular fluid output. Results. Acute adenosine A1 receptor inhibition did not affect the glomerular filtration rate (GFR) significantly. In contrast, the inhibition led to significant increases in CLi (from 290±28 to 431±28 µl/min/100 g), fractional Li⁺ excretion (FELi) (from 33±2 to 47±3%) and fractional Na⁺ excretion (FENA) (from 0.44±0.07 to 2.03±0.42%). Sodium excretion, expressed as a fraction of proximal tubular fluid output (CNa/CLi), rose from 1.3±0.2 to 4.2±0.4%, suggesting that the natriuretic effect was supported by inhibition of distal nephron Na⁺ reabsorption. All values returned to baseline values during the clearance study and thereby indicated that neither proximal tubular fluid output nor urinary sodium excretion remained elevated for a prolonged time. Conclusion. It is concluded that in conscious unstressed rats, acute adenosine A1 receptor inhibition by FK 838 led to a significant natriuresis that was caused by inhibition of proximal tubular Na⁺

reabsorption, possibly with a contribution from inhibition of distal nephron Na⁺ reabsorption. The increased proximal tubular fluid output and the increased urinary Na⁺ excretion returned to baseline values during the clearance study, indicating that none of these effects of adenosine A1 blockade were long lasting.

IT 131185-37-0, FR 838
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diuretic FK 838 increased CLi, FELi, CNa/CLi and FENA without causing any significant change in GFR in conscious rat showing that natriuretic effect was due to combined effect on proximal tubules and distal nephron)
RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 19 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:333716 CAPLUS
DOCUMENT NUMBER: 140:337367
TITLE: Preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection
INVENTOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033454	A1	20040422	WO 2003-US30334	20030924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003275266	A1	20040504	AU 2003-275266	20030924
EP 1546148	A1	20050629	EP 2003-759540	20030924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MK, PT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504728	T	20060209	JP 2004-543022	20030924
US 2005282842	A1	20051222	US 2005-530101	20050401
US 7153863	B2	20061226		
US 2007112014	A1	20070517	US 2006-554615	20061031

PRIORITY APPLN. INFO.:
US 2002-415939P P 20021003


WO 2003-US30334 W 20030924
US 2005-530101 A3 20050401
OTHER SOURCE(S): MARPAT 140:357367
GI




AB The title componds. [I: p = 0-4; R1 = halo, alkyl, cycloalkyl, etc.; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; R5 = H, halo, alkyl, etc.] were prepared. Thus, coupling 2-fluoro-4-iodopyridine with pentene followed by reacting 3-fluoro-4-(pent-1-ynyl)pyridine with 1-aminopyridinium iodide afforded 3-(2-fluoropyridin-4-yl)-2-propylpyrazolo[1,5-a]pyridine which showed IC50 of >40 µM against HSV-1. The pharmaceutical compns. comprising the compound I are claimed.

IT 681262-20-4P, 2-Cyclopropyl-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 681262-21-5P, N-Cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681262-22-6P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-cyclopropylpyrazolo[1,5-a]pyridin-7-amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection)

RN 681262-20-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-cyclopropyl-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681262-21-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 681262-22-6 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-cyclopropyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

I5 ANSWER 20 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:267334 CAPLUS
DOCUMENT NUMBER: 140:303661
TITLE: Preparation of pyrazolopyridines as TGF-β signal transduction inhibitors useful against cancer and other diseases

INVENTOR(S): Beight, Douglas Wade; Bonjoukian, Rosanne; Liao, Junkai; McMillen, William Thomas; Parkhurst, Brandon Lee; Sawyer, Jason Scott; Yingling, Jonathan Michael; York, Jeremy Schulenburg
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 98 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026871	A1	20040401	WO 2003-US26297	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003268156	A1	20040408	AU 2003-268156	20030916
EP 1543001	A1	20050622	EP 2003-749105	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005222197	A1	20051006	US 2005-524577	20050215
PRIORITY APPLN. INFO.: US 2002-411560P			WO 2003-US26297	W 20030916
OTHER SOURCE(S): MARPAT 140:303661				
GI				




AB Novel pyrazolopyridines (shown as I; variables defined below; e.g. II) are disclosed and their use as pharmaceutical agents, in particular their use as TGF- β signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF β . Inhibitory activities (IC50 in μ M) for >100 examples of I against TGF- β type I receptor kinase, TGF- β type II receptor kinase, p38 α /SRPK2 α , and TGF- β dependent luciferase production was at least 10, 20, 20, and 20, resp.; several specific values in each case are reported, e.g. 0.102 μ M for 4-[(2-(5-butylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinoline] in the TGF- β type I receptor kinase test. Although the methods of preparation are not claimed, approx. 130 I and approx. 90 intermediate example preps. and/or characterization data are included. For example, II was prepared (62 %) by coupling 3-bromo-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine with p-fluorophenylboronic acid. The pyridine reactant was prepared by action of N-bromosuccinimide on 2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid, which was prepared by base hydrolysis of 2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid Et ester, which was prepared by cyclization of 1-aminopyridinium iodide with (6-methylpyridin-2-yl)propynoic acid Et ester, which was prepared by reaction of Et chloroformate and BuLi with 2-ethyl-6-methylpyridine, which was prepared from 2-bromo-6-methylpyridine and trimethylsilylacetylene. For I: R1 is (un)substituted pyridine, furyl or thiophenyl; R2 is (un)substituted quinoline, Ph, naphthalene, pyridine, quinazoline, cinnoline, indole, imidazo[1,2-a]pyridin-2-yl, benzofuran, dihydrobenzofuran, dihydrobenzo[1,4]dioxane, benzodioxolane, benzothiofuran, 2-aminobenzimidazole, imidazo[1,2-a]pyridine. R7 is H, benzyl, aryl, Cl-C4 alkyls, halogen, -CO2(Cl-C4 alkyl), -CONR6R6, -Cl-C4 alc., -SO2(Cl-C4 alkyl), or -COR8, wherein R6 is (Cl-C4 alkyl)R9, R8 is (Cl-C4 alkyl) or (C2-C4 alkenyl), and R9 is NR3R4; wherein R3 and R4 = (Cl-C4 alkyl); addnl. details are given in the claims.

IT 676343-50-3p, 7-Methoxy-4-[(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinoline-3-yl]quinoline 676343-74-1p, 2-Fluoro-5-[(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-84-3p, 4-[(2-(6-chloropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinoline-3-yl]quinoline 676344-03-9p, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid ethyl ester 676344-04-0p, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-4-carboxylic acid ethyl ester 676344-14-2p, 7-Bromo-4-[(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinoline-3-yl]quinoline 676344-19-7p, 2-(6-Chloropyridin-2-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 676344-23-3p, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-bromoquinoline 676344-24-4p, 2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid ethyl ester 676344-25-5p, 2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid ethyl ester 676344-29-9p, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid methyl ester 676344-40-4p, 3-[4-[(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinolin-7-yl]acrylic acid


methyl ester 676344-54-0p, [3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-6-yl]methanol
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; Preparation of pyrazolopyridines as TGF- β signal transduction inhibitors useful against cancer and other diseases)
 RN 676343-50-3 CAPLUS
 CN Quinoline, 7-methoxy-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676343-52-5 CAPLUS
 CN Quinoline, 7-methoxy-4-[(2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI)
 (CA INDEX NAME)




RN 676343-74-1 CAPLUS
 CN Benzaldehyde, 2-fluoro-5-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676343-84-3 CAPLUS
 CN Quinoline, 4-[(2-(6-chloro-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI)
 (CA INDEX NAME)




RN 676344-03-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 676344-04-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 676344-14-2 CAPLUS
CN Quinoline, 7-bromo-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-19-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-chloro-2-pyridinyl)-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 676344-23-3 CAPLUS
CN Quinoline, 7-bromo-4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-24-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 2-(2-pyridinyl)-3-(4-quinolinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 676344-25-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(2-pyridinyl)-3-(4-quinolinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 676344-29-9 CAPLUS
CN 7-Quinolincarboxylic acid, 4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 676344-40-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 676344-54-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




IT 676343-55-8P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-58-1P, Dimethyl[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]amine 676343-59-2P, 3-(4-Methoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-60-3P, 3-[4-(Methanesulfonyl)phenyl]-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-61-6P, 2-(6-Methylpyridin-2-yl)-3-phenylpyrazolo[1,5-a]pyridine 676343-62-7P, 2-(6-Methylpyridin-2-yl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyridine 676343-63-8P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-6-phenylpyrazolo[1,5-a]pyridine 676343-64-9P, 3-(4-Fluorophenyl)-6-methanesulfonyl-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-65-0P, 2-(6-Methylpyridin-2-yl)-3-(4-trifluoromethylphenyl)pyrazolo[1,5-a]pyridine 676343-66-1P, 3-(6-Methoxypyridin-3-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-67-2P, 3-(Benzodioxol-5-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-68-3P, 3-(3,5-Difluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-69-4P, 2-(6-Methylpyridin-2-yl)-3-(p-tolyl)pyrazolo[1,5-a]pyridine 676343-70-7P, 3-(1H-Indol-5-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-71-8P, 3-[2-(6-Methylpyridin-2-

yl)pyrazolo[1,5-a]pyridin-3-yl]benzamide 676343-72-9P, 3-(3,4-Dimethoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-73-0P, N,N-Dimethyl-3-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzamide 676343-75-2P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenylamine 676343-76-3P, N-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]acetamide 676343-77-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenol 676343-78-5P, 3-(2,3-Dihydro-benzof[1,4]dioxin-6-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-79-6P, 3-(3-Methoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-80-9P, 3-(3-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-81-0P, 2-(6-Ethylpyridin-2-yl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine 676343-82-1P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenol 676343-83-2P, N-[2-Fluoro-5-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzyl]-N,N-dimethylethane-1,2-diamine 676343-85-4P, 3-(4-Fluorophenyl)-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-86-5P, 7-Ethoxy-4-[4-phenyl]-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-87-6P, 7-Ethoxy-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-88-7P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-89-8P, 7-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-90-1P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-91-2P, 6,7-Dimethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-92-3P, 7-Chloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-93-4P, 6-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-94-5P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-95-6P, 4-[2-(Furan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-96-7P, 4-[2-(Thiophen-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-97-8P, 6,7-Difluoro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-98-9P, 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-99-0P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-100-6P, 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-01-7P, 7-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-02-8P, 2-(6-Ethylpyridin-2-yl)-3-(4-fluoronaphthalen-1-yl)pyrazolo[1,5-a]pyridine 676344-05-1P, 3-(4-Fluorophenyl)-4-iodo-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-06-2P, 3-(4-Fluorophenyl)-2-(6-propylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-07-3P, 2-(6-Ethylpyridin-2-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 676344-08-4P, 3-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-09-5P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-10-8P, 4-[2-(6-Fluoropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-11-9P, 4-[2-(3-Butylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-12-0P, 8-Fluoro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-13-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-6-trifluoromethylquinoline 676344-15-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-trifluoromethylquinoline 676344-16-4P, 3-(3-Chloro-4-fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-17-5P, 2-(6-Methylpyridin-2-yl)-3-(12,4,5-trifluorophenyl)pyrazolo[1,5-a]pyridine 676344-18-6P, 3-(4-Fluoro-3-trifluoromethylphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-20-0P, 4-[2-(5-Bromopyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-21-1P, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-22-2P, 4-[5-Benzyl-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-bromoquinoline 676344-26-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-

carboxylic acid methyl ester 676344-27-P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-6-carboxylic acid methyl ester 676344-30-2P, 3-(4-Fluorophenyl)-2-[6-methylpyridin-2-yl]pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylaminoethyl)amide 676344-31-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 676344-32-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (2-dimethylaminoethyl)amide 676344-33-5P, 5-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzofuran-2-carboxylic acid (2-dimethylaminoethyl)amide 676344-34-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-(4-methylpiperazin-1-yl)propyl)amide 676344-35-7P, 4-[2-(6-Methoxypyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-36-8P, 4-[2-(6-Ethoxypyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-37-9P, 3-(4-Fluorophenyl)-2-(6-methoxypyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-38-0P, 2-(6-Ethoxypyridin-2-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 676344-39-1P, 7-Benzyl-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-41-5P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]acrylic acid 676344-42-6P, 4-[2-(6-Ethylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-43-7P, 4-[2-(6-Phenylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-44-8P, 4-[2-(6-Morpholin-4-yl)pyridin-2-yl]pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-45-9P, 3-(4-Fluorophenyl)-2-(6-methylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-46-0P, 3-(4-Methylsulfonylphenyl)-2-(6-methylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-47-1P, Dimethyl[2-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]sulfonyl]ethyl]amine 676344-48-2P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid dimethylamide 676344-49-3P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid dimethylamide 676344-50-6P, 4-[2-(6-Vinylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-51-7P, 6-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]imidazo[1,2-a]pyridin-2-yl]amine 676344-52-8P, 6-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-1H-benzimidazol-2-yl]amine 676344-55-1P, 6-[(Alliloxymethyl)-3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(pyrrolidin-1-yl)propyl]amide 676344-57-3P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]propionamide 676344-58-4P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]-N-[3-(pyrrolidin-1-yl)propyl]propionamide 676344-59-5P, N-(2-Dimethylaminoethyl)-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]propionamide 676344-60-6P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid (3-dimethylaminopropyl)amide 676344-61-9P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (2-hydroxyethyl)amide 676344-62-0P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic hydrazide 676344-63-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-hydroxypropyl)amide 676344-64-2P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid methylamide 676344-65-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-ethoxypropyl)amide 676344-66-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(morpholin-4-yl)propyl]amide 676344-67-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(imidazol-1-yl)propyl]amide 676344-68-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-dimethylaminopropyl)amide 676344-69-7P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-


carboxylic acid [2-(2-methoxyphenyl)ethyl]amide 676344-70-0P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [2-(morpholin-4-yl)ethyl]amide 676344-71-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid amide 676344-72-2P, Dimethyl[3-[[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]pyrazolo[1,5-a]pyridin-7-yl]oxy]propyl]amine 676344-73-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(morpholin-4-yl)ethoxy]quinoline 676344-74-4P, Disopropyl[2-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-75-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]ethoxyquinoline 676344-76-6P, Dimethyl[1-methyl-2-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]ethoxy]ethyl]amine 676344-77-7P, Methyl[3-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]pyrazolo[1,5-a]pyridin-7-yl]oxy]ethyl]amine 676344-78-8P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(piperidin-1-yl)ethoxy]quinoline 676344-79-9P, Diethyl[2-[[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-80-2P, Dimethyl[3-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-81-3P, 7-[2-(Morpholin-4-yl)ethoxy]-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-82-4P, Disopropyl[2-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-83-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(morpholin-4-yl)propoxy]quinoline 676344-84-6P, 1-[3-[[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]-1,3-dihydrobenzimidazol-2-one 676344-85-7P, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]propionic acid methyl ester 676344-86-8P, Diethyl[3-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-87-9P, [5ethyl]methyl[3-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]propyl]amine 676344-88-0P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(Piperidin-1-yl)propoxy]quinoline 676344-89-1P, 7-[3-(Piperidin-1-yl)propoxy]-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-90-4P, Diethyl[2-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine 676344-91-5P, Dimethyl[2-[[4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]oxy]ethyl]amine




RN 676343-58-1 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

(drug candidate; preparation of pyrazolopyridines as TGF- β signal transduction inhibitors useful against cancer and other diseases)
RN 676343-55-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


(Therapeutic use): BIOL (Biological study); PREP (Preparation); USES (Uses)




RN 676343-59-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-methoxyphenyl)-2-(6-methyl-2-pyridinyl)-phenyl- (9CI) (CA INDEX NAME)




RN 676343-60-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676343-61-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 676343-62-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-63-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 676343-64-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676343-65-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676343-66-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-67-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(1,3-benzodioxol-5-yl)-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 676343-68-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3,5-difluorophenyl)-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 676343-69-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-methylphenyl)-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 676343-70-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(1H-indol-5-yl)-2-(6-methyl-2-pyridinyl)-
(CA INDEX NAME) (9CI)




RN 676343-71-8 CAPLUS
CN Benzamide, 3-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(CA INDEX NAME) (9CI)




RN 676343-72-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3,4-dimethoxyphenyl)-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 676343-73-0 CAPLUS
CN Benzamide, N,N-dimethyl-3-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 676343-75-2 CAPLUS
CN Benzenamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 676343-76-3 CAPLUS
CN Acetamide, N-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 676343-77-4 CAPLUS
CN Phenol, 4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676343-78-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-79-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methoxyphenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-80-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-81-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 676343-82-1 CAPLUS
CN Phenol, 4-[(2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676343-83-2 CAPLUS
CN 1,2-Ethanediamine, N'-[(2-fluoro-5-{2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl}phenyl)methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 676343-85-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-86-5 CAPLUS
CN Quinoline, 7-ethoxy-4-(4-phenyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-87-6 CAPLUS
CN Quinoline, 7-ethoxy-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-88-7 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-89-8 CAPLUS
CN Quinoline, 7-ethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-90-1 CAPLUS
CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676343-91-2 CAPLUS
CN Quinoline, 6,7-dimethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-92-3 CAPLUS
CN Quinoline, 7-chloro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-93-4 CAPLUS
CN Quinoline, 6-ethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


CN Quinoline, 6,7-difluoro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-98-9 CAPLUS
CN Quinoline, 6,7-dichloro-4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-99-0 CAPLUS
CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 676344-00-6 CAPLUS
CN Quinoline, 6,7-dichloro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-94-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluoro-1-naphthalenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-95-6 CAPLUS
CN Quinoline, 4-[2-(2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-96-7 CAPLUS
CN Quinoline, 4-[2-(2-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-97-8 CAPLUS




RN 676344-01-7 CAPLUS
CN Quinoline, 7-ethoxy-4-([2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 676344-02-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-fluoro-1-
naphthalenyl)- (9CI) (CA INDEX NAME)




RN 676344-05-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-4-iodo-2-(6-methyl-2-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-06-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-propyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 676344-07-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 676344-08-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-pyridinyl)-3-(4-pyridinyl)- (9CI) (CA INDEX
NAME)




RN 676344-09-5 CAPLUS
CN Quinoline, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA
INDEX NAME)




RN 676344-10-8 CAPLUS
CN Quinoline, 4-[2-(6-fluoro-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 676344-11-9 CAPLUS
CN Quinoline, 4-[2-(5-butyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 676344-12-0 CAPLUS
CN Quinoline, 8-fluoro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-13-1 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 676344-15-3 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676344-16-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-chloro-4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-17-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(2,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)


(phenylmethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-26-6 CAPLUS
CN 7-Quinolincarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676344-27-7 CAPLUS
CN 6-Quinolincarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676344-30-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-31-3 CAPLUS




RN 676344-18-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-fluoro-3-(trifluoromethyl)phenyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 676344-20-0 CAPLUS
CN Quinoline, 4-[2-(5-bromo-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-21-1 CAPLUS
CN Quinoline, 4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-22-2 CAPLUS
CN Quinoline, 7-bromo-4-[2-(6-methyl-2-pyridinyl)-5-


CN 6-Quinolinescarboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-32-4 CAPLUS
CN 7-Quinolinescarboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-33-5 CAPLUS
CN 2-Benzofurancarboxamide, N-[2-(dimethylamino)ethyl]-5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-34-6 CAPLUS
CN 7-Quinolinescarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-35-7 CAPLUS
CN Quinolines, 4-[2-(6-methoxy-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-36-8 CAPLUS
CN Quinolines, 4-[2-(6-ethoxy-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-37-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-38-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethoxy-2-pyridinyl)-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 676344-39-1 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 676344-41-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]- (9CI) (CA INDEX NAME)




RN 676344-42-6 CAPLUS
CN Quinoline, 4-[2-[6-(ethylthio)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-43-7 CAPLUS
CN Quinoline, 4-[2-[6-(phenylthio)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-44-8 CAPLUS
CN Quinoline, 4-[2-[6-(4-morpholinyl)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-45-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-[6-(methylthio)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 676344-46-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylthio)phenyl]-2-[6-(methylthio)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 676344-47-1 CAPLUS
CN Ethanamine, N,N-dimethyl-2-[[4-(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl)thio]- (9CI) (CA INDEX NAME)



Me₂N-CH₂-CH₂-S
RN 676344-48-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N,N-dimethyl-2-(2-pyridinyl)-3-(4-quinolinyl)- (9CI) (CA INDEX NAME)




Me₂N-C(=O)-
RN 676344-49-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N,N-dimethyl-2-(2-pyridinyl)-3-(4-quinolinyl)- (9CI) (CA INDEX NAME)




RN 676344-50-6 CAPLUS
CN Quinoline, 4-[2-(6-ethenyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)


(CA INDEX NAME)




RN 676344-51-7 CAPLUS
CN Imidazo[1,2-a]pyridin-2-amine, 6-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676344-52-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-[(2-propenyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 676344-56-2 CAPLUS
CN 7-Quinolincaboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


RN 676344-60-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[3-(dimethylamino)propyl]-2-(2-pyridinyl)-3-(4-quinolinyl)- (9CI) (CA INDEX NAME)




RN 676344-61-9 CAPLUS
CN 7-Quinolincarboxamide, N-(2-hydroxyethyl)-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-62-0 CAPLUS
CN 7-Quinolincarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrazide (9CI) (CA INDEX NAME)




RN 676344-63-1 CAPLUS
CN 7-Quinolincarboxamide, N-(3-hydroxypropyl)-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-57-3 CAPLUS
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-58-4 CAPLUS
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 676344-59-5 CAPLUS
CN 7-Quinolincarboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)







RN 676344-64-2 CAPLUS
CN 7-Quinolonecarboxamide, N-methyl-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-65-3 CAPLUS
CN 7-Quinolonecarboxamide, N-(3-ethoxypropyl)-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-66-4 CAPLUS
CN 7-Quinolonecarboxamide, 4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 676344-67-5 CAPLUS
CN 7-Quinolonecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-68-6 CAPLUS
CN 7-Quinolonecarboxamide, N-[3-(dimethylamino)propyl]-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-69-7 CAPLUS
CN 7-Quinolonecarboxamide, N-(2-(2-methoxyphenyl)ethyl)-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-70-0 CAPLUS
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 676344-71-1 CAPLUS
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-72-2 CAPLUS
CN 1-Propanamine, N,N-dimethyl-3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-73-3 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 676344-74-4 CAPLUS
CN 2-Propanamine, N-(1-methylethyl)-N-[2-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 676344-75-5 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(1H-pyrol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 676344-76-6 CAPLUS
CN 2-Propanamine, N,N-dimethyl-1-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-77-7 CAPLUS
CN 1-Propanamine, N-methyl-3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-

alpyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




MeNH- (CH₂)₃-O-

RN 676344-78-8 CAPLUS
CN Quinoline, 4-[2-[6-methyl-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 676344-79-9 CAPLUS
CN Ethanamine, N,N-diethyl-2-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




Et₂N-CH₂-CH₂-O-

RN 676344-80-2 CAPLUS
CN 1-Propanamine, N,N-dimethyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




O- (CH₂)₃-NMe₂


RN 676344-81-3 CAPLUS
CN Quinoline, 7-[2-[4-morpholinyl]ethoxy]-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-82-4 CAPLUS
CN 2-Propanamine, N-(1-methylethyl)-N-[2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 676344-83-5 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 676344-84-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 676344-85-7 CAPLUS
CN 7-Quinolonepropanoic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676344-86-8 CAPLUS
CN 1-Propanamine, N,N-diethyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-87-9 CAPLUS
CN 1-Propanamine, N-ethyl-N-methyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-88-0 CAPLUS
CN Quinolone, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 676344-89-1 CAPLUS
CN Quinolone, 7-[3-(1-piperidinyl)propoxy]-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676344-90-4 CAPLUS
CN Ethanamine, N,N-diethyl-2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-91-5 CAPLUS
CN Ethanamine, N,N-dimethyl-2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




IT 676344-28-8, 6-Bromo-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as TGF-β signal transduction inhibitors useful against cancer and other diseases)


RN 676344-28-8 CAPLUS
CN Quinoline, 6-bromo-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




IT 676343-49-0P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-ol 676343-51-4P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-ol 676343-53-6P, 7-(3-Chloropropoxy)-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-54-7P, 7-(2-Chloroethoxy)-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-53-9P, [6-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-1-(propan-2-ylsulfonyl)-1H-benzimidazol-2-yl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as TGF- β signal transduction inhibitors useful against cancer and other diseases)
RN 676343-49-0 CAPLUS
CN 7-Quinolol, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 676343-51-4 CAPLUS
CN 7-Quinolol, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-53-6 CAPLUS
CN Quinoline, 7-(3-chloropropoxy)-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676343-54-7 CAPLUS
CN Quinoline, 7-(2-chloroethoxy)-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676344-53-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[[1-(methylethyl)sulfonyl]-6-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 21 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:220201 CAPLUS
DOCUMENT NUMBER: 140:270867
TITLE: Preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4
INVENTOR(S): Lee, Wen-Cherng; Carter, Mary Beth; Sun, Lihong; Lyne, Paul; Chuang, Claudio; Zheng, Zhongli; Singh, Jusvinder; Boriack-Sjodin, Paula
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2004022054
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, LC, LG, LI, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CA 2497970 AU 20040318 WO 2003-2497970 20030905
AU 2003268447 AU 20040329 CA 2003-268447 20030905
EP 1531398 AU 20050713 EP 2003-749412 20030905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003014053 A 20050719 BR 2003-14053 20030905
CN 1694698 A 20051109 CN 2003-824867 20030905
JP 2006502165 T 20060119 JP 2004-534571 20030905
NZ 539069 A 20070330 NZ 2003-539069 20030905
IN 2005DN00810 A 20070302 IN 2005-DN810 20050302
ZA 2005001856 A 20060426 ZA 2005-1856 20050303
NO 2005001503 A 20050321 NO 2005-1503 20050321
US 2006106033 A 20060518 US 2005-526839 20051101
P 20020906
US 2002-408811P 20020906
WO 2003-US27722 20030905
MARPAT 140:270867

OTHER SOURCE(S):
GI

PRIORITY APPL. INFO.:



AB The title compds. [I; wherein each of X1-X4 is independently CRx or N; provided that only two of X1-X4 can be N simultaneously; each of Y1 and Y2 is independently CRy or N; provided that at least one of Y1 and Y2 must be N; R1 = alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfonyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxy, carbonyl, cycloalkyl, cycloalkoxy, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkoxy, cycloalkylsulfonyl, heterocycloalkyl, heterocycloalkoxy, etc.; R2 = alkyl, alkenyl, alkynyl, acyl, halo, hydroxy, NH2, NH(alkyl), N(alkyl)2, NH(cycloalkyl), N(alkyl)(cycloalkyl), NH(heterocycloalkyl), NH(heteroaryl), NH-alkylheterocycloalkyl, NH-alkylheteroaryl, NH(aralkyl), cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, aroyl, heterocycloalkyl, (heterocycloalkyl)alkyl, etc.; m = an integer of 0-4; n = an integer of 0-3; provided that when m > 2, two adjacent R1 or R2 groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety; Rx, Ry = H, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfonyl, alkylsulfinyl, alkylsulfonyl, cycloalkylcarbonyl, (cycloalkyl)alkylcarbonyl, aroyl, aralkylcarbonyl, etc.] or pharmaceutically acceptable salts or N-oxides thereof. These compds. possess unexpectedly high affinity for transforming growth factor β .


(TGF β) type I receptor (Alk 5) and/or activin receptor type I (Alk 4), and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders or diseases or disorders mediated by an overexpression of TGF β . The fibrotic condition is selected from the group consisting of scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis, restenosis, cardiac fibrosis, peritoneal scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, and keloid. The diseases or disorders mediated by an overexpression of TGF β are selected from the group consisting of demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.

IT 672932-46-6P, [4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 672932-50-2P, [4-(2-Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 672932-51-3P, 2-(6-Methylpyridin-2-yl)-3-(2-methylsulfonylpyrimidin-4-yl)pyrazolo[1,5-a]pyridine


RI: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4 for treating fibrotic disorders or diseases or disorders mediated by an overexpression of TGF β)

RN 672932-46-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 672932-50-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 672932-51-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(2-methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


RN 437612-03-8 CAPLUS
CN 2-Pyrimidinamine, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl]- (9CI) (CA INDEX NAME)




RN 437612-22-1 CAPLUS
CN 2-Pyrimidinamine, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 437612-48-1 CAPLUS
CN 2-Pyrimidinamine, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl]- (9CI) (CA INDEX NAME)



RN 437612-94-7 CAPLUS
CN 2-Pyrimidinamine, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

I5 ANSWER 22 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:827761 CAPLUS
DOCUMENT NUMBER: 140:59556
TITLE: novel class of antihyperpetics
Pyrazolo[1,5-a]pyridines: synthetic approaches to a
AUTHOR(S): Johns, Brian A.; Gudmundsson, Kristjan S.; Turner, Elizabeth M.; Allen, Scott H.; Jung, David K.; Sexton, Connie J.; Boyd, F. Leslie; Peel, Michael R. Department of Medicinal Chemistry and Department of Virology, GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709-3398, USA
Tetrahedron (2003), 59(45), 9001-9011
CODEN: TETRAH; ISSN: 0040-4020
Elsevier Science B.V.
JOURNAL

OTHER SOURCE(S): CASREACT 140:59556
AB Synthesis of a novel class of 7-amino-3-pyrimidinylpyrazolo[1,5-a]pyridine antihyperpetic compds. is described. The synthetic methodol. is designed to allow for rapid analog synthesis around the C-3 and C-7 positions of the pyrazolo[1,5-a]pyridine. 7-Chloropyrazolo[1,5-a]pyridine, produced through an azirine rearrangement, served as a key building block. Two complementary methodologies for construction of the C-3 pyrimidine are described. These methods include the development of a novel cyclization utilizing alkynyl ketones or enones to give highly substituted pyrimidines. The outlined strategies facilitated late stage manipulation of either the C-3 or C-7 positions providing flexibility for rapid analog synthesis. Compds. thus prepared included N-[3-{2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-1,2-ethanediolamine, N-cyclopentyl-3-{2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-{2-(cyclopentylamino)-6-methyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-{2-(cyclopentylamino)-6-methyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-[3-{2-(cyclopentylamino)-6-methyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]glycine Me ester, etc. Only the preparation of these compds. was reported; pharmacol. data were not given. 437612-03-8P, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl]-2-pyrimidinamine 437612-22-1P, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl]-2-pyrimidinamine 437612-48-1P, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]-2-pyrimidinamine 437612-94-7P, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]-2-pyrimidinamine 437612-97-0P, 4-[[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl-2-pyrimidinamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolo[1,5-a]pyridine derivs.)


IT

pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-04-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-10-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-11-8 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 437612-97-0 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)




IT


437611-97-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-04-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-10-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl-2-pyrimidinamine 437612-11-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl-2-pyrimidinamine 437612-12-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-[[tetrahydro-2H-pyran-2-yl]oxylmethyl]-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-15-2P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-2-pyrimidinamine hydrochloride 437612-16-3P, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-1,2-ethanediamine 437612-19-6P, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-20-9P, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]glycine methyl ester 437612-49-2P, N-Cyclopentyl-3-[2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-78-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of pyrazolo[1,5-a]pyridine derivs.)

RN 437611-97-7 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-




RN 437612-12-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-fluorophenyl]pyrazolo[1,5-a]pyridin-7-amine, N-[[2-(cyclopentylamino)-6-phenyl-4-fluorophenyl]pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 437612-16-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 437612-15-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 437612-19-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 437612-20-9 CAPLUS
CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)


NAME)



RN 437612-49-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437612-78-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

I5 ANSWER 23 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:740795 CAPLUS
DOCUMENT NUMBER: 139:301697
TITLE: An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats


AUTHOR(S): Schnackenberg, Christine G.; Merz, Emily; Brooks, David P.
CORPORATE SOURCE: Department of Renal Biology, UW-2521, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA
SOURCE: British Journal of Pharmacology (2003), 139(8), 1383-1388
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 1 Loop and thiazide diuretics are common therapeutic agents for the treatment of sodium retention and edema. However, resistance to diuretics and decreases in renal function can develop during diuretic therapy. Adenosine causes renal vasoconstriction, sodium resorption, and participates in the tubuloglomerular feedback mechanism for the regulation of glomerular filtration rate. 2 We tested the hypothesis that the selective adenosine A1 receptor antagonist FK838 is orally active and causes diuresis and natriuresis, but maintains glomerular filtration rate in normal rats or in rats with furosemide resistance. 3 In normal male Sprague-Dawley rats, FK838 dose-dependently increased urine flow and sodium and chloride excretion while sparing potassium. In combination with furosemide, FK838 enhanced the diuretic and natriuretic actions of furosemide to the same extent as hydrochlorothiazide and did not increase the potassium loss in normal rats. In furosemide-resistant rats, FK838 increased urine flow and electrolyte excretion to a greater extent than hydrochlorothiazide. In addition, hydrochlorothiazide significantly decreased glomerular filtration rate, whereas FK838 maintained glomerular filtration rate in furosemide-resistant rats. 4 This study shows that the adenosine A1 receptor antagonist FK838 is orally active and causes potent diuresis and natriuresis and maintains glomerular filtration rate in normal or furosemide-resistant rats. Adenosine A1 receptor antagonists may be novel therapeutics for the treatment of edema in normal or otherwise diuretic-resistant patients.

IT 131185-37-0, FK838
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
 (orally active adenosine A1 receptor antagonist, FK838, increases renal
 excretion and maintains glomerular filtration rate in
 furosemide-resistant rats)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:652131 CAPLUS
 DOCUMENT NUMBER: 139:214237

TITLE: Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
 Scaramuzzino, Giovanni

INVENTOR(S): Italy
 PATENT ASSIGNEE(S): Eur. Pat. Appl., 313 pp.
 SOURCE: CODEN: EPXXDM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPL. INFO.: EP 2002-425075 20020213				




AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as 8-tocopherol, clidanac, diethyhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thioinitrite, SNO, etc.; T = OR1-M, OR1R1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc.; R1 = saturated or unsatd., linear or

branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd., optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OR, SH, F, Cl, Br, OFO3R2, CO2H, etc.; bond between F and Y = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, O2-M2, NR2R1-M; ZM2 = COCH2CH(M2)CH2N-Me3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared. For example, 8-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT 586347-52-6P
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)

RN 586347-52-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-, mononitrate (9CI) (CA INDEX NAME)

CM: 1
 CRN 340321-70-2
 CMF C20 H17 N3 O3 S



CM 2
 CRN 7697-37-2
 CMF H N O3




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:472515 CAPLUS
 DOCUMENT NUMBER: 139:53015
 TITLE: Preparation of pyrazolopyridine derivatives as

antiherpes agents
 Gudmundsson, Kristjan; Johns, Brian A.
 Smithkline Beecham Corporation, USA
 PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 Patent
 English
 1


INVENTOR(S):
 PATENT ASSIGNEE(S):
 SOURCE:
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT:
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050120	A1	20030619	WO 2002-US37052	20021120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UM, VC, VU, ZA, ZM, ZW				
RW: GH, GM, KE, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
AU 2002357740	A1	20030623	AU 2002-357740	20021120
EP 1453830	A1	20040908	EP 2002-792278	20021120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005316916	T	20050609	JP 2003-551144	20021120
US 2004248903	A1	20041209	US 2004-496358	20040520
US 7199120	B2	20070403	US 2001-339585P	P 20011211
PRIORITY APPL. INFO.:			WO 2002-US37052	W 20021120
OTHER SOURCE(S):			MARPAT 139:53015	




AB Pyrazolopyridines I (R = (un)substituted aryl, heteroaryl; R1 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted OH, CO2H, CONH2, C(=O)NH2, SH, S(O)H, SO2H, NH2, acyl, CN, NO2, N3; p = 0-4; R2 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, (un)substituted OH, SH, S(O)H, SO2H, NH2; R3, R4 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, (un)substituted OH, CO2H, CONH2, CSNH2, SH, S(O)H, SO2H, NH2, acyl) were prepared Thus, 7-chloro-2-(4-pyridinyl)pyrazolo[1,5-a]pyridine was obtained from 6-chloro-2-picolone and Et isonicotinate in 3 steps and was acetylated, treated with cyclopentylamine, and cyclized with N-cyclopentylguanidine to give the pyrazolopyridine II which had IC50


IT 544675-24-3P
 against HSV-1 of 1.5 µM.
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolopyridine derivs. as antihelminth agents)
 RN 544675-24-3 CAPLUS
 CN 2-Pyrimidinamine, 4,4'-pyrazolo[1,5-a]pyridine-2,3-diylbis (N-cyclopentyl- (9CI) (CA INDEX NAME)




IT 544675-20-9P 544675-22-1P 544675-28-7P
 544675-31-2P 544675-32-3P 544675-33-4P
 544675-34-5P 544675-35-6P 544675-36-7P
 544675-40-3P 544675-41-4P 544675-42-5P
 544675-43-6P 544675-44-7P 544675-45-8P
 544675-46-9P 544675-47-0P 544675-48-1P
 544675-49-2P 544675-50-5P 544675-51-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridine derivs. as antihelminth agents)
 RN 544675-20-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 544675-22-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 544675-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2,3-bis(2-(cyclopentylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-31-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2,3-bis(2-(butylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-32-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-2,3-bis(2-(cyclopropylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-33-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(4-morpholinyl)-2,3-bis(2-(4-morpholinyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-34-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-methylpropyl)-2,3-bis(2-(2-methylpropylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(phenylmethyl)-2,3-bis(2-(phenylmethylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN * 544675-36-7 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(1-methylethyl)-2,3-bis[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-40-3 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-[(1-methylethyl)amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 544675-41-4 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-[2-(cyclopentylamino)-4-pyridinyl]-3-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)





RN 544675-42-5 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-[(1-methylethyl)amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 544675-43-6 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(1-methylethyl)amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 544675-44-7 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 544675-45-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (9CI) (CA INDEX NAME)





RN 544675-46-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 544675-47-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (9CI) (CA INDEX NAME)




RN 544675-48-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)







RN 544675-49-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 544675-50-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(5-bromo-2-furanyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-51-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



IT 544675-66-3P 544675-67-4P 544675-68-5P
544675-70-9P 544675-71-0P 544675-72-1P
544675-73-2P 544675-74-3P 544675-75-4P
544675-76-5P 544675-77-6P 544675-83-4P
544675-90-3P 544675-91-4P 544675-95-8P
544675-99-2P 544676-06-4P 544676-07-5P
544676-08-6P
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of pyrazolopyridine derivs. as antiherpes agents)
RN 544675-66-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2,3-bis[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-67-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2,3-bis[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-68-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2,3-bis[2-(methylsulfinyl)-4-


pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-70-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluoro-4-pyridinyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-71-0 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544675-72-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(2-(1-methylethyl)amino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544675-73-2 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-[2-(cyclopentylamino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 544675-74-3 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-[2-(cyclopentylamino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)






RN 544675-75-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-(1-methylethyl)amino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544675-99-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(5-bromo-2-furanyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 544676-06-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-fluoro-4-pyridinyl)-2-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 544676-07-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methyl-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544676-08-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(2-methyl-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




IT 544675-26-5P 544675-37-8P 544675-38-9P
RL: RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(preparation of pyrazolopyridine derivs. as antihelminthics agents)
RN 544675-26-5 CAPLUS
CN 2-Pyrimidinamine, 4,4'-(7-chloropyrazolo[1,5-a]pyridine-2,3-diyl)bis[N-cyclopentyl]- (9CI) (CA INDEX NAME)




RN 544675-37-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluoro-4-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-38-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 544675-21-0P 544675-30-1P 544675-39-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolopyridine derivs. as antiherpes agents)
RN 544675-21-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-cyclopentyl-3-[2-(methylethylamino)-4-pyrimidinyl]-2-(2-pyridinyl))- (9CI) (CA INDEX NAME)



RN 544675-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-methoxyethyl)-2,3-bis(2-(2-methoxyethyl)amino)-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 544675-39-0 CAPLUS
CN 2-Pyrimidinamine, N-(1-methylethyl)-4-[2-(2-(1-methylethylamino)-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:434561 CAPLUS
DOCUMENT NUMBER: 139:22210
TITLE: Preparation of pyrazolopyridine derivatives as adenosine antagonists
INVENTOR(S): Tanaka, Akira; Minagawa, Masatoshi; Akahane, Atsushi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCI Int. Appl., 63 pp.
CODEN: PIXXDZ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045950	A1	20030605	WO 2002-JP12381	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, SN, TD, TG				
AU 2002347633	A1	20030610	AU 2002-347633	20021127
PRIORITY APPLN. INFO.:			AU 2001-9163	A 20011129
OTHER SOURCE(S):			WO 2002-JP12381	W 20021127
			MARKPAT 139:22210	

GI.




AB Pyrazolopyridine compds. of formula I (R1 = H, alkyl, cycloalkyl; R2 = H, (substituted) OH, acyl, (substituted) amino; R3 = H, halo) are prepared. The pyrazolopyridine compds. and salts thereof of are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like. Thus, II was prepared and showed adenosine antagonist activity and anticatalepsy activity.


IT 537047-93-1P 537047-96-4P 537047-97-5P
537047-98-6P 537048-06-9P 537048-11-6P
537048-15-0P 537048-16-1P 537048-17-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(Preparation of pyrazolopyridine derivs. as adenosine antagonists)
RN 537047-93-1 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 537047-96-4 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 537047-97-5 CAPLUS
CN Acetic acid, [[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 537047-98-6 CAPLUS
CN Acetic acid, [[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 537048-06-9 CAPLUS
CN Carbamic acid, [2-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-11-6 CAPLUS
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[5-[(5-nitro-2-pyridinyl)oxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 537048-15-0 CAPLUS
CN Methanesulfonic acid, trifluoro-, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX NAME)



RN 537048-16-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 537048-17-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




IT 537047-87-3P 537047-88-4P 537047-89-5P
537047-90-8P 537047-91-9P 537047-92-0P
537047-94-2P 537047-95-3P 537047-99-7P
537048-00-3P 537048-01-4P 537048-02-5P
537048-03-6P 537048-04-7P 537048-05-8P
537048-07-0P 537048-08-1P 537048-09-2P
537048-10-5P 537048-12-7P 537048-13-8P
537048-14-9P 537048-18-3P 537048-19-4P
537048-20-7P 537048-21-8P 537048-22-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolopyridine derivs. as adenosine antagonists)


RN 537047-87-3 CAPLUS
CN 2(1H)-Pyridinone, 1-methyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-88-4 CAPLUS
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-89-5 CAPLUS
CN 2(1H)-Pyridinone, 1-ethyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-90-8 CAPLUS
CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-propyl- (9CI) (CA INDEX NAME)




RN 537047-91-9 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-92-0 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methyl- (9CI) (CA INDEX NAME)




RN	537047-94-2	CAPLUS
CN	2(1H)-Pyridinone, 1-ethyl-5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI)	(CA INDEX NAME)




RN	537047-95-3	CAPLUS
CN	2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-propyl- (9CI)	(CA INDEX NAME)




537047-99-7 CAPLUS
Acetamide, 2-([3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN	537048-00-3	CAPLUS
CN	Acetamide, 2-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-N-methyl-	(9CI) (CA INDEX NAME)




RN	537048-01-4	CAPLUS
CN	Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-ethyl-	(9CI) (CA INDEX NAME)




RN	537048-02-5	CAPLUS
CN	2(1H)-Pyridinone, 5-[5-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5- a]pyridin-3-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)	




URN	537048-03-6	CAPLUS
CN	2(1H)-Pyridinone, 1-(1-methylethyl)-5-[5-[2-(4-morpholinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-	(9CI) (CA INDEX NAME)




URN	537048-04-7	CAPLUS
CN	2(1H)-Pyridinone, 1-(1-methylethyl)-5-[2-phenyl-5-(2-pyridinyloxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




RN 537048-05-8 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(2-methoxyethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-07-0 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(2-aminoethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-08-1 CAPLUS
CN Carbamic acid, {2-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]ethyl}methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-09-2 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(2-(methyldimino)ethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-10-5 CAPLUS
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[(2-phenyl-5-[(tetrahydro-2H-pyran-2-yl)methoxy]pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 537048-12-7 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(2-amino-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-13-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-14-9 CAPLUS
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[(2-phenyl-5-(4-piperidinyloxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 537048-18-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 537048-19-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-N-methyl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 537048-20-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-N-ethyl-2-phenyl]- (9CI) (CA INDEX NAME)



RN 537048-21-8 CAPLUS
CN Carbamic acid, [3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenylpyrazolo[1,5-a]pyridine-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-22-9 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 131185-46-1P 537048-24-1P 537048-25-2P
537048-26-3P 537048-27-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


RN 131185-46-1 CAPLUS
CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537048-24-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[6-(methylsulfonyl)-3-pyridinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 537048-25-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 537048-26-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 537048-27-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-3-(6-methoxy-3-pyridinyl)-2-phenyl-
(9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:251382 CAPLUS
DOCUMENT NUMBER: 139:223688
TITLE: Allosteric interactions and QSAR: on the role of
ligand hydrophobicity
AUTHOR(S): Hansch, Corwin; Garg, Rajni; Kurup, Alka; Mekapati,
Suresh Babu
CORPORATE SOURCE: Department of Chemistry, Pomona College, Claremont,
CA, 91711, USA
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(9),
2075-2084
CODEN: BMECEP; ISSN: 0968-0896


PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A study of a very large database of QSAR (9100) has uncovered a few
unusual examples where as one increases the hydrophobicity of the members
of a set of congeners, activity decreases until at a certain point,
activity begins to increase. Obviously a change in mechanism is involved.
The only way we have found to rationalize this unusual event is by a
change in the structure of the receptor. We have found this to occur with
Hb, a substance first used to define allosteric reactions.

IT 131185-37-0 171050-45-6 171050-95-6
171050-96-7 171050-97-8 171051-01-7
171051-02-8 171051-08-4 171051-34-6
171051-47-1 171051-52-8
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological
study)
(AZA adenosine receptor antagonist activity; parabolic relationship
between ligand hydrophobicity and activity in QSAR studies in relation
to allosteric interactions)


RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinobutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171050-95-6 CAPLUS
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-96-7 CAPLUS
CN 1-Cyclohexene-1-butanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-97-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-
pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-01-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-02-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-08-4 CAPLUS
CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 171051-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(2-hydroxyethyl)-1-cyclohexen-1-yl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171051-52-8 CAPLUS
CN 1-Cyclohexene-1-acetonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 28 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:221686 CAPLUS
DOCUMENT NUMBER: 138:238180
TITLE: Preparation of pyrazolopyridines for treatment of herpes infections
INVENTOR(S): Johns, Brian A.; Gudmundsson, Kristjan
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022845	A1	20030320	WO 2002-US27251	20020827
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RU, SC, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VJ, VN, YU, ZA, ZM, ZW			

their use as pharmaceutical agents against herpes infections. IC50 values are reported for 10 examples of I against HSV-1, e.g. 0.074 μ M for II. Thirteen example preps. of I are included. For example, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-5-amine was prepared in 7 steps starting from 4-chloro-2-picoline and Et 4-fluorobenzoate and involving the following intermediates: 2-(4-chloro-2-pyridinyl)-1-(4-fluorophenyl)ethanone, 2-(4-chloro-2-pyridinyl)-1-(4-fluorophenyl)ethanone, 5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine, 5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxaldehyde, 1-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-butan-1-one, and 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine. For I: R1 = alkyl, alkenyl, alkynyl, cycloalkenyl, cycloalkenyl, -OR, -ORV, -OR10AY, -OR10Het, -C(O)R, -C(O)Het, -CO2R9, -C(O)NR788, -C(O)NR7AY, -C(O)NHR10AY, -C(S)NR11, -C(NH)NR788, -C(NH)NR7AY, -S(O)R9, -S(O)R9, -S(O)Nhet, -R10OC(O)R9, -S(O)NR7AY, -R10Cycloalkyl, -R10AY, -R10Het, -R10OR9, -R10OC(O)R9, -R10OC(O)AY, -R10OC(O)Het, -R10OS(O)nR9, -R10C(O)R9, -R10CO2R9, -R10C(O)NR911, -R10C(S)NR911, -R10C(NH)NR11, -R10SO2R9, -R10SO2NR911, -R10NHCO9, -R10NR788, -R10NR7AY, -R10NHCO9, -R10NHCO2R9, -R10NHCO9(NH)NR11, cyano, azido and nitro; AY is aryl. R2 = halo, alkyl, alkenyl, cycloalkyl, cycloalkenyl, Alk, Het, -OR, -ORV, -OR10Het, -OR10Het, -S(O)R9, -S(O)AY, -NR788, -NHHet, -NHR10AY, -NHR10Het, -R10NR788 and -S(O)R9.

II

INJECTIONS/ 473711-94-3 CAPLUS


C1CCN(C1)c2ccc(Nc3cc4c(cc3)nc5ccccc5n4)cc2

473712-02-6 CAPLUS
Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentylamino)-4-
pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

(Uses)
(drug candidate; preparation of pyrazolopyridines for treatment of herpes infections)


RN 501953-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 501953-13-5 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-ethoxy-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 501953-15-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 501953-16-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(4-methoxyphenyl)-7- (methylthio)- (9CI) (CA INDEX NAME)




RN 501953-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethylthio)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 501953-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(methylthio)- (9CI) (CA INDEX NAME)




IT 501953-12-4P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-5-amine
501953-13-5P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-ethoxy-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-amine
501953-15-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(2-methoxyethoxy)pyrazolo[1,5-a]pyridin-5-amine
501953-16-8P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-amine
501953-17-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethylthio)pyrazolo[1,5-a]pyridin-5-amine
501953-18-0P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(isopropylsulfonyl)pyrazolo[1,5-a]pyridin-5-amine
501953-19-1P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(phenylsulfonyl)pyrazolo[1,5-a]pyridin-5-amine
501953-20-4P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(isopropylsulfonyl)pyrazolo[1,5-a]pyridin-5-amine
RL: PAC (Pharmacological activity); SEN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


RN 501953-20-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-[(1-methylethyl)thio]- (9CI) (CA INDEX NAME)




IT 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-87-5P, 4-[5-Chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridines for treatment of herpes infections)
RN 468062-85-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-87-5 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT
L5 ANSWER 29 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:221519 CAPLUS
DOCUMENT NUMBER: 138:231748




RN 501953-17-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(ethylthio)- (9CI) (CA INDEX NAME)



RN 501953-18-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-[(1-methylethyl)thio]- (9CI) (CA INDEX NAME)



RN 501953-19-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(phenylthio)- (9CI) (CA INDEX NAME)



TITLE: Methods using adenosine A1 receptor antagonists for treating pulmonary disease

INVENTOR(S): Smiths, Glenn J.; Spina, Francis G.

PATENT ASSIGNEE(S): Biogen, Inc.; USA; Musc Foundation for Research Development

SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200202284	A1	20030320	WO 2002-US28580	20020906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PI, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, TC, TD, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MN, ND, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, BT, BY, CA, CH, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, CN, CU, GW, ML, MR, NE, SN, TD, TG				
CA 2459533	A1	20030320	CA 2002-2459533	20020906
AU 20020341618	A1	20030324	AU 2002-341618	20020906
EP 1429775	A1	20030623	EP 2002-715769	20020906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012329	A	20040921	BR 2002-12329	20020906
HU 200401805	A2	20041228	HU 2004-1805	20020906
HU 200401805	A3	20070502		20020906
CN 1564688	A	20050112	CN 2002-819526	20020906
JP 200501915	T	20050120	JP 2003-526413	20020906
NZ 532083	A	20051028	NZ 2002-532083	20020906
IN 2004K00276	A	20050331	IN 2004-KN276	20040301
ZA 2004001765	A	20050405	ZA 2004-1765	20040303
NO 2004000982	A	20040603	NO 2004-982	20040305
US 2004259889	A1	20041223	US 2001-317908P	20010906
PRIORITY APPL. INFO.:			WO 2002-US28580	W 20020906

OTHER SOURCE(S): MARPAT 138:231748

AB Methods useful for reducing pulmonary vasoconstriction or improving pulmonary hemodynamics in a patient are disclosed. More particularly, the invention discloses administering adenosine A1 receptor antagonists to reduce pulmonary vasoconstriction and improve pulmonary hemodynamics.


IT 131185-37-0 141060-57-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A1 receptor antagonists for treating pulmonary disease)


RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 141060-57-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-(1H-tetrazol-5-yl)ethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:177128 CAPLUS

DOCUMENT NUMBER: 139:276830

TITLE: Manufacturing process development of new adenosine antagonist FR120838

AUTHOR(S): Hashimoto, Norio

CORPORATE SOURCE: Lab. for Synthetic Technology, Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: Purosesu Kemisutori no Shintenkai (2003), 228-237. Shi Emu Shi Shuppan: Tokyo, Japan. CODEN: 69DQZQ; ISBN: 4-88231-384-7

DOCUMENT TYPE: Conference; General Review

LANGUAGE: Japanese

AB A review on development of synthetic process for a new adenosine antagonist FR 120838 (FK 838).


IT 131185-37-0P, FK838

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(development of synthetic process for a new adenosine antagonist FR 120838 (FK 838))

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 31 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:42271 CAPLUS

DOCUMENT NUMBER: 138:106706

TITLE: Preparation of pyridazinones as adenosine receptor antagonists

INVENTOR(S): Tsutsumi, Hideo; Akahane, Atsushi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 107 pp. CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO. _____ KIND DATE APPLICATION NO. DATE
 WO 2003004494 AI 20030116 WO 2002-JP6671 20020702
 W: JP, US
 RW: AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU,
 NL, PT, SE, SK
 PRIORITY APPLN. INFO.: AU 2001-6064 A 20010702
 OTHER SOURCE(S): MARPAT 138:106706
 GI




AB Title compds. [I; R1-R4 = H, suitable substituent; R1R2, R2R3 = (substituted) (heteroatom-interrupted) (CH2)n; n = 1-12; W = CH:CHCH:CH, CH:NCH:CH2, etc.], were prepared thus, 6-[2-(1-hydroxycyclopentyl)pyrazolo[1,5-a]pyridin-3-yl]-2-isopropyl-3(2H)-pyridazinone was refluxed 14 h with Nafion NR50 in HOAc 6-[2-(1-cyclopenten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-isopropyl-3(2H)-pyridazinone. This showed adenosine A1 receptor binding activity with Ki = 0.19 nM.
 IT 487062-21-5P 487062-24-8P 487062-27-1P
 487062-28-2P 487062-29-3P 487062-30-6P
 487062-31-7P 487062-32-8P 487062-33-9P
 487062-34-0P 487062-35-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyridazinones as adenosine receptor antagonists)
 RN 487062-21-5 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-24-8 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclopenten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-27-1 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclobuten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-28-2 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclohepten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-29-3 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cycloocten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-30-6 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(6-methyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-31-7 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-32-8 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(4,4-dimethyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-33-9 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(2,5-dihydro-2-methyl-3-furyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-34-0 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-35-1 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,6-dihydro-2H-thiopyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 487062-98-6P 487063-04-7P 487063-29-6P
 487063-30-9P 487063-31-0P 487063-32-1P
 487063-33-2P 487063-34-3P 487063-35-4P
 487063-36-5P 487063-37-6P 487063-38-7P
 487063-39-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Preparation of pyridazinones as adenosine receptor antagonists)
 RN 487062-98-6 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-04-7 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclopentyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-29-6 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclobutyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 487063-30-9 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycycloheptyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-31-0 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclooctyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-32-1 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-[(1R,2S)-1-hydroxy-2-methylcyclohexyl]pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 487063-33-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-((1R,2R)-1-hydroxy-2-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 487063-34-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(cis-1-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 487063-35-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(trans-1-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 487063-36-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxy-4,4-dimethylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-37-6 CAPLUS
CN Pentitol, 1,4-anhydro-2,5-dideoxy-3-C-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)pyrazolo[1,5-a]pyridin-2-yl]]- (9CI) (CA INDEX NAME)



RN 487063-38-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(tetrahydro-4-hydroxy-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



URN	487063-39-8	CAPLUS
CN	3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(tetrahydro-4-hydroxy-2H-thiopyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 32 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:906238 CAPLUS
DOCUMENT NUMBER: 138:4598
Preparation of substituted 5,6-dihydro-4H-pyrrrole[1,2-


INVENTOR(S) : Jason Scott; Bright, Douglas Wade; Ciapetti, Sawyer; DeBello, Todd Vincent; Coffey, Alexander; Glenn; Goodson, Theodore Jr.; Herring, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Smith, Nicolas Anthony; Vingling, Jonathan Michael; Worth, Edward C. R. Eli Lilly and Company, USA; et al.
PCT Int. Appl., 305 pp.

CODEN: FRAADZ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MA, MD, ME, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, TD, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VU, WO, ZA, ZM, ZW				

[illegible]

OTHER SOURCE(S): MARPAT 138:4598
GI




Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinoxaline, etc.; p = 1-8; R3 = H, alkyl, alkyldihydroxy, hydroxy, dialkylamino, etc.; X = O, C, S] were prepared. For instance, 1-[(2-(6-bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene)amino]pyrididin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.0 μ M for the TGF- β type I receptor.


receptor.
476477-76-6p, 2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-

aliperidin-7-ol
 RU: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


INDEX NAME 2-(2-pyridinyl)-3-(4-quinolinyl) - (9CI) (CA
INDEX NAME)
CAPUS 476477-76-6
bPyrazoles as TGF- β signal transduction inhibitors
(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-a]pyrazoles as TGF- β signal transduction inhibitors)
REAGENT OR REAGENT; USES [USES]



IT 476476-22-9P, 7-Benzyloxy-2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]piperidine 476477-77-7P, 7-Acetoxy-2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]piperidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrazole(1,2-b)pyrazoles as TGF- β signal transduction inhibitors)
 RN 476476-22-9 CAPLUS
 CN Quinoline, 4-[7-(phenylmethoxy)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 476477-77-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-ol, 2-(2-pyridinyl)-3-(4-quinolinyl)-, acetate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L5 ANSWER 33 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:849629 CAPLUS
 DOCUMENT NUMBER: 137:337887
 TITLE: Pyrazolopyridines as virucides for herpes virus infections
 INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 150 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088124	A2	20021107	WO 2002-US10687	20020405
WO 2002088124	A3	20030508		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, ZA, ZM, ZW				
RW: GH, GM, KE, LS, LZ, MG, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002305143	A1	20021111	AU 2002-305143	20020405
EP 1385847	A2	20040204	EP 2002-733945	20020405
EP 1385847	B1	20050601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004527560	T	20040909	JP 2002-585423	20020405
AT 296826	T	20050615	AT 2002-733945	20020405
ES 2242028	T3	20051101	ES 2002-2733945	20020405
US 2004142941	A1	20040722	US 2003-473751	20031001
US 6962914	B2	20051108		
US 2005192303	B1	20050901	US 2005-95212	20050331
US 7030134	B2	20060418		
US 2005192295	B1	20050901	US 2005-95361	20050331
PRIORITY APPL. INFO.:			US 2001-286948P	P 20010427
			WO 2002-US10687	W 20020405
			US 2003-473751	A3 20031001
OTHER SOURCE(S):		MARPAT 137:337887		
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazolopyridines I [Y = N, CH; R = (un)substituted Ph; R1 = halo, aryl, heterocyclic, amino; R2 = halo, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted OH, SH, S(O)H, SO2H, NH2; R3, R4 = H, halo, alkyl, alkenyl, cycloalkyl, aryl, heterocyclic, (un)substituted OH, CO2H, SO2NH2, NH2, alkyl, acyl; R5 = halo, alkenyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted alkyl, OH, CO2H, CONH2, CSNH2, c(-NH)NH2, SH, SO2H, SO2NH2, NH2, acyl, CN, NO2, N3; p = 1-3] were prepared for use in treating herpes virus infections. Thus, the pyrazolopyridine II was prepared from 4-FC6H4COMe, 2-chloro-5-trifluoromethylpyridine, 1-pyrrolidinedicarboximide, and cyclopentylamine in 9 steps. II had IC50 against HSV-1 of 5.3 μ M.
 IT 474303-58-7P 474303-59-8P 474303-67-8P
 474303-72-5P 474303-85-0P 474303-86-1P
 474303-88-3P 474303-90-7P 474303-91-8P
 474303-92-9P 474303-93-0P 474303-94-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); THU (Reactant or reagent); USES (Uses)
 (Preparation of pyrazolopyridines as virucides for herpes virus infections)
 RN 474303-58-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-

(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI)
(CA INDEX NAME)




RN 474303-59-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 474303-67-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[5,7-dichloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 474303-72-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[5,7-dichloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 474303-85-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 474303-86-1 CAPLUS
CN Phenol, 4-[5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 474303-88-3 CAPLUS
CN Phenol, 4-[5-chloro-7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 474303-90-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5,7-dichloro-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 474303-91-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 474303-92-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 474303-93-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 474303-94-1 CAPLUS
CN Phenol, 4-[5-chloro-7-(cyclopropylamino)-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




IT 474303-56-5P 474303-57-6P 474303-60-1P
474303-61-2P 474303-62-3P 474303-63-4P
474303-64-5P 474303-65-6P 474303-66-7P
474303-68-9P 474303-69-0P 474303-70-3P
474303-71-4P 474303-73-6P 474303-74-7P
474303-75-8P 474303-76-9P 474303-77-0P
474303-78-1P 474303-79-2P 474303-80-5P
474303-81-6P 474303-82-7P 474303-83-8P
474303-84-9P 474303-87-2P 474303-89-4P
474303-95-2P 474303-96-3P 474303-97-4P
474303-98-5P 474303-99-6P 474304-00-2P
474304-01-3P 474304-08-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


[Preparation of pyrazolopyridines as virucides for herpes virus infections]
RN 474303-56-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 474303-57-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 474303-60-1 CAPLUS
CN Pyrrolidine, 1-[[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 474303-61-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 474303-62-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-hydroxy- (9CI) (CA INDEX NAME)




RN 474303-63-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-(4-morpholinylethyl)- (9CI) (CA INDEX NAME)




RN 474303-64-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(3-(1H-imidazol-1-yl)propyl)- (9CI) (CA INDEX NAME)




RN 474303-65-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 474303-66-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-methanol, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-68-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-69-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5,7-diamine, N'-dicyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-70-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474303-71-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5,7-diamine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N'-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474303-73-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 474303-74-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474303-75-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474303-76-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474303-77-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-78-1 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 474303-79-2 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 474303-80-5 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 474303-81-6 CAPLUS
CN Guanidine, N-[5-chloro-3-((2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl)-N'-cyclopentylmonohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 474303-82-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-83-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[5,7-dichloro-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 474303-84-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 474303-87-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 474303-89-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI)
(CA INDEX NAME)



RN 474303-95-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI)
(CA INDEX NAME)




RN 474303-96-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 7-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 474303-97-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 4,6-dibromo-N-cyclopentyl-3-[2-


(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)



RN 474303-98-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 4,6-dibromo-3-[5-bromo-2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 474303-99-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 6-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 474304-00-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-


pyrimidinyl]-2-(4-fluorophenyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 474304-01-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(4-fluorophenyl)-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 474304-08-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-85-3P
468062-87-5P 468063-27-6P 473711-94-3P
474304-02-4P 474304-03-5P 474304-04-6P
474304-05-7P 474304-07-9P
RL: RCT (Reactant); SEN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as virucides for herpes virus infections)
RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 468062-85-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-87-5 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-27-6 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 473711-94-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474304-02-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




RN 474304-03-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




RN 474304-04-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 474304-05-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




RN 474304-07-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-chloro-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 34 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:814131 CAPLUS
 DOCUMENT NUMBER: 137:325427
 TITLE: Preparation of antiviral 3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridines
 INVENTOR(S): Cheung, Mui; Gudmundsson, Kristjan; Johns, Brian A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083672	A1	20021024	WO 2002-08793	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, TC, TD, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GT, GW, HN, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, TC, TD, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
AU 2002254326	A1	20021028	AU 2002-254326	20020321
EP 1377575	A1	20040107	EP 2002-723554	20020321
EP 1377575	B1	20060705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529926	T	20040930	JP 2002-581427	20020321
AT 332301	T	20060715	AT 2002-723554	20020321
US 2004167335	A1	20040826	US 2003-473491	20030925
US 7141569	B2	20061128		
US 2006235043	A1	20061019	US 2006-422357	20060606
PRIORITY APPLN. INFO.:			US 2001-282749P	P 20010410
			WO 2002-US8793	W 20020321
			US 2003-473491	A3 20030925
OTHER SOURCE(S):				
GI			MARKPAT 137:325427	




AB The title compds. [I; R1 = H; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, cycloalkyl, etc.; p = 1-3; R6 = halo, alkyl, cycloalkyl, etc.], useful in treatment of herpes viral infections, were prepared E.g., a 7-step synthesis of I [R1 = H; R2 = cyclopentylamino; Y = N; R3, R4 = H; q = 1; R5 = 4-F; p = 1; R6 = 5-(cyclopentylamino)], starting from 4-chloro-2-picolone and Et 4-fluorobenzoate, which showed IC50 of 0.5 µM against HSV-1, was given.
 IT 468062-85-3P 468062-87-5P 473711-94-3P
 473711-95-4P 473711-97-6P 473712-02-6P
 473712-09-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Preparation of antiviral pyrazolopyridines for treating herpes viral infections)
 RN 468062-85-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-87-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 473711-94-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473711-95-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473711-97-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 473712-02-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 473712-09-3 CAPLUS
CN Phenol, 4-[5-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




IT 473711-96-5P 473711-98-7P 473711-99-8P
473712-00-4P 473712-01-5P 473712-03-7P
473712-04-8P 473712-05-9P 473712-06-0P
473712-07-1P 473712-08-2P 473712-10-6P
473712-11-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of antiviral pyrazolopyridines for treating herpes viral infections)

RN 473711-96-5 CAPLUS
CN Methanesulfonamide, N-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 473711-98-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-6-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 473712-04-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-bromo-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473712-05-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473712-06-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-bromo-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 473711-99-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 473712-00-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 473712-01-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 473712-03-7 CAPLUS




RN 473712-07-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 473712-08-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-butyl-3-[2-(butylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473712-10-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473712-11-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-81-9P
473712-17-3P 473712-18-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antiviral pyrazolopyridines for treating herpes viral infections)
RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 468062-81-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 473712-17-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 473712-18-4 CAPLUS
CN Carbanic acid, [3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

I5 ANSWER 35 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:77725 CAPLUS
DOCUMENT NUMBER: 137:288973
TITLE: Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections
INVENTOR(S): Boyd, F. Leslie; Gudmundsson, Kristjan; Johns, Brian A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078701	A1	20021010	WO 2002-US8621	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
AU 2002254310	A1	20021015	AU 2002-254310	20020320
EP 1372642	A1	20040102	EP 2002-723538	20020320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525150	T	20040819	JP 2002-576967	20020320
US 2005107400	A1	20050519	US 2003-473197	20030924
PRIORITY APPL. INFO.:			US 2001-280047P	P 20010330
			US 2001-307189P	P 20010723
			WO 2002-US8621	W 20020320
OTHER SOURCE(S):			MARPAT 137:288973	
GI				




I


AB The present invention provides methods using I (e.g. 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1H-imidazol-5-yl)ethyl]-2-pyridinamine) for the treatment or prophylaxis of viral infections such as herpes viral infections. IC50 values are reported for about 70 of the claimed compounds against HSV-1 (e.g. 0.2 µM for N-cyclopropyl-4-[6-cyano-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine). In I, Z is CH or N; a is 1 or 2; b is 1, 2 or 3; c is 1, 2 or 3; each R1 is independently selected from -(X)d-(CH2)e-R5 wherein d is 0 or 1; e is 0 to 6; X is selected from O, NR6 and S(O)f where f is 0, 1 or 2. R5 is selected from H, halo, Cl-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, cyano, nitro, trihalomethyl, NR7R8, C6H4(CH2)NR7R8, C(O)R7, C(O)NR7R8, C(O)NR7R8, C(O)NR7R8, CO2R7, CO2R7, SO2R7, SO2NR7R8, C(NR7)NR7R8, N(R7)C(NR7)NR7R8, NHC(O)R7 and N(C1-3alkyl)C(O)R7. Each R2 is independently selected from H, cyano, halo, trihalomethyl, OCl-6alkyl, Cl-6alkyl, C2-6alkenyl, C2-6alkynyl, S(O)GCl-6alkyl where g is 0, 1 or 2, NCl-6alkyl(Cl-6alkyl), wherein d is 0 or 1; e is 0 to 6; Y is O or S(O)f where f is 0, 1 or 2. R3 is selected from H, halo, Cl-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, cyano, nitro, trihalomethyl, phthalimido, C6H4NR7R8, C6H4(CH2)NR7R8, C(O)R7, C(O)NR7R8, OC(O)R7, OC(O)NR7R8, CO2R7, CO2NR7R8 and C(NR7)NR7R8. R6 is selected from H, Cl-6alkyl, C2-6alkenyl, heteroaryl, cycloalkyl, and heterocyclyl. R7 and R8 are each independently selected from H, Cl-8alkyl, C2-6alkenyl, SO2Cl-6alkyl, (CH2)m-cycloalkyl, (CH2)m-aryl, (CH2)m-heterocyclyl and (CH2)m-heteroaryl, wherein m is 0, 1 or 2, or R7 and R8 together with the N atom to which they are bound, form a heterocyclyl group. Addnl. conditions for I are stated in the claims. Although neither the methods of preparation nor the compounds are claimed, approx. 100 example preps. are included.

IT 401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-(2-methylthio)-4-pyrimidinylpyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-(2-methylthio)-4-pyrimidinylpyrazolo[1,5-a]pyridine 437612-52-7P, 7-Chloro-2-(4-fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 468062-75-1P, [3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]methanol 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-95-5P, 2-(4-Fluorophenyl)-7-methylthio-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-97-7P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-(2-methylthio)-4-pyrimidinylpyrazolo[1,5-a]pyridine 468063-00-5P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-(2-methylthio)-4-pyrimidinylpyrazolo[1,5-a]pyridine 468063-02-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-04-9P, 2-(4-Fluorophenyl)-3-(2-methylthio)-4-pyrimidinyl-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-13-0P,

2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(ethylsulfinyl)pyrazolo[1,5-a]pyridine 468063-14-1P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(ethylthio)pyrazolo[1,5-a]pyridine 468063-15-2P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 468063-21-0P 468063-25-4P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylate 468063-29-8P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylic acid 468063-49-2P, N-Cyclopentyl-4-[2-(2,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (intermediate; preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 401815-63-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-32-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-34-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


RN 468062-85-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)





RN 468062-95-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-97-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-00-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468062-75-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)







RN 468063-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylethio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-04-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylethio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-13-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(ethylethio)-2-(4-fluorophenyl)-3-[2-(methylethio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-14-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(ethylethio)-2-(4-fluorophenyl)-3-[2-(methylethio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-15-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468063-21-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 468063-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 468063-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 468063-49-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




IT 401815-97-2P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-15-7P, 3-(2,6-Difluoro-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-18-0P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-24-8P, 6-Bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-55-3P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methoxybenzyloxy)propyl]-2-pyrimidinamine 437612-75-4P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 437613-05-3P, N-Butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-79-5P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-

6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-80-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-81-9P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468062-83-1P, 4-[6-(Bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-98-8P, 7-Chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-17-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 468063-27-6P, 4-[7-Chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-28-7P, Ethyl 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate
RU: RCI (Reactant); SFN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 401815-97-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-15-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-18-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-81-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 401816-24-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-55-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[(4-methoxyphenyl)methoxy]propyl]- (9CI) (CA INDEX NAME)




RN 437612-75-4 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)







RN 468062-83-1 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468062-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-17-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 468063-27-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468063-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT 468063-31-2P, N-Butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 468063-31-2 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




IT

401815-99-4P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyridinamine 401816-00-0P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-01-1P, 3-[[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-propanol 401816-03-3P, N'-[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]-1,3-propanediamine 401816-04-4P, 3-(2-Butoxypropyl)-4-yl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine 401816-05-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl-2-pyridinamine 401816-06-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxybenzyl)-2-pyridinamine 401816-07-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl-2-pyridinamine 401816-08-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyridinamine 401816-09-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-2-pyridinamine 401816-12-4P, 2-[[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-ethanol 401816-13-5P, N-Benzyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-14-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl-2-pyridinamine 401816-17-9P, N-Benzyl-6-fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-19-1P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-isopropyl-2-pyridinamine 401816-22-6P, 3-[[4-(2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-propanol 401816-25-9P, N-(3-Aminopropyl)-4-[6-bromo-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-37-3P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-40-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyrimidinamine 401816-41-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-44-2P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)-2-pyrimidinamine 401816-48-6P, N-Butyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-49-7P, N-Benzyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-50-0P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-53-3P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)-2-pyrimidinamine 401816-54-4P, 3-[[4-(2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-propanol 401816-57-7P, N-Cyclopropyl-4-[6-cyano-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-62-4P, 4-[2-(4-Fluorophenyl)-3-[2-(1,3-dihydroxypropyl)amino]-4-pyridinyl]-6-pyrazolo[1,5-a]pyridinecarboxamide 401816-68-0P, N-[4-(2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl)]pyrimidin-2-yl]-N-(3-(4-methylpiperazin-1-yl)propyl)amine 401816-71-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyrimidinamine 401816-72-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyrimidinamine 401816-73-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)-2-pyrimidinamine


401816-74-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)-2-pyrimidinamine 401816-79-3P, N-[4-(2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl)]pyrimidin-2-yl]-N3,N3-dimethylpropane-1,3-diamine 437612-79-8P, N-Cyclopentyl-6-[2-(4-Fluorophenyl)-7-(methoxythio)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468062-82-0P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-84-2P, N-Cyclopentyl-4-[6-(cyclopentylamino)methyl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-86-4P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-5-(1-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-87-5P, 4-[5-Chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-94-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-96-6P, 2-(4-Fluorophenyl)-7-methylsulfinyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-99-9P, N-Butyl-4-[7-(2-Fluoroethoxy)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-01-6P, N-Benzyl-4-[7-(2-Fluoroethoxy)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-03-8P, N-Butyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-05-0P, N-Benzyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-06-1P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-07-2P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-08-3P, N-Cyclohexyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-09-4P, 3-[[4-(2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]-1-propanol 468063-10-7P, 2-(4-Fluorophenyl)-3-(2-methoxy-4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-11-8P, 2-(4-Fluorophenyl)-3-(2-phenyloxy-4-pyridinyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-12-9P, 2-(4-Fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-20-9P, 2-(4-Fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-23-2P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-24-3P, N-[4-(5-Chloro-7-(ethylsulfonyl)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]-N-cyclopentylamine 468063-30-1P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-32-3P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-33-4P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-34-5P, N-Cyclopropyl-4-[7-ethyl-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-35-6P, N,N-Dimethyl-2-(4-Fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-7-pyrazolo[1,5-a]pyridinecarboxamide 468063-36-7P, 1-[3-[[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]propyl]-2-pyrrolidinone 468063-37-8P, 6-Fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-methyl-2-pyrimidinamine 468063-38-9P, 4-[4-Fluoro-2-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-Dimethyl-2-pyrimidinamine 468063-39-0P, N-Allyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-40-3P, 5-[6-Chloro-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 468063-41-4P, 3-[[5-Bromo-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]-1-propanol 468063-42-5P, Methyl 3-[2-[[3-(acetyloxypropyl)amino]-4-pyridinyl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468063-43-6P, 3-[2-(Cyclopropylamino)-4-pyrimidinyl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylic acid 468063-44-7P, 3-[2-(Cyclopropylamino)-4-pyrimidinyl]-2-(4-Fluorophenyl)-N,N-

dimethylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-45-8P,
N-Cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxamide 468063-46-9P,
N-Cyclopentyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-2-pyrimidinamine 468063-48-1P 468063-50-5P,
5-Bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentylpyrimidin-2-amine 468063-51-6P, N-Cyclopentyl-6-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468063-52-7P, N-Cyclopropyl-4-[2-(4-methoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-53-8P, N-Cyclopropyl-4-[2-(4-methoxyphenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-54-9P, Ethyl 3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468063-55-0P, 3-[2-(cyclopropylamino)pyrimidin-4-yl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-6-carboxamide 468063-56-1P, 4-[5-Chloro-2-(4-cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 468063-57-2P, 4-[7-Butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-58-3P, 4-[5-Chloro-2-(3-chlorophenyl)-7-(methanesulfanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-59-4P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-60-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(isopropylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl] pyrimidin-2-amine (Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 401815-99-4 CAPIUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-{2-(1H-imidazol-4-yl)ethyl}- (9CI) (CA INDEX NAME)




RN 401816-00-0 CAPIUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-01-1 CAPIUS


CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-03-3 CAPIUS
CN 1,3-Propanediamine, N-{4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl}- (9CI) (CA INDEX NAME)




RN 401816-04-4 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-butoxy-4-pyridinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-05-5 CAPIUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl- (9CI) (CA INDEX NAME)




RN 401816-06-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 401816-07-7 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl- (9CI) (CA INDEX NAME)




RN 401816-08-8 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-09-9 CAPLUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl- (9CI) (CA INDEX NAME)



RN 401816-12-4 CAPLUS
CN Ethanol, 2-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-13-5 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenylmethyl- (9CI) (CA INDEX NAME)




RN 401816-14-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


CN 1,3-Propanediamine, N-[4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-37-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-40-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-41-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-17-9 CAPLUS
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 401816-19-1 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-22-6 CAPLUS
CN 1-Propanol, 3-[[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]- (9CI) (CA INDEX NAME)




RN 401816-25-9 CAPLUS


CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-53-3 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 401816-54-4 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-57-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-50-0 CAPLUS


RN 401816-44-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-48-6 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-49-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-72-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-73-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-74-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-79-3 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-62-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-68-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401816-71-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




469062-86-4	CAPLUS	2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)
-------------	--------	---




RN	468062-87-5	CAPLUS
CN	2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo(1,5-a)pyridin-3-yl]-N-cyclopentyl-	(9CI) (CA INDEX NAME)




RN	468062-94-4	CAPLUS
CN	Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)-(9CI) (CA INDEX NAME)	




RN	468062-96-6	CAPLUS
CN	Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylsulfinyl)-3-(4-pyrimidinyl)-(9CI)	(CA INDEX NAME)




437612-79-8	CAPLUS	4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)
-------------	--------	---




NR	468062-82-0	CAPLUS
CN	2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




NRN	CN	468062-84-2	CAPLUS	Pyrazolo[1,5-a]pyridine-6-methanamine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)	(CA INDEX NAME)







RN 468062-99-9 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[(7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-01-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 468063-03-8 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-05-0 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 468063-06-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-07-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-08-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)


RN 468063-12-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-20-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468063-23-2 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-24-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-09-4 CAPLUS
CN 1-Propanol, 3-[(4-{2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 468063-10-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-methoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-11-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-phenoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-34-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468063-36-7 CAPLUS
CN 2-Pyrrolidinone, 1-[3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 468063-37-8 CAPLUS
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 468063-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 468063-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-33-4 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)







RN 468063-38-9 CAPLUS
CN 2-Pyridinamine, 4-[(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468063-39-0 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 468063-40-3 CAPLUS
CN 2-Pyridinamine, 5-[6-chloro-2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 468063-41-4 CAPLUS
CN 1-Propanol, 3-[[5-bromo-4-[2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 468063-42-5 CAPLUS
CN Pyrazolo(1,5-a)pyridine-6-carboxylic acid, 3-[2-[(3-(acetyloxy)propyl)amino]-4-pyridinyl]-2-(4-fluorophenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 468063-43-6 CAPLUS
CN Pyrazolo(1,5-a)pyridine-6-carboxylic acid, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468063-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468063-45-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468063-46-9 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 468063-48-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-50-5 CAPLUS
CN 2-Pyrimidinamine, 5-bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-51-6 CAPLUS
CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-52-7 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-53-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-methoxyphenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-54-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 468063-55-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 468063-56-1 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-[4-(cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 468063-57-2 CAPLUS
CN 2-Pyrimidinamine, 4-[7-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-58-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(3-chlorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468063-59-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



468063-60-7 CAPLUS
2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-{[1-methylethyl]thio]-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl}]- (9CI)
(CA INDEX NAME)



1 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 36 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:77724 CAPLUS
DOCUMENT NUMBER: 137:294953

DOCUMENT NUMBER: 157-234555
TITLE: Preparation and use of pyrazolopyridines for treatment

INVENTOR(S): Alberti, Michael John; Chamberlain, Stanley D.;

Chueng, Mui; Gudmundsson, Kristjan; Harris, Philip

Anthony; Johns, Brian A.; Jung, David Kendall; Peel,

Michael Robert; Stanford, Jennifer Badiang

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English



LANGUAGE:	English
FAMILY ACC	NUM COUNT- 2

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078700	A1	20021010	WO 2002-US8524	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TZ, UA, US, UZ, VN, YU, ZA, ZM, ZW				
RG: GH, GM, KE, LS, MM, ME, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PL, SE, TR, BF, BJ, CF, CG, CI, CN, CO, CR, CZ, DE, DK, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TZ, UA, US, UZ, VN, YU, ZA, ZM, ZW				


AU 2002305067	A1	20021015	AU 2002-305067	20020320
EP 1372643	A1	20040102	EP 2002-733866	20020320
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525149	T	20040819	JP 2002-576966	20020320
US 200509677	A1	20050317	US 2003-473196	20030924
US 7034030	B2	20060425		
US 2006058319	A1	20060316		
US 7109209	B2	20060919		
PRIORITY APPLN. INFO.:				
			US 2005-245972	20051007
			US 2001-280047P	P 20010330
			US 2001-307189P	P 20010723
			US 2001-307786P	P 20010725
			US 2001-315090P	P 20010827
			WO 2002-US8524	W 20020320
			US 2003-473196	A3 20030924

OTHER SOURCE(S): MARPAT 137:294953




The present invention provides I (variables defined below; e.g. 4-[7'-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (Example 41)), methods for their preparation and their use for the treatment or prophylaxis of viral infections such as herpes viral infections. IC50 values are reported for about 20 of the claimed compounds. against HSV-1, e.g. 0.28 μ M for Example 41. In I, R1 is alkyl, alkylaryl, alkynyl, cycloalkyl, cycloalkenyl, $\text{R}^{10}\text{Cycloalkyl}$, $\text{R}^{10}\text{Alkyl}$, R^{10}Het , OR^7 , OR^8 , OR^9 , OR^{10} , OR^{11} , OR^{12} , OR^{13} , OR^{14} , OR^{15} , OR^{16} , OR^{17} , OR^{18} , OR^{19} , OR^{20} , OR^{21} , OR^{22} , OR^{23} , OR^{24} , OR^{25} , OR^{26} , OR^{27} , OR^{28} , OR^{29} , OR^{30} , OR^{31} , OR^{32} , OR^{33} , OR^{34} , OR^{35} , OR^{36} , OR^{37} , OR^{38} , OR^{39} , OR^{40} , OR^{41} , OR^{42} , OR^{43} , OR^{44} , OR^{45} , OR^{46} , OR^{47} , OR^{48} , OR^{49} , OR^{50} , OR^{51} , OR^{52} , OR^{53} , OR^{54} , OR^{55} , OR^{56} , OR^{57} , OR^{58} , OR^{59} , OR^{60} , OR^{61} , OR^{62} , OR^{63} , OR^{64} , OR^{65} , OR^{66} , OR^{67} , OR^{68} , OR^{69} , OR^{70} , OR^{71} , OR^{72} , OR^{73} , OR^{74} , OR^{75} , OR^{76} , OR^{77} , OR^{78} , OR^{79} , OR^{80} , OR^{81} , OR^{82} , OR^{83} , OR^{84} , OR^{85} , OR^{86} , OR^{87} , OR^{88} , OR^{89} , OR^{90} , OR^{91} , OR^{92} , OR^{93} , OR^{94} , OR^{95} , OR^{96} , OR^{97} , OR^{98} , OR^{99} , OR^{100} , OR^{101} , OR^{102} , OR^{103} , OR^{104} , OR^{105} , OR^{106} , OR^{107} , OR^{108} , OR^{109} , OR^{110} , OR^{111} , OR^{112} , OR^{113} , OR^{114} , OR^{115} , OR^{116} , OR^{117} , OR^{118} , OR^{119} , OR^{120} , OR^{121} , OR^{122} , OR^{123} , OR^{124} , OR^{125} , OR^{126} , OR^{127} , OR^{128} , OR^{129} , OR^{130} , OR^{131} , OR^{132} , OR^{133} , OR^{134} , OR^{135} , OR^{136} , OR^{137} , OR^{138} , OR^{139} , OR^{140} , OR^{141} , OR^{142} , OR^{143} , OR^{144} , OR^{145} , OR^{146} , OR^{147} , OR^{148} , OR^{149} , OR^{150} , OR^{151} , OR^{152} , OR^{153} , OR^{154} , OR^{155} , OR^{156} , OR^{157} , OR^{158} , OR^{159} , OR^{160} , OR^{161} , OR^{162} , OR^{163} , OR^{164} , OR^{165} , OR^{166} , OR^{167} , OR^{168} , OR^{169} , OR^{170} , OR^{171} , OR^{172} , OR^{173} , OR^{174} , OR^{175} , OR^{176} , OR^{177} , OR^{178} , OR^{179} , OR^{180} , OR^{181} , OR^{182} , OR^{183} , OR^{184} , OR^{185} , OR^{186} , OR^{187} , OR^{188} , OR^{189} , OR^{190} , OR^{191} , OR^{192} , OR^{193} , OR^{194} , OR^{195} , OR^{196} , OR^{197} , OR^{198} , OR^{199} , OR^{200} , OR^{201} , OR^{202} , OR^{203} , OR^{204} , OR^{205} , OR^{206} , OR^{207} , OR^{208} , OR^{209} , OR^{210} , OR^{211} , OR^{212} , OR^{213} , OR^{214} , OR^{215} , OR^{216} , OR^{217} , OR^{218} , OR^{219} , OR^{220} , OR^{221} , OR^{222} , OR^{223} , OR^{224} , OR^{225} , OR^{226} , OR^{227} , OR^{228} , OR^{229} , OR^{230} , OR^{231} , OR^{232} , OR^{233} , OR^{234} , OR^{235} , OR^{236} , OR^{237} , OR^{238} , OR^{239} , OR^{240} , OR^{241} , OR^{242} , OR^{243} , OR^{244} , OR^{245} , OR^{246} , OR^{247} , OR^{248} , OR^{249} , OR^{250} , OR^{251} , OR^{252} , OR^{253} , OR^{254} , OR^{255} , OR^{256} , OR^{257} , OR^{258} , OR^{259} , OR^{260} , OR^{261} , OR^{262} , OR^{263} , OR^{264} , OR^{265} , OR^{266} , OR^{267} , OR^{268} , OR^{269} , OR^{270} , OR^{271} , OR^{272} , OR^{273} , OR^{274} , OR^{275} , OR^{276} , OR^{277} , OR^{278} , OR^{279} , OR^{280} , OR^{281} , OR^{282} , OR^{283} , OR^{284} , OR^{285} , OR^{286} , OR^{287} , OR^{288} , OR^{289} , $\text{OR}^{290}</$

CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 468063-15-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 437612-75-4P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 437613-05-3P, N-Butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-79-5P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-80-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-98-8P, 7-Chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-17-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 468063-27-6P, 4-[7-Chloro-2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-28-7P, Ethyl 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Intermediate; preparation and use of pyrazolopyridines for treatment of prophylaxis of herpes viral infections)


RN 437612-75-4 CAPLUS
CN Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)

-R10NR10R10. Each R10 is the same or different and is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl; Ar is an aryl; Het is a 5- or 6-membered heterocyclic or heteroaryl group; n is 0-2. R2 is H, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -NR7R8, Ar, -NHR10Ar, -OR7, -OAr, -S(O)nAr, -C(O)nAr, -R10NR7Ar, Het, -NHR10Het, -NHR10Het, -OHet and -OR10Het. Y is N or CH; R3 and R4 are the same or different and are each independently H, halo, alkyl, cycloalkyl, alkenyl, Ar, -OR7, -OAr, -R10OR7, -R10ORAr, -NR7R8, -R10NR7R8, -R10NR7Ar, -C(O)R7, C(O)Ar, -CO2R7, -CO2Ar, -SO2NR9, Het, -NHR10Het and -NHR10Het; q is 0-5. Each R5 is the same or different and is independently halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, Ar, -NHR10Ar, -NR7Ar, Het, -NHR10Het, -NHR10Het, -OAr, -OAr, -R10OR9, -OR10Ar, -OR10Het, -R10NR7R8, -R10NR7Ar, -R10C(O)R9, -C(O)Ar, -C(O)Het, -CO2R9, -R10CO2R9, -C(O)NR7R8, -C(O)NR7Ar, -C(O)NHR10Het, -R10C(O)NR9R11, -C(S)N R9R11, -R10C(S)NR9R11, -R10NHC(NH)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ar, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7Ar, -R10SO2NHCOR9, -R10SO2NR9R11, -R10SO2R9, -S(O)NR9, cyano, azido and nitro; or two adjacent R5 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or aryl. P is 0-3; and each R6 is the same or different and is independently halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, Ar, Het, -R10Ar, -R10Het, -OR7, -OAr, -OAr, -R10OR9, -OR10Ar, -OR10Het, -R10NR7R8, -R10NR7Ar, -R10C(O)R9, -C(O)Ar, -C(O)Het, -CO2R9, -R10CO2R9, -C(O)NR7R8, -C(O)NR7Ar, -C(O)NHR10Het, -R10C(O)NR9R11, -C(S)NR9R11, -R10C(S)NR9R11, -R10NHC(NH)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ar, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7Ar, -R10SO2NHCOR9, -R10SO2NR9R11, -R10SO2R9, -S(O)NR9, cyano, azido and nitro; or two adjacent R6 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms; wherein when Y is CH, R3 is not -NR7Ar; . . . apprx.45 Example preps. are included. Several methods of preparation are claimed, e.g. reaction of II (R1a = H, halo, etc. as specified in the claims) with H2NC(NH)R2 to give I (R1a in place of R1 and other variables are subsets of those defined for I above) and when R1a = H, halo, converting this compound to a subset of I. For example, to a solution of 1-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-butyne-1-one (2.0 mmol) in DMF was added cyclohexylamine (4.1 mmol). The resulting mixture was heated at 80° for 12 h; upon cooling to room temperature, H2O was added, the mixture was extracted with EtOAc, the EtOAc phase was washed with brine, dried (Mg sulfate), filtered and concentrated in vacuo; the resulting residue was purified by flash chromatog. (1:1 EtOAc-hexane) to give, after recrystn. from MeCN, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (74%) as a white solid. To a solution of 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (0.37 mmol) in anhydrous THF (5 ml) at -78° was added BuLi (1.1 mmol of 1.6M solution in hexane); the resulting solution was stirred for 10 min at -78°, followed by addition of di-Et disulfide (1.1 mmol). The reaction was stirred at -78° for 20 min and then allowed to warm to room temperature; H2O and EtOAc were added to the reaction mixture; the phases were separated, the aqueous phase washed with EtOAc and the combined organic phase dried (Mg sulfate), filtered and concentrated in vacuo; the resulting solid was purified by flash chromatog. (1:1 EtOAc-hexane) to give, after recrystn. from EtOAc N-[4-[5-chloro-7-(ethylsulfanyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N-cyclopentylamine (52%) as a solid.


IT 401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 468063-15-2P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Intermediate; preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)

RN 401815-63-2 CAPLUS


CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468062-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-17-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 468063-27-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-85-3 CAPLUS




RN 468063-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI)
(CA INDEX NAME)




IT 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 437612-52-7P, 7-Chloro-2-(4-fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-95-5P, 2-(4-Fluorophenyl)-7-methylthio-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-97-7P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-00-5P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-02-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-04-9P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-13-0P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(ethylsulfinyl)pyrazolo[1,5-a]pyridine 468063-14-1P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(ethylthio)pyrazolo[1,5-a]pyridine 468063-21-0P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)-7-methoxy-pyrazolo[1,5-a]pyridine 468063-25-4P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylate 468063-29-8P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 401816-32-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-34-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468062-95-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-97-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-00-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-04-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-13-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(ethylsulfinyl)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-14-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(ethylthio)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-21-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 468063-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 468063-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, (9CI) (CA INDEX NAME)




RN 401816-37-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

IT


401816-37-3P, N-Butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 437612-79-8P, N-Cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468062-94-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-96-6P, 2-(4-Fluorophenyl)-7-methylsulfanyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-99-9P, N-Butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-01-6P, N-Benzyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-03-8P, N-Butyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-05-0P, N-Benzyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-06-1P, N-Cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-07-2P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-08-3P, N-Cyclohexyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-09-4P, 3-(4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinylamino)-1-propanol 468063-10-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-11-8P, 2-(4-Fluorophenyl)-3-[2-(phenyloxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-12-9P, 2-(4-Fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-20-9P, 2-(4-Fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-23-2P, N-Butyl-4-[2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-24-3P, N-[4-[5-Chloro-7-(ethylsulfanyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N-cyclopentylamine 468063-30-1P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-31-2P, N-Butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-32-3P, N-Butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-33-4P, N-Butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-34-5P, N-Cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-35-6P, N-Dimethyl 2-(4-fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-7-pyrazolo[1,5-a]pyridinylcarboxamide 468063-57-2P, 4-[7-Butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-58-3P, 4-[5-Chloro-2-(3-chlorophenyl)-7-(methylsulfanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-59-4P, morpholinopyrazolo[1,5-a]pyridin-3-yl-7-(methylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-amine 468063-60-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(isopropylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)




RN 437612-79-8 CAPLUS
CN 4-Pyrimidinamine, N-cyclopentyl-6-(2-(4-fluorophenyl)-7-(methythio)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 468062-94-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-96-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-(4-fluorophenyl)-7-(methylsulfinyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468063-05-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 468063-01-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 468063-03-8 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)







RN 468063-06-1 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopropyl-4-[[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)



RN 468063-07-2 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 468063-08-3 CAPLUS
 CN 2-Pyrimidinamine, N-cyclohexyl-4-[[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 468063-09-4 CAPLUS


CN 1-Propanol, 3-[[4-[[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 468063-10-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-methoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-11-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-phenoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-12-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)-3-[[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]]- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-{2-(cyclopentylamino)-4-pyrimidinyl}-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 468063-31-2 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-{7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl}- (9CI) (CA INDEX NAME)




RN 468063-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-{2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl}- (9CI) (CA INDEX NAME)




RN 468063-33-4 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-{2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl}- (9CI) (CA INDEX NAME)




RN 468063-20-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 468063-23-2 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-{2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl}- (9CI) (CA INDEX NAME)




RN 468063-24-3 CAPLUS
CN 2-Pyrimidinamine, 4-{5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl}-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-30-1 CAPLUS


CN 2-Pyrimidinamine, 4-[5-chloro-2-(3-chlorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468063-59-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-60-7 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-[(1-methylethyl)thio]-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:720128 CAPLUS
DOCUMENT NUMBER: 137:379680
TITLE: Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists
AUTHOR (S): Bondavalli, Francesco; Botta, Maurizio; Bruno, Olga; Ciacci, Andrea; Corelli, Federico; Fossa, Paola;



RN 468063-34-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 468063-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468063-57-2 CAPLUS
CN 2-Pyrimidinamine, 4-[7-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468063-58-3 CAPLUS

CORPORATE SOURCE: Lucacchini, Antonio; Manetti, Fabrizio; Martini, Claudia; Menozzi, Giulia; Mosti, Luisa; Ranise, Angelo; Schenone, Silvia; Tafi, Andrea; Trincavelli, Maria Letizia
SOURCE: dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Genoa, I-16132, Italy
Journal of Medicinal Chemistry (2002), 45(22), 4875-4887
CODEN: JMCWAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:379680
AB We present a combined computational study aimed at identifying the three-dimensional structural properties required for different classes of compounds to show antagonistic activity toward the A1 adenosine receptor (AR). Particularly, an approach combining pharmacophore mapping, mol. alignment, and pseudoreceptor generation was applied to derive a hypothesis of the interaction pathway between a set of A1 AR antagonists taken from the literature and a model of the putative A1 receptor. The pharmacophore model consists of seven features and represents an improvement of the N6-C8 model, generally reported as the most probable pharmacophore model for A1 AR agonists and antagonists. It was used to build up a pseudoreceptor model able to rationalize the relationships between structural properties and biol. data of, and external to, the training set. In fact, to further assess its statistical significance and predictive power, the pseudoreceptor was employed to predict the free energy of binding associated with compounds constituting a test set. While part of these mols. was also taken from the literature, the remaining compounds were designed and synthesized by our research group. All of the new compounds were tested for their affinity toward A1, A2a, and A3 AR, showing interesting antagonistic activity and A1 selectivity.
IT 131185-37-0
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (therapeutic use); BIOL (biological study); USES (Uses)
Al receptor antagonists
RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L5 ANSWER 38 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:716277 CAPLUS
DOCUMENT NUMBER: 137:247709
TITLE: Preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amine for treating herpes viral infections
INVENTOR(S): Boyd, F. Leslie; Gudmundsson, Kristjan; Johns, Brian A.
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
PCT Int. Appl., 191 pp.
SOURCE: CODEN: PIXX2D

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072581	A2	20020919	WO 2002-US6552	20020305
WO 2002072581	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248531	A1	20020924	AU 2002-248531	20020305
EP 1366048	A2	20031203	EP 2002-717537	20020305
EP 1366048	B1	20040825		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 274515	T	20040915	AT 2002-717537	20020305
JP 2004529119	T	20040924	JP 2002-717497	20020305
ES 2227451	T3	20050401	ES 2002-2717537	20020305
US 2005049260	A1	20050303	US 2003-468729	20030822
US 7153855	B2	20061226		
US 2006293344	A1	20061228	US 2006-468319	20060830
PRIORITY APPL. INFO.:			US 2001-274297P	P 20010308
			WO 2002-US6552	W 20020305
			US 2003-468729	A3 20030822

OTHER SOURCE(S): MARPAT 137:247709
GI




AB The title compds. [I; R1 = halo, NR7R8, aryl, etc. (wherein R7, R8 = H, alkyl, cycloalkyl, etc.); R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, alkenyl, etc.; when q = 1 and R5 is in the para position, R5 is not halo; when Y = CH, R3 is not NR7(aryl)], useful for the prophylaxis or treatment of herpes viral infections, were prepared E.g., a multi-step synthesis of I [R1, R2 = cyclopentylamino; R3, R4 = H; Y = N; R5 = 4-MeO], starting with 6-chloro-2-picolone, which showed IC50 of 0.3 µM against HSV-1, was given.
IT 437611-98-8P 460078-20-OP 460078-24-4P
460078-25-5P 460078-26-6P 460078-37-9P
460078-46-0P 460078-47-1P 460078-55-1P
460078-60-8P 460078-67-5P 460078-70-OP
460078-71-1P 460078-74-4P 460078-78-8P


460078-80-2P 460078-86-8P 460078-87-9P
 460078-88-0P 460078-89-1P 460079-01-0P
 460079-04-3P 460079-10-1P 460079-11-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 Preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 Preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amines
 for treating herpes viral infections)
 RN 437611-98-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-
 (butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-20-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-
 pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-24-4 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-7-(1-
 pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460078-25-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(4-methoxyphenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-
 a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460078-26-6 CAPLUS
 CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-
 pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-37-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-aminophenyl)-N-butyl-3-[2-
 (butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-46-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-
 (cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-47-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-aminophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-60-8 CAPLUS
CN Benzonitrile, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-67-5 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5,6-dimethyl- (9CI) (CA INDEX NAME)




RN 460078-70-0 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-71-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-74-4 CAPLUS
CN Phenol, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-78-8 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 460078-80-2 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-86-8 CAPIUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460079-01-0 CAPIUS
CN 1,4-Butanediolamine, N-[3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)


RN 460078-87-9 CAPIUS
CN Phenol, 4-[3-[2-(cyclopropylamino)-4-pyrimidinyl]-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-88-0 CAPIUS
CN Phenol, 4-[7-(cyclopropylamino)-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-89-1 CAPIUS
CN Phenol, 4-[7-(cyclopropylamino)-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)






RN 460079-04-3 CAPLUS

Carbamic acid, [(4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9C) (CA INDEX NAME)




RN · 460079-10-1 CAPLUS

CA INDEX NAME	(9CI)	methoxyphenyl]pyrazolo[1,5-a]pyridin-7-ylamino)-	pyrazolo[1,5-a]pyridin-7-ylamino)-	4-pyrimidinyl]-2-(4-	1-Butanol, 4-[[3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-
1-Butanol, 4-[[3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-methoxyphenyl]pyrazolo[1,5-a]pyridin-7-ylamino)-	(9CI)				



RN	460079-11-2	CAPLUS
----	-------------	--------

phosphoric acid, 4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



II


437613-19-9P	460078-19-9P	460078-27-7P	460078-28-8P
460078-29-9P	460078-30-2P	460078-31-3P	460078-31-3P
460078-32-4P	460078-33-4P	460078-34-6P	460078-34-6P
460078-35-7P	460078-36-4P	460078-38-0P	460078-38-0P
460078-39-1P	460078-40-4P	460078-41-5P	460078-41-5P
460078-42-6P	460078-43-7P	460078-44-8P	460078-44-8P
460078-45-9P	460078-48-2P	460078-49-3P	460078-49-3P
460078-50-6P	460078-51-7P	460078-52-8P	460078-52-8P
460078-53-9P	460078-54-1P	460078-56-2P	460078-56-2P
460078-57-3P	460078-58-4P	460078-59-5P	460078-59-5P
460078-61-9P	460078-62-0P	460078-63-1P	460078-63-1P
460078-64-2P	460078-65-3P	460078-66-4P	460078-66-4P
460078-68-6P	460078-69-7P	460078-72-2P	460078-72-2P
460078-73-3P	460078-75-5P	460078-76-6P	460078-76-6P
460078-77-7P	460078-79-9P	460078-81-3P	460078-81-3P
460078-82-4P	460078-83-5P	460078-84-6P	460078-84-6P
460078-85-7P	460078-90-4P	460078-91-5P	460078-91-5P
460078-92-6P	460078-93-7P	460078-94-8P	460078-94-8P
460078-95-9P	460078-96-0P	460078-97-1P	460078-97-1P
460078-98-2P	460078-98-3P	460079-00-9P	460079-00-9P
460079-02-1P	460079-03-2P	460079-03-4P	460079-03-4P
460079-06-5P	460079-07-6P	460079-08-7P	460079-08-7P
460079-09-8P	460079-10-9P	460079-11-8P	460079-11-8P
460079-19-0P	460079-21-4P	460079-22-5P	460079-22-5P
460079-23-6P	460079-24-7P	460079-25-8P	460079-25-8P
460079-26-9P	460079-27-0P	460079-28-1P	460079-28-1P
460079-29-2P	460079-30-5P	460079-31-6P	460079-31-6P

460079-32-1E
URL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(uses)
preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amines
for treating herpes viral infections)


RN 437613-19-9 CAPLUS

Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




NRN 460078-27-7 CAPLUS


CN Phenol, 4-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-28-8 CAPLUS
CN Phenol, 4-[3-(2-amino-4-pyrimidinyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-29-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-30-2 CAPLUS
CN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460078-31-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-32-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-33-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN	460078-34-6	CAPLUS
CN	Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-(cyclobutylmethoxy)phenyl]-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)	




460078-35-7	CAPLUS
Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-phenoxyphenyl)- (9CI)	(CA INDEX NAME)




460078-36-8 CAPLUS
Pyrazolo[1,5-a]pyridin-7-amine, 2-{[1,1'-biphenyl]-4-yl-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]}- (9CI) (CA INDEX NAME)




Pyrazolo[1,5-*a*]pyridin-7-amine, N-butyl-3-{2-(butylamino)-4-pyrimidinyl}-2-[4-(cyclohexylamino)phenyl]- (9CI) (CA INDEX NAME)




Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(1-methylethenyl)phenyl]- (9CI) (CA INDEX NAME)




460078-40-4	CAPLUS	N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-pyrazol[1,5-a]pyridin-7-amine,
		[4-(phenylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-41-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-N-phenyl-2-[4-(phenylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-42-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-(bis(cyclopropylmethyl)amino)phenyl]-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-43-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-[(cyclopropylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-44-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-45-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(2-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-48-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-2-(3-bromophenyl)-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-49-3 CAPLUS
CN 2-Pyrimidinamine, 4-[[2-[(3-bromophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-50-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[[1,1'-biphenyl]-3-yl]-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-51-7 CAPLUS
CN 2-Pyrimidinamine, 4-[[2-[(1,1'-biphenyl)-3-yl]-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl]- (9CI) (CA INDEX NAME)




RN 460078-52-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-53-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-54-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-56-2 CAPLUS
CN Acetamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-57-3 CAPLUS
CN Methanesulfonamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-58-4 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)-7-(1-pyrazolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-59-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 460078-61-9 CAPLUS
CN Benzamide, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-62-0 CAPLUS
CN Benzoic acid, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-63-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-methoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-64-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-amino-4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-65-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-[(phenylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-66-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460078-68-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5,6-dimethyl-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460078-69-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460078-72-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 460078-73-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 460078-75-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-(cyclopropylmethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 460078-81-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460078-77-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-79-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)



RN 460078-90-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-91-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-92-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)


RN 460078-82-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-83-5 CAPLUS
CN 2-Pyrimidine, N-cyclopropyl-4-[2-(4-methoxyphenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460078-84-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-85-7 CAPLUS




RN 460078-93-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(2-(cyclopropylamino)-4-pyrimidinyl)-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-94-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(((4-methoxyphenyl)methyl)amino)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-95-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-96-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-97-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 460078-98-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-99-3 CAPLUS
 CN Glycine, N-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 460079-00-9 CAPLUS
 CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[4-{7-(butylamino)-3-[2-(butylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460079-02-1 CAPLUS
 CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[4-{[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460079-03-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 460079-05-4 CAPLUS
 CN Guanidine, [4-{[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 460079-06-5 CAPLUS
 CN Methanesulfonamide, N-[4-{[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 460079-07-6 CAPLUS
CN Benzenesulfonamide, N-([4-([3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl)amino]carbonyl)-4-methyl- (9CI) (CA INDEX NAME)


PAGE 1-A




RN 460079-08-7 CAPLUS
CN Butanoic acid, 4-([4-([3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl)amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 460079-09-8 CAPLUS
CN Phosphoramidic acid, [4-([3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl- (9CI) (CA INDEX NAME)




RN 460079-14-5 CAPLUS
CN 1-Butanol, 4-([3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]-, dihydrogen phosphate (ester), diammonium salt (9CI) (CA INDEX NAME)




PAGE 2-A

● 2 NH₃


RN 460079-17-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-azidophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN	460079-19-0	CAPLUS
CN	Pyrovalidone, 1-[[[3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]acetyl]- (9CI)	(CA INDEX NAME)




460079-21-4	CAPLUS
Methanesulfonamide, N-[2-([3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl)amino]ethyl)- (9CI) (CA INDEX NAME)	




URN	460079-22-5	CAPLUS
CN	1,2-Ethanediamine, N-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI)	(CA INDEX NAME)




SRN	460079-23-6	CAPLUS
CN	2-Pyrimidinamine, N-cyclopentyl-4-[2-(3-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




SRN	460079-24-7	CAPLUS
CN	Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI)	(CA INDEX NAME)




REF	DATE	BY	DESCRIPTION
460079-25-8	CAPLUS		Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460079-26-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 460079-27-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460079-28-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 460079-29-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-30-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 460079-31-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 460079-32-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



IT 460079-83-8


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amines
for treating herpes viral infections)

RN 460079-83-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-chloro-3-
(diphenylmethylen)aminophenyl]-N-cyclopentyl-3-[2-(cyclopentylamino)-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 460079-35-0P 460079-50-9P 460079-51-0P
460079-63-6P 460079-73-6P 460079-74-7P
460079-80-5P 460079-81-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


RN 460079-35-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-
[4-[(diphenylmethylen)aminophenyl]- (9CI) (CA INDEX NAME)




RN 460079-50-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-
pyrimidinyl]-2-[3-[(diphenylmethylen)aminophenyl]- (9CI) (CA INDEX
NAME)




RN 460079-51-0 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-[3-[(diphenylmethylen)aminophenyl]-
7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460079-65-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-
yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-73-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-
yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-74-7 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 460079-80-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 460079-81-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



L5 ANSWER 39 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:466008 CAPLUS
DOCUMENT NUMBER: 137:33325
TITLE: Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyrimidine derivs. as antiviral agents
INVENTOR(S): Boyd, F. Leslie; Chamberlain, Stanley D.; Cheung, Mui; Gudmundsson, Kristjan; Harris, Philip Anthony; Johns, Brian A.; Jung, David Kendall; Peel, Michael Robert; Stanford, Jennifer Badiang; Sexton, Connie Jo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048148	A2	20020620	WO 2001-US44231	20011126
WO 2002048148	A3	20030501		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MM, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 200239348	A	20020624	AU 2002-39348	20011126
EP 1377573	A2	20040107	EP 2001-987099	20011126
EP 1377573	B1	20050727		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004515550	T	20040527	JP 2002-549679	20011126
AT 300541	T	20050815	AT 2001-987099	20011126
ES 2243579	T3	20051201	ES 2001-1987099	20011126
US 2005049259	A1	20050303	US 2003-433881	20030605
US 7163940	B2	20070116		
PRIORITY APPLN. INFO.:				
			US 2000-255763P	P 20001215
			US 2001-274284P	P 20010308
			WO 2001-US44231	W 20011126
OTHER SOURCE(S):			MARPAT 137:33325	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I: R1 = cyclopentylamino, CH3(CH2)3NH, Cl, NHNH2, H2NCH2CH2NH, NH2, 4-methylpiperidinyl, 4-CH3OC6H4NH, Br, CH3OCH2NH, HO2CCH2NH, cyclopropylamino, (CH3)2N, 4-morpholinyl, R2 = NH2, cyclopentylamino, CH3(CH2)3NH, CH3S-O, HO(CH2)3NH, CH2:CHCH2NH, 4-morpholinyl, cyclopropylamino, pyrrolidinyl, (CH3)2N, 3-(4-morpholinyl)propylamino, CH3(HOOCCH2)2N, R3 = H, CH3, (CH3)2NCH2, (tetrahydro-2H-pyran-2-yl)oxy)methyl, HOCH2, C6H5, COOH, 4-pyridinyl, R4 = H, CH3; R5 = F, Br, Cl; X = N, CH], salts, and pharmaceutical compds. containing the same are prepared as antiviral agents. Title compds. I are tested for HSV-1 inhibition and the results demonstrate that title compds. I are useful for the treatment and prophylaxis of herpes viral infections. Thus, the title compound II was prepared from 6-chloro-2-picoline, Et 4-fluorobenzoate, and cyclopentylamine via cyclization.

IT 437612-03-8P 437612-12-9P 437612-13-0P
 437612-20-9P 437612-22-1P 437612-23-2P
 437612-33-4P 437612-46-9P 437612-48-1P
 437612-50-5P 437612-52-7P 437612-57-2P
 437612-60-7P 437612-70-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)


RN 437612-03-8 CAPLUS
 CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-12-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-[[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-13-0 CAPLUS
 CN 4-Pyrimidinmethanol, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




RN 437612-20-9 CAPLUS
 CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 437612-22-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 437612-23-2 CAPLUS
 CN 4-Pyrimidinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




RN 437612-33-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-(2-(methylsulfinyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437612-46-9 CAPLUS
CN 4-Pyrimidinmethanamine, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 437612-48-1 CAPLUS
CN 2-Pyrimidinamine, 4-(7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl-5-methyl- (9CI) (CA INDEX NAME)




RN 437612-50-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-(butylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 437612-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-57-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-bromo-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 437612-60-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3,7-bis(2-fluoro-4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 437612-70-9 CAPLUS
CN 4-Pyrimidinecarboxamide, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




IT 437611-97-7P 437611-98-8P 437611-99-9P
437612-00-5P 437612-01-6P 437612-02-7P
437612-04-9P 437612-05-0P 437612-06-1P
437612-07-2P 437612-08-3P 437612-09-4P
437612-10-7P 437612-11-8P 437612-14-1P
437612-15-2P 437612-16-3P 437612-17-4P
437612-18-5P 437612-19-6P 437612-21-0P
437612-24-3P 437612-25-4P 437612-26-5P
437612-27-6P 437612-28-7P 437612-29-8P
437612-30-1P 437612-31-2P 437612-32-3P
437612-34-5P 437612-35-6P 437612-36-7P
437612-37-8P 437612-38-9P 437612-39-0P


437612-40-3P 437612-41-4P 437612-42-5P
437612-43-6P 437612-44-7P 437612-45-8P
437612-47-0P 437612-49-2P 437612-51-6P
437612-53-8P 437612-54-9P 437612-55-0P
437612-56-1P 437612-58-3P 437612-59-4P
437612-61-8P 437612-62-9P 437612-63-0P
437612-64-1P 437612-65-2P 437612-66-3P
437612-67-4P 437612-68-5P 437612-69-6P
437612-71-0P 437612-72-1P 437612-73-2P
437612-74-3P 437612-75-4P 437612-76-5P
437612-77-6P 437612-78-7P 437612-79-8P
437612-80-1P 437613-20-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)
RN 437611-97-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-{2-(cyclopentylamino)-4-pyrimidinyl}-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437611-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437611-99-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-00-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-01-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-04-9 CAPLUS




RN 437612-05-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-06-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-07-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-08-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-09-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[[3-(4-morpholinyl)propylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-10-7 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-11-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-14-1 CAPLUS
CN Glycine, N-[4-{7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 437612-15-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 437612-16-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-{2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl}] - (9CI) (CA INDEX NAME)




RN 437612-17-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-18-5 CAPLUS
CN 4-Pyrimidinmethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]] - (9CI) (CA INDEX NAME)




RN 437612-19-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 437612-21-0 CAPLUS
CN Glycine, N-[3-{2-(cyclopentylamino)-6-methyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]] - (9CI) (CA INDEX NAME)




RN 437612-24-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-26-5 CAPLUS
CN 2[(1H)-Pyridinone, 4-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrazone (9CI) (CA INDEX NAME)




RN 437612-27-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-28-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 437612-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 437612-31-2 CAPLUS


CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-34-5 CAPLUS
CN 1-Propanol, 3-[(4-{7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 437612-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(2-propenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-39-0 CAPLUS




RN 437612-36-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-37-8 CAPLUS
CN 1-Piperazineethanol, 4-[4-{7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-38-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-(2-methoxyethyl)-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-40-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-41-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-(4-morpholinyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-42-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-(4-morpholinyl)ethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-43-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 437612-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 437612-45-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 437612-47-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-
((dimethylamino)methyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA
INDEX NAME)




RN 437612-49-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5-
methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-51-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-
fluorophenyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 437612-53-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-fluorophenyl)-N-(2-(1-methyl-2-
pyrrolidinylethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-54-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-fluorophenyl)-N-methyl-3-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-55-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N,N-diethyl-2-(4-fluorophenyl)-3-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-56-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-iodo-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-58-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-butyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-59-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(1H-imidazol-1-yl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 437612-61-8 CAPLUS
CN 1,3-Propanediamine, N,N'-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3,7-diyl]di-4,2-pyridinediyl]bis- (9CI) (CA INDEX NAME)




H₂N⁺ (CH₂)₃⁺ NH₂
RN 437612-62-9 CAPLUS
CN 2-Pyridinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl- (9CI) (CA INDEX NAME)




RN 437612-63-0 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclohexyl-3-[2-(cyclohexylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437612-68-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-69-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(2-phenyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437612-71-0 CAPLUS
CN 4-Pyrimidinecarboxamide, N-cyclopentyl-2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


RN 437612-64-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-65-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-[(1-pyrrolidinyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)]-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-66-3 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-7-[[[(2-hydroxyethyl)methyl]amino]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)]-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-67-4 CAPLUS
CN 4-Pyrimidinecarboxamide, N-cyclopentyl-2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-78-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-79-8 CAPLUS
CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 437612-80-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[6-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437613-20-2 CAPLUS
CN 4-Pyrimidinmethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


IT 401815-63-2P 437612-94-7P 437612-97-0P
437613-02-0P 437613-05-3P 437613-07-5P
437613-08-6P 437613-09-7P 437613-12-2P
437613-19-9P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)
RN 401815-63-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-94-7 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]- (9CI) (CA INDEX NAME)




RN 437612-97-0 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 437613-02-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437613-07-5 CAPLUS
CN 2(1H)-Pyrimidinethione, 4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437613-08-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-(2-(methythio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437613-09-7 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-(iodomethyl)- (9CI) (CA INDEX NAME)



RN 437613-12-2 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-{7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-
alpyridin-3-yl]-2-(cyclopentylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 437613-19-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-chlorophenyl)-N-cyclopentyl-3-
[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 40 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:466007 CAPLUS
DOCUMENT NUMBER: 137:33316
TITLE: Preparation of pyrazolopyridinamine derivatives as
antiviral agents
INVENTOR(S): Chamberlain, Stanley D.; Gudmundsson, Kristjan; Johns,
Brian A.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048147	A2	20020620	WO 2001-US44210	20011126
WO 2002048147	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			


KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, IQ, GW, ML, MR, NE, SN, TD, TG
AU 200239344 A 20020624 AU 2002-39344 20011126
EP 1341788 A2 20030910 EP 2001-987095 20011126
EP 1341788 B1 20050810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004518651 T 20040624 JP 2002-549678 20011126
AT 301653 T 20050815 AT 2001-987095 20011126
ES 2245380 T3 20060101 ES 2001-1987095 20011126
US 2004072853 A1 20040415 US 2003-433884 20030605
US 6919352 B2 20050719
US 2005182080 A1 20050818 20050317
US 7087618 B2 20060808
US 2005171133 A1 20050804 20050318
US 7160897 B2 20070109
PRIORITY APPL. INFO.:
OTHER SOURCE(S): MARPAT 137:33316
G1




AB Title compds. [I; R = F, OCH3; R1 = 3-N3, 3-NH2, 3-CH2OH, 3-NO2, H, 3-COC6H5, 4-F, 4-OCH3, 3,4,5-(OCH3)3; R2 = 7-cyclopentylamino, H, SCH2CH3; R3 = Cl, cyclopentylamino, H] are prepared from condensation of picolines and alkyl benzoates followed by cyclization and addition reaction. Title compds. 1, pharmaceutically acceptable salt, solvate, or physiol. functional derivative are useful in the prophylaxis or treatment of conditions or diseases associated with herpes viral infections in an animal.
IT 437384-04-8P 437384-11-7P 437384-12-8P
437384-13-9P 437384-14-0P 437384-23-1P
437384-32-2P 437384-33-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
[preparation of pyrazolopyridinamine derivs. as antiviral agents]
RN 437384-04-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437384-11-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-12-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-13-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-14-0 CAPLUS
CN Methanone, [3-[[4-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)




RN 437384-23-1 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 437384-32-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-33-3 CAPLUS
CN Benzenemethanol, 3-((4-((4-((4-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl)amino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-phenyl)-(9CI) (CA INDEX NAME)




IT 437384-29-7P 437384-30-OP 437384-31-1P
437384-36-6P 437384-37-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolopyridinamine derivs. as antiviral agents)
RN 437384-29-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-30-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-31-1 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 437384-36-6 CAPLUS
CN 1,3-Benzenediamine, N-[4-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)





RN 437384-37-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-((3-azidophenyl)amino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 41 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:171898 CAPLUS
 DOCUMENT NUMBER: 136:232298
 TITLE: Pyrazolopyridine compounds and pharmaceutical use thereof as adenosine receptor antagonists
 INVENTOR(S): Akanane, Akiyoshi; Tanaka, Akira; Minagawa, Masatoshi; Itani, Hiroshi; Ohtake, Hiroaki
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018382	A1	20020307	WO 2001-JP7322	20010827
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GU, HK, HN, IL, IN, LU, NL, SE, MC, PT, R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004507542	T	20040311	JP 2002-523897	20010827
US 2004110763	A1	20040610	US 2003-348894	20030226
PRIORITY APPLN: INFO:			AU 2000-9698	A 20000828
			WO 2001-JP7322	W 20010827
OTHER SOURCE(S):				
GI				




AB Pyrazolopyridines I are disclosed (wherein: R1 = H, (un)substituted lower alkyl or cycloalkyl which may be interrupted by an O or N; R2 = H, halo, or lower alkoxy; R3 = independent substituent(s); and n = 1 to 4; or a salt thereof). The compds. are adenosine antagonists, and are thus useful for the prevention and/or treatment of a wide variety of medical conditions, e.g., depression, dementia (e.g., Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. In particular, treatment of Parkinson's disease and/or associated symptoms is specifically claimed. Over 330 example compds. are described. For instance, cyclization of 1-amino-4-methoxypyridinium iodide with 3-(benzenesulfonyl)-6-(phenylethynyl)pyridazine, gave 3-(3-phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine. This compound was hydrolyzed at the phenylsulfinyl group, and the resultant pyridazinone was N-alkylated with NaH/DMF and iso-PrI to give title compound II. In radioligand binding assays, II had Ki values of 0.15 nM for human A1 receptors and 1.38 nM for human A2A receptors. In an anticonvulsant test in mice, 6 tested example compds. I at 3.2 mg/kg orally completely suppressed the cataleptic effects of haloperidol at 0.32 mg/kg i.p.


IT 403490-01-7P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-03-9P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-05-1P, 5-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-24-4P, 2-[[3-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetate 403490-59-5P, Tert-Butyl 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]piperidinecarboxylate 403490-61-9P, 5-(4-Piperidin-1-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride 403490-77-7P, Ethyl [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetate 403490-79-9P, [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetic acid 403490-87-9P, 5-(2-Oxo-2-(1-piperazinyl)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride 403491-38-3P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine trifluoromethanesulfonate 403491-41-8P, Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-

yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylate 403491-43-OP.
 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylic acid 403492-02-4P, 3-(4-Hydroxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-07-9P, tert-Butyl 4-(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)-1-piperazinecarboxylate 403492-13-7P, 5-(1-Piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-89-7P, tert-Butyl [3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbamate 403492-91-1P, 5-Amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-06-1P, 5-(4-Bromobutanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-91-4P, 4-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Drug candidate; Preparation of pyrazolopyridines as adenosine receptor antagonists)


RN 403490-01-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-03-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-05-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(5-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-24-4 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 403490-59-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403490-61-9 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-piperidinyl)oxy]pyrazolo[1,5-a]pyridin-3-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 403490-77-7 CAPLUS
CN Acetic acid, 1-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403490-79-9 CAPLUS
CN Acetic acid, 1-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, hydrochloride (9CI) (CA INDEX NAME)




RN 403490-87-9 CAPLUS
CN Piperazine, 1-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 403491-38-3 CAPLUS
CN Methanesulfonic acid, trifluoro-, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX NAME)




RN 403491-41-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 403491-43-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 403492-02-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[(5-(4-hydroxy-1-piperidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 403492-07-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403492-13-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-89-7 CAPLUS
CN Carbamic acid, [3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403492-91-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403493-06-1 CAPLUS
CN Butanamide, 4-bromo-N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)



RN 403493-91-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 403490-07-3P, 5-[2-(Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-10-8P, 5-[2-(4-Morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

403490-13-1P, 5-[(4-Methoxyphenylsulfonyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-15-3P, 5-Benzoyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-16-4P, 5-Phenethyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-18-6P, 5-Isopropoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-20-0P, 5-(3-(2R)-2-(Methoxymethyl)-4-morpholinyl)propoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-22-2P, 5-(2-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-26-6P, 5-(2-Aminoethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-28-8P, 5-(3-Dimethylaminopropoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-30-2P, 5-(2-(1-Piperidinyl)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-32-4P, 5-(2-(1-Pyrrolidinyl)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-34-6P, 5-(2-(3R,5S)-3,5-Dimethyl-4-morpholinyl)ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-36-8P, 5-(4-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-38-0P, 5-(3-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-40-4P, 5-Propoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-42-6P, 5-Isopentyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-47-1P, 5-(2-Cyclohexylethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-49-3P, 5-(2-(2R,6S)-2,6-Dimethyl-4-morpholinyl)ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-51-7P, 5-(2-Diethylamino)ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-53-9P, 5-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-55-1P, 5-(2-Oxopropoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-57-3P, 5-(2-Oxo-1-pyrrolidinyl)ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-63-1P, 5-(2-Pyridinyloxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-65-3P, Benzyl [(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]acetate 403490-67-5P
403490-69-7P, 2-Phenylpyrazolo[1,5-a]pyridine
403490-71-1P, 2-Phenylpyrazolo[1,5-a]pyridine
403490-73-3P, N-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]phenylacetamide 403490-75-5P, 5-Phenoxo-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-77-7P, 2-Phenylpyrazolo[1,5-a]pyridine
403490-79-9P, 2-Phenylpyrazolo[1,5-a]pyridine
403490-81-3P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethylacetamide
403490-83-5P, N-Benzyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-85-7P, tert-Butyl 4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]piperazine-1-carboxylate 403490-89-1P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-phenylacetamide 403490-91-5P, N-Isobutyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403490-93-7P,

5-(Tetrahydropyran-4-yl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-95-9P, 5-[(5-Methoxy-2-pyridinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-97-1P, 5-[(5-Nitro-2-pyridinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-99-3P, Methyl [(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]acetate 403491-01-0P, 5-[2-(4-Methyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-03-2P, 5-[2-(4-Morpholinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-05-4P, N,N-Bis(2-ethoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-07-6P, 5-[2-(4-Benzyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-09-8P, 5-[2-(4-Acetyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-11-2P, N,N-Dimethyl-4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-1-piperazinecarboxamide 403491-13-4P, N,N-Dimethyl-4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-1-piperidinecarboxamide 403491-15-6P, 5-[[1-Acetyl-4-piperidinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-17-8P, N-[2-(Dimethylamino)ethyl]-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-19-0P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(3-methoxybenzyl)acetamide 403491-21-4P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-[2-(2-pyridinyl)ethyl]acetamide 403491-23-6P, N-Cyclopropyl-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-25-8P, N-Cyclopentyl-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-27-0P, N-Cyclohexyl-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-29-2P, N-(4-Hydroxycyclohexyl)-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-31-6P, N-Butyl-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-33-8P, N-(2-Methoxyethyl)-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-36-1P, N-(2-Ethoxyethyl)-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-45-2P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carbonitrile 403491-47-4P, N,N-Dimethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-49-6P, 5-(1-Pyrrolidinyl)carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-51-0P, 5-[(4-Methyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-53-2P, N-(2-Hydroxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-55-4P, N-[2-(Dimethylamino)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-58-7P, N-(2-Ethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-60-1P, N-Methyl-N-[2-(pyridin-2-yl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-62-3P, 5-[(4-Acetyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-64-5P, 5-[(cis-2,6-Dimethyl-4-

morpholinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-66-7P, N-Benzyl-N-methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-68-9P, N-(tert-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-70-3P, 5-[[4-Phenyl-1-piperidinyl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-72-5P, N-Diethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-74-7P, N-(2-Isopropoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-76-9P, N-(3-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-78-1P, N-Methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-80-5P, 5-(1-Piperidinylcarbonyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-82-7P, N-[2-(1-Pyrolidinyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-84-9P, N-(5-Methyl-1,3-thiazol-2-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-86-1P, N-(2-Phenoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-88-3P, N-Bis(2-methoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-90-7P, N-(1-Methyl-1-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-92-9P, N-Isopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-93-0P, 5-(4-Methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-96-3P, 5-(4-Morpholinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-98-5P, 5-(4-Phenyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-00-2P, 5-(cis-2,6-Dimethyl-4-morpholinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-04-6P, 5-[4-(2-Pyridinyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-09-1P, 5-(4-Benzyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-11-5P, 5-(4-Methoxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-15-9P, Methyl 4-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-1-piperazinecarboxylate 403492-17-1P, 4-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-N,N-dimethyl-1-piperazinecarboxamide 403492-19-3P, 5-[4-(Methylsulfonyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-21-7P, 5-[4-(Phenylsulfonyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-23-9P, 5-(4-Benzoyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-25-1P, 5-(4-Acetyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-27-3P, 5-[4-(Dimethylamino)acetyl]-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-29-3P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-31-9P, 5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-33-1P, 5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-35-3P, 5-Methoxy-3-(3-oxo-2-tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-37-5P, 5-Methoxy-3-(3-oxo-2-(3R)-tetrahydrofuran-3-yl)-2,3-


dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-39-7P, 5-Methoxy-3-(3-oxo-2-((3S)-tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-41-1P, 5-Methoxy-3-(3-oxo-2-(1-methoxy-2-propyl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-43-3P, 5-Methoxy-3-(3-oxo-2-(1-methylpiperidin-4-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-45-5P, 5-Methoxy-3-(3-oxo-2-(1-methylpiperidin-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-47-7P, 5-Methoxy-3-(3-oxo-2-(tetrahydrofuran-4-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-49-9P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-51-3P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-53-5P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-55-7P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-57-9P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-59-1P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-61-5P, 5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-63-7P, 5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-65-9P, 7-Amino-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-67-1P, 7-Amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-69-3P, 4-Bromo-5-methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-71-7P, 5-(3-Hydroxy-3-methyl-1-butanyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-73-9P, 5-[(1-Hydroxycyclohexyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-75-1P, 5-Phenylethynyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-77-3P, N-Cyclopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-79-5P, N-Cycloheptyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-81-9P, 5-[(Hexahydro-1H-azepin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-83-1P, 5-[[4-(2-Pyridinyl)-1-piperazinyl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-85-3P, N-(n-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-87-5P, N-(2-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-89-9P, 5-Acetyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-95-5P, 5-Benzoyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-97-7P, 5-(2-Methylpropanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-99-9P, 5-(Methylsulfonylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-04-9P, Methyl 13-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbamate 403493-08-3P, 5-(2-Oxo-1-pyrrolidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-10-7P, 5-Bis(methoxymethylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-12-9P, 5-[[1-Methyl-4-piperidinyl]oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-

phenylpyrazolo[1,5-a]pyridine 403493-80-1P, 7-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-82-3P, 7-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-84-5P,
7-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-85-6P, 7-Methoxy-3-(3-oxo-2-n-propyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-87-8P, 4-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-89-0P, 4-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-91-2P, 4-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-93-6P, 4-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-95-8P,
4-(n-Propoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-97-0P, 4-[2-(Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-99-2P, 4-[2-(4-Morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-01-9P, 5-{[(1,4-Diazabicyclo[4.3.0]non-4-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-03-1P, 5-{[Morpholin-4-yl]carbonyl}-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-05-3P, N-Allyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-07-5P, N-(1-Phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-09-7P, N-(4-Methoxyphenetyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-11-1P, N-(2-Hydroxymethylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-15-5P, N-(3-Methoxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-17-7P, N-(1-Phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-19-9P, N-(2-Methoxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-21-3P, 5-{[(4-Hydroxy-piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-23-5P, N-(2-Methoxyethyl)-N-methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-25-7P, N-(4-Hydroxybutyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-27-9P, N-[2-Pyridinylethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-29-1P, N-[2-Chlorophenylethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-31-5P, N-(5-Methylisoxazol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-33-7P, N-(6-Methoxy-3-pyridinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-35-9P 403494-37-1P, N-[4-(Difluoromethoxy)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-39-3P, (S)-5-{{[2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl}-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-41-7P, N-(4-Phenoxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-43-9P, N-Cyclooctyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-45-1P, N-(1-Naphthylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-47-3P, N-(5-Hydroxy-1-naphthyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-49-5P, 5-{[(4-Methanesulfonylamino)piperidin-1-yl]carbonyl}-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]


alpyridine 403494-51-9p, 5-[(3-Hydroxypiperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-53-1p, N-(2-Oxohomopiperidin-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolopyridines as adenosine receptor antagonists)


RN 403490-07-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-10-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-[2-(1-methylethyl)-6-[5-[2-(4-morpholinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-13-1 CAPLUS
 CN Benzenesulfonic acid, 4-methoxy-, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX NAME)




RN 403490-15-3 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(phenylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 403490-16-4 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-phenylethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-18-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-(1-methylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-20-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-[3-[(2R)-2-(methoxymethyl)-4-morpholinyl]propoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403490-22-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-


pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-26-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-aminoethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-28-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[3-(dimethylamino)propoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403490-30-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-[2-(1-piperidinyl)ethoxy]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-[2-(1-pyrrolidinyl)ethoxy]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-34-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-(1-methylethyl)-4-morpholinylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 403490-36-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-38-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(3-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403490-40-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-(2-phenyl-5-propoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-42-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(3-methylbutoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-cyclohexylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-49-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-[(2R,6S)-2,6-dimethyl-4-morpholinylethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)



RN 403490-51-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[2-(diethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-53-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-ethoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-55-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(2-oxopropoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


CN 3(2H)-Pyridazinone, 6-[5-(2-cyclopentylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-69-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[2-(1-aziridinylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403490-71-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-pyridinyloxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-73-3 CAPLUS
CN Acetamide, N-[3-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 403490-67-5 CAPLUS


RN 403490-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-[2-(2-oxo-1-pyrrolidinylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-63-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-pyridinyloxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-65-3 CAPLUS
CN Acetic acid, [[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)







RN 403490-75-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-81-3 CAPLUS
CN Acetamide, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-83-5 CAPLUS
CN Acetamide, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-85-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403490-89-1 CAPLUS
CN Acetamide, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-91-5 CAPLUS
CN Acetamide, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-93-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-95-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[[3-[(1-methoxy-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 403490-97-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[3-[(1-methylethyl)-6-[[5-[(5-nitro-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 403490-99-3 CAPLUS
CN Acetic acid, [[3-[(1-methylethyl)-6-[[5-[(5-nitro-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 403491-01-0 CAPLUS
CN Piperazine, 1-[[3-[(1-methylethyl)-6-[[5-[(5-nitro-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 403491-03-2 CAPLUS
CN Morpholine, 4-[[3-[(1-methylethyl)-6-[[5-[(5-nitro-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 403491-05-4 CAPLUS
CN Acetamide, 2-[[3-[(1-methylethyl)-6-[[5-[(5-nitro-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 403491-07-6 CAPLUS
CN Piperazine, 1-[[3-[(1-methylethyl)-6-[[5-[(5-nitro-2-pyridinyloxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 403491-09-8 CAPLUS
CN Piperazine, 1-acetyl-4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-N,N-dimethyl-1-piperazine-1-carboxamide] (CA INDEX NAME) (9CI) (CA)




RN 403491-11-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-N,N-dimethyl-1-piperazine-1-carboxamide] (CA INDEX NAME) (9CI) (CA INDEX NAME)




RN 403491-13-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-N,N-dimethyl-1-piperazine-1-carboxamide] (CA INDEX NAME) (9CI)




RN 403491-15-6 CAPLUS
CN Piperazine, 1-acetyl-4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-N,N-dimethyl-1-piperazine-1-carboxamide] (CA INDEX NAME) (9CI) (CA INDEX NAME)




RN 403491-17-8 CAPLUS
CN Acetamide, 2-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-N,N-dimethyl-1-piperazine-1-carboxamide] (CA INDEX NAME) (9CI)




RN 403491-19-0 CAPLUS
CN Acetamide, 2-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-N,N-dimethyl-1-piperazine-1-carboxamide] (CA INDEX NAME) (9CI)




RN 403491-21-4 CAPLUS
 CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-[2-(2-pyridinylethyl)]- (9CI) (CA INDEX NAME)




RN 403491-23-6 CAPLUS
 CN Acetamide, N-cyclopropyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-25-8 CAPLUS
 CN Acetamide, N-cyclopentyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-27-0 CAPLUS
 CN Acetamide, N-cyclohexyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-29-2 CAPLUS
 CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)




RN 403491-31-6 CAPLUS
 CN Acetamide, N-butyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-33-8 CAPLUS
 CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403491-36-1 CAPLUS
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 403491-45-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carbonitrile, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403491-47-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-dimethyl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403491-49-6 CAPLUS
CN Pyrrolidine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 403491-51-0 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 403491-53-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxyethyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403491-55-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(dimethylamino)ethyl]-2-phenyl]- (9CI) (CA INDEX NAME)

RN 403491-62-3 CAPLUS
CN Piperazine, 1-acetyl-4-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403491-64-5 CAPLUS
CN Morpholine, 4-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 403491-66-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403491-68-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1,1-dimethylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-56-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403491-58-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-ethoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-60-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403491-78-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 403491-80-5 CAPLUS
CN Piperidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403491-82-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[2-(1-pyrrolidinylethyl)]- (9CI) (CA INDEX NAME)





RN 403491-76-9 CAPLUS


RN 403491-70-3 CAPLUS
CN Piperidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 403491-72-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-diethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-74-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(1-methylethoxyethyl)]-2-phenyl- (9CI) (CA INDEX NAME)







RN 403491-84-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(5-methyl-2-thiazolyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-86-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-phenoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-88-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-bis(2-methoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-90-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-methyl-1-phenylethyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403491-92-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-93-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(4-methyl-1-piperazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403491-96-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(4-morpholinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


RN 403492-09-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-5-(4-(phenylmethyl)-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-11-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(4-methoxy-1-piperidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-15-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 403492-17-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 403491-98-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-5-(4-phenyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-00-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403492-04-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-5-(4-(2-pyridinyl)-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-19-3 CAPLUS
CN Piperazine, 1-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-(methylsulfonyl)]- (9CI) (CA INDEX NAME)



RN 403492-21-7 CAPLUS
CN Piperazine, 1-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-(phenylsulfonyl)]- (9CI) (CA INDEX NAME)




RN 403492-23-9 CAPLUS
CN Piperazine, 1-benzoyl-4-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]]- (9CI) (CA INDEX NAME)




RN 403492-25-1 CAPLUS
CN Piperazine, 1-acetyl-4-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]]- (9CI) (CA INDEX NAME)


RN 403492-27-3 CAPLUS
CN Piperazine, 1-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-[(dimethylamino)acetyl]]- (9CI) (CA INDEX NAME)




RN 403492-29-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 403492-31-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethyl-6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 403492-33-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 403492-35-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)




RN 403492-37-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-((3R)-tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403492-39-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-((3S)-tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403492-41-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methoxy-1-methylethyl)-6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-43-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 403492-45-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methyl-3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 403492-47-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 403492-49-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-51-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 403492-53-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-55-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-57-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-59-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 403492-61-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethyl-6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-63-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-propyl- (9CI) (CA INDEX NAME)




RN 403492-65-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(7-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-67-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(7-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-69-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-bromo-5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-71-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-73-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(1-hydroxycyclohexylethynyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-75-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(phenylethynyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-77-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclopropyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403492-79-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cycloheptyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403492-81-9 CAPLUS
CN 1H-Azepine, 1-[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]hexahydro- (9CI) (CA INDEX NAME)




RN 403492-83-1 CAPLUS
CN Piperazine, 1-[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 403492-85-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-butyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403492-87-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403492-93-3 CAPLUS
CN Acetamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 403492-95-5 CAPLUS
CN Benzamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 403492-97-7 CAPLUS
CN Propanamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 403492-99-9 CAPLUS
CN Methanesulfonamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 403493-04-9 CAPLUS
CN Carbamic acid, [3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 403493-08-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(2-oxo-1-pyrrolidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403493-10-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(bis(methoxymethyl)amino)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-12-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-[(1-methyl-4-piperidinyl)oxy]-2-

phenylpyrazolo[1,5-a]pyridin-3-yl]-, Hydrochloride (9CI) (CA INDEX NAME)




• x HCl

RN 403493-14-1 CAPLUS
CN Piperidinium, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-1,1-bis(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)




• Br⁻


RN 403493-16-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[[4-methoxyphenyl)methoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-18-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-[[2-phenyl-5-[[4-(trifluoromethyl)-2-pyridinyloxy]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403493-20-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 403493-22-1 CAPLUS
CN Piperidine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403493-24-3 CAPLUS
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 403493-26-5 CAPLUS


CN Acetamide, N-cycloheptyl-2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo(1,5-a)pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403493-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(1,6-dihydro-3-pyridazinyl)-6-methoxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 403493-30-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(6-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-32-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(6-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-34-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[6-(2-(dimethylamino)ethoxy)-2-phenylpyrazolo(1,5-a)pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-36-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[6-(2-[(2R,6S)-2,6-dimethyl-4-morpholinylethoxy]-2-phenylpyrazolo(1,5-a)pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 403493-38-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-6-(2-pyridinylmethoxy)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403493-40-3 CAPLUS
CN Acetic acid, [[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo(1,5-a)pyridin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403493-42-5 CAPLUS

CN Acetic acid, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403493-44-7 CAPLUS

CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 403493-46-9 CAPLUS

CN Pyrrolidine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)



RN 403493-48-1 CAPLUS


CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 403493-50-5 CAPLUS


CN Morpholine, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 403493-52-7 CAPLUS

CN Acetamide, N-cyclopentyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403493-54-9 CAPLUS


CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403493-56-1 CAPLUS
 CN Acetamide, 2-[[3-[[1, 6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 403493-58-3 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 3-[[1, 6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl ester (9CI) (CA INDEX NAME)




RN 403493-60-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[[6-[[2R,6S]-2, 6-dimethyl-4-morpholinyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403493-62-9 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[[6-(1-methylethyl)-6-[[6-(4-methyl-1-piperazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403493-64-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[[1, 6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 403493-66-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[[1, 6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403493-68-5 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[[1, 6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403493-70-9 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 403493-72-1 CAPLUS
CN Morpholine, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]carbonyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403493-74-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methylpropyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403493-76-5 CAPLUS
CN Acetamide, N-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 403493-78-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403493-80-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-82-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 403493-84-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethyl-6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403493-85-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 403493-87-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403493-89-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-93-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-ethoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-95-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-4-propoxypyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403493-97-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-99-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(4-[2-(4-morpholinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403494-01-9 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]octahydro- (9CI)
(CA INDEX NAME)




RN 403494-03-1 CAPLUS
CN Morpholine, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403494-05-3 CAPLUS
CN Pyrrolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 403494-07-5 CAPLUS
CN Pyrrolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]-N-[[1R]-1-phenylethyl]- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 403494-09-7 CAPLUS
CN Pyrrolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[[2-(4-methoxyphenyl)ethyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-11-1 CAPLUS
CN Pyrrolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[[2-(hydroxymethyl)phenyl]-2-phenyl]- (9CI) (CA INDEX NAME)

CN 4-Piperidinol, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403494-23-5 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyethyl)-N-methyl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxybutyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-27-9 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-(2-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 403494-15-5 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-methoxypropyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-17-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-phenylethyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-19-9 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-21-3 CAPLUS




RN 403494-29-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2-(4-chlorophenyl)ethyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-31-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(5-methyl-3-isoxazolyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-33-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(6-methoxy-3-pyridinyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403494-35-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-chloro-4-methylphenyl)-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-37-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(difluoromethoxy)phenyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-39-3 CAPLUS
CN 2-Pyrazolidinemethanol, 1-[(3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl)carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403494-41-7 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-phenoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-43-9 CAPLUS

403454-43-9 CAPTOS
Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclooctyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




NRN 403494-45-1 CAPLUS

403494-43-1	CAPLUS	Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-naphthalenylmethyl)-2-phenyl-	(9CI)	(CA INDEX NAME)
403494-43-1	CAPLUS	Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-naphthalenylmethyl)-2-phenyl-	(9CI)	(CA INDEX NAME)




RN 403494-47-3 CAPLUS

NAME	CA INDEX
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-5-pyridazinyl]-N-(5-hydroxy-1-naphthalenyl)-2-phenyl-	(9CI)




RN	403494-49-5	CAPLUS
----	-------------	--------

403494-49-5 CAPLUS
Piperidine, 1-({3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl}carbonyl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




NRN 403494-51-9 CAPLUS

3-Piperidinol, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 403494-53-1 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(hexahydro-2-oxo-1H-azepin-3-yl)-2-phenyl]- (9CI) (CA INDEX NAME)



IT

403494-55-3P, N-(5-Phenyl-1H-pyrazol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-57-5P, (S)-5-[(2-Methoxymethyl)pyrrolidin-1-yl]carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-59-7P, N-(2,3-Dihydroxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-61-1P, N-(2-Hydroxy-3-chlorophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-63-3P, (R)-5-[(2-Methoxymethyl)pyrrolidin-1-yl]carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-66-6P, N-(2-Fenylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-68-8P, N-(2-Morpholinoethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-70-2P, N-[(1S,2S)-2-Hydroxy-1-(hydroxymethyl)-2-phenylethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-72-4P, N-(4-Methylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-77-9P, N-Isobutyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-79-1P, N-Cyclohexyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-81-5P, N-(2,2-Diethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-83-7P, (S)-5-[(3-Methylaminocarbonyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-85-9P, 5-[(2,3-Dihydro-1H-indol-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-86-0P, N-Hexyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide

carboxamide 403494-88-2P, N-(3-Phenylpropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-90-6P, N-(3,4-Dimethoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-92-8P, N-[(1-(2-Hydroxyethyl)-4-(ethoxycarbonyl)-1H-pyrazol-5-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-94-0P, N-(2-Hydroxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-95-1P, N-(2-Hydroxy-2-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-97-3P, N-[(1-(1-Naphthyl)ethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-99-5P, N-[(4-Acetylaminophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-00-1P, 5-[(4-(2-Hydroxyethyl)piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-01-2P, N-(2-Methoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-03-4P, N-(3-(Dimethylamino)propyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-05-6P, N-(2-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-07-8P, N-(1H-Indol-5-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-09-0P, N-Methyl-N-phenethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-11-4P, (S)-N-(1-(Hydroxymethyl)-2-methylpropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-13-6P, N-(3-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-15-8P, (R)-N-[(1-(1-Naphthyl)ethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-17-0P, 5-[(4-[(4-Fluorophenyl)carbonyl]amino)piperidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-19-2P, N-(3-Ethoxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-20-5P, N-(4-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-21-6P, N-(3-Hydroxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-23-8P, N-(1H-Indazol-6-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-25-0P, N-(4-(Diethylamino)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-27-2P, 5-[(4-(4-(Ethoxycarbonyl)phenyl)piperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-29-4P, 5-[(4-(4-(Ethoxycarbonyl)phenyl)piperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-30-7P, N-Cyclopentyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-31-8P, N-(2,2-Dimethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-32-9P, N-(4-Hydroxyphenethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-33-0P, N-(3-Acetylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-34-1P, 5-[(4-Phenylpiperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-35-2P, N-(3-(Methylthio)propyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-36-3P, (S)-N-(2-Hydroxy-1-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide

403495-69-2P, N-[2-(Diethylamino)ethyl]-3-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide] 403495-70-5P, N-(1,2,3,4-Tetrahydrophthalen-1-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-71-6P, (S)-N-[1-(tert-Butoxycarbonyl)methyl]-2-oxo-2,3,4,5-tetrahydro-1H-benz[*b*]azepin-3-yl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-72-7P, 5-[(4-Benzhydryl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine 403495-73-8P, N-Phenethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine 403495-74-9P, N-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-75-0P, 5-[(4-Benzhydryloxy)piperidin-1-yl]carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine 403495-76-1P, N-(4-Methylbenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine 403495-77-2P, N-(3,4-Methylenedioxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-78-3P, N-(4-Anilinophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-79-4P, N-(3-Phenoxymethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-80-7P, N-(4-Bromo-3-methylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-81-8P, N-(2-Phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-82-9P, N-(2-Phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-82-9P, N-[5-(4-Chlorophenyl)-1H-pyrazol-3-yl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-83-0P, N-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-84-1P, N-(3-Benzoylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-85-2P, N-[4-(4-Methylphenoxy)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-86-3P, N-(3-Iodophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-87-4P, N-[2-(Methoxycarbonyl)-4,5-dihydro-3-thienyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-88-5P, N-[4-(4-Fluorophenoxy)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403495-89-6P, (S)-N-(4-Hydroxy-2-[3,4-dichlorophenyl]butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridine-5-carboxamide 403496-05-9P, N-Bis[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-*a*]pyridin-5-yl]urea

THU (Synthetic preparation); THU (Pharmacological activity); PAC (Pharmacological study); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Drug candidate; preparation of pyrazolopyridines as adenosine receptor antagonists)

403494-55-3 CAPUUS

Pyrazolo[1,5-*a*]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


403494-55-3 CAPLUS
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

RN	CN
----	----




RN 403494-57-5 CAPLUS
CN Pyrazolidine, 1-[(3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl]-2-(methoxymethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403494-59-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2,3-dihydroxypropyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-61-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(5-chloro-2-hydroxyphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-63-3 CAPLUS
CN Pyrazolidine, 1-[(3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl]-2-(methoxymethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403494-66-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-furanylmethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-68-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(4-morpholinyl)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-70-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-2-phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403494-72-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-methylphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-77-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methylpropyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403494-79-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclohexyl-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-81-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(2,2-diethoxyethyl)-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-83-7 CAPLUS
CN 3-isoquinolinecarboxamide, 2-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-1,2,3,4-tetrahydro-N-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403494-85-9 CAPLUS
CN 1H-Indole, 1-([3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 403494-86-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-[[[3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-1-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 403494-88-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 403494-90-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-92-8 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-[[[3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-1-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 403494-94-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxypropyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-95-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxy-2-phenylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-97-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[1-(1-naphthalenylethyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-99-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(acetamino)phenyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-00-1 CAPLUS
CN 4-Piperidineethanol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403495-01-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-03-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[3-(dimethylamino)propyl]-2-phenyl- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403495-13-6 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(3-methoxyphenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-15-8 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1R)-1-(1-naphthalenyl)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403495-17-0 CAPLUS


CN Benzamide, N-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-piperidinyl]-4-fluoro- (9CI) (CA INDEX NAME)

RN 403495-05-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(2-methoxyphenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-07-8 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-1H-indol-5-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-09-0 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-11-4 CAPLUS




RN 403495-19-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(3-ethoxypropyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-20-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-[(4-methoxyphenyl)methyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-21-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(3-hydroxyphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-23-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-1H-indazol-6-yl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-25-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(diethylamino)phenyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-27-2 CAPLUS
CN Benzoic acid, 4-[(3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl)carbonyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403495-29-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-([3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 403495-30-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclopentyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-31-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2,2-dimethoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-32-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-(4-hydroxyphenyl)ethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-33-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-acetylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-34-1 CAPLUS
CN Piperazine, 1-([3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 403495-35-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-[(3-(methylthio)propyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-36-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]-2-phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-37-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-38-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(4-fluorophenyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403495-39-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(3-methylbutyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-40-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403495-41-0 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(3-chlorophenyl)methyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-42-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-43-2 CAPLUS
CN 1H-Indole, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3-dihydro-6-nitro- (9CI) (CA INDEX NAME)




RN 403495-44-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-pentyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-45-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(2-chlorophenyl)methyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-46-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-(1-methylethyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-47-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(phenylmethyl)-N-(6,7,8,9-tetrahydro-1-hydroxy-5H-benzocyclohepten-6-yl)- (9CI) (CA INDEX NAME)




RN 403495-48-7 CAPLUS
CN Piperidine, 4-cyclohexyl-1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403495-49-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[[4-chlorophenyl)methyl]-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-50-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(diphenylmethyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-51-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-cyanophenyl)-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-52-3 CAPLUS
CN 1H-Pyrido[3,4-b]indole, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 403495-53-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 403495-54-5 CAPLUS
CN Pyrazolo[1,5-α]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2,4-dimethylphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-55-6 CAPLUS
CN Pyrazolo[1,5-α]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-(2-hydroxyethyl)phenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-56-7 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-α]pyridin-5-yl]carbonyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 403495-57-8 CAPLUS
CN Pyrazolo[1,5-α]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3,4-dimethylphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-58-9 CAPLUS
CN Pyrazolo[1,5-α]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-methoxy-2-methylphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-59-0 CAPLUS
CN Pyrazolo[1,5-α]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxy-3-nitrophenyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403495-60-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(5-chloro-2-nitrophenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-61-4 CAPLUS
CN 1H-Pyrido[3,4-b]indole, 2-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl)pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3,4,9-tetrahydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 403495-62-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(trans-4-hydroxycyclohexyl)-2-phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403495-63-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(2-[bis(1-methylethyl)amino]ethyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-64-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1,2-diphenylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-65-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxy-2-nitrophenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN	403495-66-9	CAPLUS
----	-------------	--------


Carbamic acid, ((1R)-2-(((3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)amino)-1-(1H-indol-3-ylmethyl)ethyl)-, 1,1-dimethylethyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.




RN 403495-67-0 CAPLUS

Piperidine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)]- (9CI) (CA INDEX NAME)




403495-68-1 CAPLUS

INDEX NAME	CA	9CI
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxy-1,1-dimethylethyl)-2-phenyl-		




403495-69-2 CAPLUS

NAME	CA INDEX
Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2-(diethylamino)ethyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-	9CI



403495-70-5 CAPLUS


Pyrazolo[1,5-a]pyridine-5-carboxamide, 3- $\{1,6$ -dihydro-1- $\{1$ -methylethyl $\}$ -6-oxo-3-pyridazinyl $\}$ -2-phenyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-(9CI)
(CA INDEX NAME)




403495-71-6 CAPLUS

11-1-Benzazepine-1-acetic acid, 3-[[13-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-72-7 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)




RN 403495-73-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 403495-74-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-fluoro-3-(trifluoromethyl)phenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-75-0 CAPLUS
CN Piperidine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(diphenylmethoxy)- (9CI) (CA INDEX NAME)



RN 403495-76-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[[4-methylphenyl)methyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-77-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




NRN 403495-78-3 CAPLUS

NAME	(9CI)	(CA INDEX)
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[4-(phenylamino)phenyl]-	(9CI)	(CA INDEX)




NRN 403495-79-4 CAPLUS

403935-15-4 CMLD03
pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-
oxo-3-pyridazinyl]-N-(3-phenoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




403495-80-7 CAPLUS

403493-80-1 CAPLUS
Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(4-bromo-3-methylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




403495-81-8 CAPLUS

403495-81-8 CAPLUS
pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-bromo-4-methylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl)- (9CI) (CA INDEX NAME)




RN 403495-82-9 CAPLUS

403495-82-9 CAPLUS
Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[5-(4-chlorophenyl)-1*H*-pyrazol-3-yl]-3-[1,1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI)
(CA INDEX NAME)




103495-83-0 CAPLUS *


403495-83-0 CAPIUS *
Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-84-1 CAPIUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-benzoylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-85-2 CAPIUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-(4-methylphenoxy)phenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-86-3 CAPIUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-iodophenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-87-4 CAPIUS
CN 2-Thiophenecarboxylic acid, 3-[[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine-5-yl]carbonyl]amino]-4,5-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 403495-88-5 CAPIUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-(4-fluorophenoxy)phenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-89-6 CAPIUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2S)-2-[3,4-dichlorophenyl]-4-hydroxybutyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Pyrazolo[1,5-a]pyridine, 2-(2-fluorophenyl)-5-methoxy-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 403495-96-5 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methoxy-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 403495-97-6 CAPIUS
CN Pyrazolo[1,5-a]pyridine-7-carboxylic acid, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-98-7 CAPIUS
CN Carbamic acid, [3-(6-methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403496-05-9 CAPIUS
CN Urea, N,N'-bis[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




IT 403495-90-9P, 3-(3-Phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine 403495-95-4P, 5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403495-96-3P, 5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403495-97-6P, 3-(6-Methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine-7-carboxylic acid 403495-98-7P, tert-Butyl [3-(3-methoxy-6-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-yl]carbamate 403495-99-8P, 7-Amino-3-(3-methoxy-6-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine 403496-03-7P, 7-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403496-04-8P, 4-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolopyridines as adenosine receptor antagonists)

RN 403495-90-9 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 403495-95-4 CAPIUS

alpyridine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (precursor; preparation of pyrazolopyridines as adenosine receptor
 antagonists)
 RN 131185-62-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (9CI) (CA
 INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 42 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:157771 CAPLUS
 DOCUMENT NUMBER: 136:200184
 TITLE: Preparation of pyrazolo[1,5-a]pyridines as protein
 kinase inhibitors for treatment of inflammatory and
 autoimmune diseases

INVENTOR(S): Alberti, Michael John; Baldwin, Ian Robert; Cheung,
 Mui; Cockerill, Stuart; Flack, Stephen; Harris, Philip
 Anthony; Jung, David Kendall; Peckham, Gregory; Peel,
 Michael Robert; Stanford, Jennifer Badiang; Stevens,
 Kirk; Veal, James Marvin
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 173 pp.
 CODEN: PIXXD2


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016359	A1	20020228	WO 2001-GB3783	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, NO, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2420024	A1	20020228	CA 2001-2420024	20010822
AU 200182318	A	20020304	AU 2001-82318	20010822
EP 1311507	A1	20030521	EP 2001-960928	20010822
EP 1311507	B1	20060301		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013448	A	20030617	BR 2001-13448	20010822
JP 2004506736	T	20040304	JP 2002-521460	20010822
HU 200400757	A2	20040728	HU 2004-757	20010822
AT 318814	T	20060315	AT 2001-960928	20010822
CN 1798747	A	20060705	CN 2001-817742	20010822
ES 2259331	T3	20061001	ES 2001-1960928	20010822
IN 2003KN00168	A	20050311	IN 2003-KN168	20030211


RN 403495-99-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl-
 (9CI) (CA INDEX NAME)



RN 403496-03-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 7-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 403496-04-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 4-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




IT 131185-62-1, 3-(6-Methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-

2A 2003001318 A 20040622 2A 2003-1318 20030218
 NO 2003000779 A 20030407 NO 2003-779 20030219
 US 2004053942 A1 20040318 US 2003-362146 20030707
 US 7166597 B2 20070123 GB 2000-20556 A 20000822
 PRIORITY APPLN. INFO.: GB 2000-20576 A 20000822
 WO 2001-GB3783 W. 20010822

OTHER SOURCE(S): MARPAT 136-200184

GI




II


AB Title compds. I (wherein Z = CH or N; m = 1-2; n = 1-3; p = 1-3; R1 = independently Xd(CH2)4R5; d = 0-1; e = 0-6; X = O, NR6, or SOO-2; R3 = H, halo, OH, CN, NO2, trihalomethyl, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, (hetero)aryl, phthalimido, aminophenyl, aminobenzyl, acyl(oxy), carbamoyl(oxy), carboxylate, sulfamoyl, carbamidamido, etc.; R4 = independently Yd(CH2)4R3; R5 = H, halo, OH, CN, NO2, trihalomethyl, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, (hetero)aryl, amino, aminophenyl, aminobenzyl, acyl(oxy), carbamoyl(oxy), carbamidamido, acylamino, sulfamoyl, etc.; R6 = H, (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or their salts, solvates, or physiol. functional derivs. thereof) were prepared as p38 and JNK3 protein kinase inhibitors. For example, cycloaddn. of Me 3-(4-fluorophenyl)propiolate (2-step preparation given) and 1-aminopyridinium iodide in AcCN in the presence of 1,8-diazabicycloundec-7-ene gave Me 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxylate (70t), which was hydrolyzed to the acid (100t). Reaction with sodium bicarbonate, followed by N-bromosuccinimide, in DMF afforded the bromo derivative (80t). Reductive addition of 4-(tributylstannyl)pyridine using Pd(PPh3)4 in toluene gave II (80t). The latter inhibited p38 kinase and tumor necrosis factor (TNF) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 values of < 0.5 μM. I are useful for the treatment of inflammatory and autoimmune diseases, cancer, and a variety of other conditions related to regulation of p38 kinase and/or JNK kinase.

IT 401816-55-5P, 4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methoxybenzyloxy)propyl]-2-pyrimidinamine
 401816-63-3P, Methyl 4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfide
 401816-84-0P, Methyl 4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfone
 401816-87-3P, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl methyl sulfide
 401816-88-4P, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl methyl sulfone
 401816-91-9P, Methyl 4-[6-(trifluoromethyl)-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfide
 401816-92-0P, Methyl 4-[6-(trifluoromethyl)-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfone
 RL: RCT (Reactant); SEN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)
 (intermediate; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)
 401816-55-5 CAPLUS
 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-((4-methoxyphenyl)methoxy)propyl]- (9CI) (CA INDEX NAME)




401816-63-5 CAPLUS
 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




401816-64-6 CAPLUS
 Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




401816-70-4 CAPLUS
 Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(4-fluorophenyl)-3-[2-[(3-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 401816-83-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[(2-(methylthio)-4-pyrimidinyl)-6-(trifluoromethyl)phenyl]-2-[(4-(trifluoromethyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 401816-84-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[(2-(methylsulfonyl)-4-pyrimidinyl)-6-(trifluoromethyl)phenyl]-2-[(4-(trifluoromethyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 401816-87-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401816-88-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401816-91-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401816-92-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 401815-73-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-methanol, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 401815-85-8 CAPLUS
CN Benzoic acid, 3-(aminosulfonyl)-4-chloro-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-90-5 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl


RN 401815-97-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-
(9CI) (CA INDEX NAME)




IT 401815-65-4P, 2-(4-Fluorophenyl)-6-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-73-4P, 2-(4-Fluorophenyl)-5-hydroxymethyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-85-8P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-(aminosulfonyl)-4-chlorobenzoate 401815-90-5P, 2-[[2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]-1H-isoindole-1,3(2H)-dione hydrochloride 401815-97-2P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-15-7P, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-18-0P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-24-8P, 6-Bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-26-0P, 6-Cyano-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-29-3P, 6-Cyano-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 401816-50-0P, N-Cyclopropyl-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-65-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-66-8P, 2-(4-Fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-68-0P, N-[3-(4-Methylpiperazin-2-yl)propyl]-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (protein kinase inhibitor; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)

RN 401815-65-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-6-methyl-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)







RN 401816-15-7 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 401816-18-0 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401816-24-8 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-26-0 CAPIUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401816-29-3 CAPIUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(2-fluoro-4-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-34-0 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylthio)-4-
pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylsulfinyl)-4-
pyrimidinyl)- (9CI) (CA INDEX NAME)




RN	401816-50-0	CAPLUS
CN	2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




401816-65-7	CAPLUS
Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI)	(CA INDEX NAME)



RN	401816-66-8	CAPLUS
CN	Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)	



RN	401816-68-0	CAPLUS
CN	2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5- alpyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)	




401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 401815-68-7P, 2-(4-Fluorophenyl)-6-methyl-3-(4-pyridyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-69-8P, 2-(4-Fluorophenyl)-5-methyl-3-(4-pyridyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-70-1P, 2-(4-Fluorophenyl)-4-methyl-3-(4-pyridyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-72-3P, 2-(4-Fluorophenyl)-5-methoxy-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 401815-74-5P, 2-(4-Fluorophenyl)-4-hydroxymethyl-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 401815-76-7P, 6-Fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-77-8P, 4-Fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-78-9P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-methylbenzoate 401815-79-0P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl isonicotinate 401815-80-3P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl nicotinate 401815-81-4P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-bromo-2-thiophenecarboxylate 401815-82-5P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 6-aminonicotinate 401815-83-6P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 5-(methylsulfonyl)-2-thiophenecarboxylate 401815-84-7P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-aminonicotinate 401815-86-9P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-methyl-2-thiophenecarboxylate 401815-87-0P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2-methoxybenzoate 401815-88-1P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 2,3-dichlorobenzoate 401815-89-2P, 2-[2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl-1H-isoindole-1,3(2H)-dione 401815-91-6P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methanamine

401815-92-7P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401815-94-9P, 5-(n-Butyl)-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-96-1P, 5-(Benzoyloxy)-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-99-4P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyridinamine 401816-00-0P, N-Butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-01-1P, 3-[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-propanol 401816-02-2P, N-(4-Chlorobenzyl)-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-03-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,3-propanediamine 401816-04-4P, 2-(Butoxy-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-05-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl-2-pyridinamine 401816-06-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxybenzyl)-2-pyridinamine 401816-07-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl-2-pyridinamine 401816-08-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyridinamine 401816-09-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-2-pyridinamine 401816-10-2P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-2-pyridinamine 401816-11-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,1'-butanediame 401816-12-4P, 2-[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinylamino]-1-ethanol 401816-13-5P, N-Benzyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-14-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-15-5P, N-Benzyl-6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-16-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyridinamine 401816-17-9P, N-Benzyl-6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-19-1P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-isopropyl-2-pyridinamine 401816-20-4P, N-Cyclopropyl-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-22-6P, 3-[4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinylamino]-1-propanol 401816-25-9P, N-(3-Aminopropyl)-4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-28-2P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine-6-carboxamide 401816-31-7P, 6-Cyano-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyridinamine 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-36-2P, 2-(4-Fluorophenyl)-3-[2-(methylethylfonylpyrimidin-4-yl)pyrazolo[1,5-a]pyridine 401816-37-3P, N-Butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-38-4P, N-Cyclopropyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-39-5P, N-Benzyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-40-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-41-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-44-2P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-48-6P, N-Butyl-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-49-7P, N-Benzyl-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-51-1P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-52-2P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-(2-propenyl)-2-pyrimidinamine 401816-53-3P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)-2-pyrimidinamine 401816-54-4P, 3-[4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinylamino]-1-propanol 401816-57-7P, N-Cyclopropyl-4-[6-cyano-2-(4-


[illegible]

yl)pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-11-6P,
N-(2-piperidin-1-ylethyl)-N-[4-{6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine
401817-12-7P, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-13-8P, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-14-9P, N-[4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-15-0P, N-(3-piperidin-1-ylpropyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine 401817-16-1P,
N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-18-3P, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-19-4P, N-(2-azepan-1-ylethyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine 401817-20-7P,
N-(2-azepan-1-ylethyl)-N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine 401817-21-8P, N-(2-azepan-1-ylethyl)-N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine 401817-22-9P, N-[4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(2-morpholin-4-ylethyl)amine 401817-23-0P, N-(2-morpholin-4-ylethyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine 401817-24-1P,
N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(2-morpholin-4-ylethyl)amine 401817-25-2P, N-(3-morpholin-4-ylpropyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine 401817-26-3P, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(3-morpholin-4-ylpropyl)amine 401817-27-4P, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-(3-morpholin-4-ylpropyl)amine 401817-28-5P,
N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]amine 401817-29-6P, N-[4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]amine 401817-31-0P,
N-[2-(4-propylpiperazin-1-yl)ethyl]-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]amine 401817-32-1P, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-[2-(4-propylpiperazin-1-yl)ethyl]amine 401817-33-2P,
N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl}pyrimidin-2-yl]-N-[2-(4-propylpiperazin-1-yl)ethyl]amine
RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)

RN 401815-63-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401815-68-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-6-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 401815-69-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 401815-70-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-4-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 401815-72-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methoxy-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 401815-74-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-methanol, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401815-76-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 401815-77-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 4-fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401815-78-9 CAPLUS
CN Benzoic acid, 2-methyl-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]
pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-79-0 CAPLUS
CN 4-Pyridinecarboxylic acid, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]
pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-80-3 CAPLUS
CN 3-Pyridinecarboxylic acid, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-
a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-81-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-bromo-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-82-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-amino-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-83-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(methylsulfonyl)-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-84-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-amino-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-86-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-methyl-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-87-0 CAPLUS
CN Benzoic acid, 2-methoxy-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-
a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-88-1 CAPLUS
CN Benzoic acid, 2,3-dichloro-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-89-2 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 401815-91-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-methanamine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401815-92-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-6-
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401815-94-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-butoxy-2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401815-96-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-(phenylmethoxy)-3-(4-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 401815-99-4 CAPLUS
CN 2-Pyridinamine, 4-[[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]]-N-[2-(1H-
imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 401816-00-0 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 401816-01-1 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]]-2-
pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-02-2 CAPLUS
CN 2-Pyridinamine, N-[(4-chlorophenyl)methyl]-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-03-3 CAPLUS
CN 1,3-Propanediamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 401816-04-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-butoxy-4-pyridinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-05-5 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl- (9CI) (CA INDEX NAME)




RN 401816-09-9 CAPLUS


RN 401816-06-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 401816-07-7 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl- (9CI) (CA INDEX NAME)




RN 401816-08-8 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-
(9CI) (CA INDEX NAME)




RN 401816-10-2 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 401816-11-3 CAPLUS
CN 1,4-Butanediamine, N-{4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl}-
(9CI) (CA INDEX NAME)




RN 401816-12-4 CAPLUS
CN Ethanol, 2-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 401816-13-5 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-
(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 401816-14-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-
dimethyl- (9CI) (CA INDEX NAME)




RN 401816-17-9 CAPLUS
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-19-1 CAPLUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-20-4 CAPLUS
CN 2-Pyridinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-22-6 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-25-9 CAPLUS
CN 1,3-Propanediamine, N-[4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-28-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-31-7 CAPLUS
CN 2-Pyridinecarbonitrile, 6-(cyclopropylamino)-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-32-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-36-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-37-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-38-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-39-5 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-40-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-41-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-44-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-48-6 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-49-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 401816-51-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-52-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 401816-53-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 401816-54-4 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-57-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-61-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-62-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-67-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-(4-methyl-1-piperazinyl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-71-5 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(2-(1H-imidazol-4-yl)ethyl)]- (9CI) (CA INDEX NAME)




RN 401816-72-6 CAPLUS



RN 401816-73-7 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(2-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 401816-74-8 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(4-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 401816-76-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(2-phenoxy-4-pyrimidinyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 401816-80-6 CAPLUS
CN 1,3-Propanediamine, N,N-dimethyl-N'-[4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-85-1 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-89-5 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-93-1 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-77-1 CAPLUS
CN Benzenamine, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-78-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[2-(2,5-dimethylphenoxy)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401816-79-3 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)







RN	CA INDEX NAME	CA INDEX NAME
401816-95-3	CAPLUS	1,4-Butanediamine, N,N-diethyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-pyrimidinyl] - (9CI)




401816-96-4 CAPIUS
1, 4-Butanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1, 5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl-
(9CI) (CA INDEX NAME)




401816-97-5 CAPLUS
1,4-Butanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl-
(9CI) (CA INDEX NAME)




401816-98-6 CAPIUS
1,2-Ethanediamine, N,N-diethyl-N'-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl)]- (9CI)
(CA INDEX NAME)




RRN	CAIPIUS	CA INDEX NAME
401816-99-7	1,2-Ethanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl-	(9CI) (CA INDEX NAME)




401817-00-3 CAPUS
1,2-Ethanediamine, N,N-dipropyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 401817-01-4 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 401817-02-5 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 401817-03-6 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 401817-04-7 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chlorophenyl)]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401817-05-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 401817-06-9 CAPLUS
CN 2-Pyrimidinamine, N-[2-(1-pyrrolidinyl)ethyl]-4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)


RN 401817-10-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-11-6 CAPLUS
CN 2-Pyrimidinamine, N-[2-(1-piperidinylethyl)-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 401817-12-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-13-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-07-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-08-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-09-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 401817-18-3 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401817-19-4 CAPLUS
CN 1H-Azepine-1-ethanamine, hexahydro-N-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401817-20-7 CAPLUS
CN 1H-Azepine-1-ethanamine, N-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]hexahydro- (9CI) (CA INDEX NAME)




RN 401817-21-8 CAPLUS
CN 1H-Azepine-1-ethanamine, N-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]hexahydro- (9CI) (CA INDEX NAME)




RN 401817-14-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401817-15-0 CAPLUS
CN 2-Pyrimidinamine, N-[3-(1-piperidinyl)propyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401817-16-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)







RN 401817-22-9 CAPLUS
CN 4-Morpholineethanamine, N-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-23-0 CAPLUS
CN 4-Morpholineethanamine, N-[4-[6-(trifluoromethyl)-2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-24-1 CAPLUS
CN 4-Morpholineethanamine, N-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-25-2 CAPLUS
CN 4-Morpholinepropanamine, N-[4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-26-3 CAPLUS
CN 4-Morpholinepropanamine, N-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-27-4 CAPLUS
CN 4-Morpholinepropanamine, N-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-28-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401817-29-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 401817-31-0 CAPLUS
CN 2-Pyrimidinamine, N-[2-(4-propyl-1-piperazinyl)ethyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401817-32-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-propyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 401817-33-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-propyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 401815-95-0, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-ol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)
RN 401815-95-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-ol, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:915602 CAPLUS
 DOCUMENT NUMBER: 136:303408
 TITLE: New developments in A1 and A2 adenosine receptor


AUTHOR(S): Kiec-Kononowicz, K.; Drabczynska, A.; Pekala, E.; Michalak, B.; Miller, C.E.; Schumacher, B.; Karolak-Wojciechowska, J.; Dudek, H.; Rockitt, S.; Warchow, R.

CORPORATE SOURCE: IUPAC Commission, Medical College, Department of Chemical Technology of Drugs, Jagiellonian University, Krakow, PL 30-688, Pol.

SOURCE: Pure and Applied Chemistry (2001), 73(9), 1411-1420

PUBLISHER: CODEN: PACHAS; ISSN: 0033-4545
 DOCUMENT TYPE: International Union of Pure and Applied Chemistry
 LANGUAGE: Journal; General Review
 AB A review with refs. The aim of this article is to briefly present progress in the development of the potent adenosine receptor (AR) antagonists with high selectivity for either A1, A2A or A2B ARs. The structural requirements for each AR subtype were discussed as well as their potential therapeutic use. In the search for new AR antagonists, series of imidazo-, pyrimido-, and diazepino-purindione derivs. as well as oxazolo-, oxazino-, and oxazepino-purindiones were designed, synthesized, and preliminarily evaluated in pharmacol. studies. Oxygen-containing tricyclic derivs. were shown to be moderately potent AR antagonists exhibiting selectivity either for A1 or A2A ARs. Tricyclic purindiones with nitrogen in the third ring were generally more A2A AR selective. The compds. tested in vivo according to the Antiepileptic Drug Development Program of the National Institutes of Health (USA) were generally active as anticonvulsants in chemical induced seizures.

IT 131185-37-0P, Fk 838
 RI: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRP (Preparation); USES (Uses)
 (new developments in A1 and A2 adenosine receptor antagonists)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 44 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:916663 CAPLUS
 DOCUMENT NUMBER: 135:357918
 TITLE: Process for the preparation of pyrazolo[1,5-a]pyridines

INVENTOR(S): Fitzgerald, Russ N.; Jung, David Kendall; Eaddy, John F.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083479	A2	20011108	WO 2001-US13801	20010427
WO 2001083479	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001059242	A5	20011112	AU 2001-59242	20010427
EP 1276742	A2	20030122	EP 2001-592738	20010427
EP 1276742	B1	20040609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531906	T	20031028	JP 2001-580907	20010427
AT 268771	T	20040615	AT 2001-932738	20010427
ES 222372	T3	20050201	ES 2001-1932738	20010427
US 2003212275	A1	20031113	US 2002-258679	20021025
US 6756498	B2	20040629	US 2000-200400P	20000428
			WO 2001-US13801	20010427
			CASREACT 135:357918; MARPAT 135:357918	
			GI	




AB The title compds. [I; R0, R1 = H, halo, alkyl, etc.; R2 = H, alkyl, alkyl substituted by one or more fluorine atoms, etc.; R3 = H, Ph substituted by SO2(alkyl) or SO2NH2] were prepared by rearrangement of an azirine II or a protected derivative thereof, in the presence of a catalyst and a solvent. Thus, treating a solution of 1-(3-fluorophenyl)-2-(5-trifluoromethyl)-2-

pyridyl)ethanone oxime (preparation given) and Et3N in CH2Cl2 with TFAA followed by rearrangement of the resulting azirine II [R0 = 3-F; R1, R3 = H; R2 = 5-CF3] in the presence of FeCl2 in DME afforded I [R0 = 3-F; R1, R3 = H; R2 = 6-CF3].

IT 267235-56-3P
RL: INF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)


RN 267235-56-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 45 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001-584502 CAPLUS
DOCUMENT NUMBER: 135:352333
TITLE: Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability

AUTHOR(S): Kuroda, Satoru; Takamura, Fujiko; Tenda, Yoshiyuki; Itani, Hiromichi; Tomishima, Yasuyo; Akahane, Atsushi; Sakane, Kazuo
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka 532-8514, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(8), 988-998

PUBLISHER: CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Pharmaceutical Society of Japan
LANGUAGE: Journal
OTHER SOURCE(S): English
CASREACT 135:352333
GI




AB

A novel series of 3-(2-substituted-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines were synthesized and evaluated for their in vitro adenosine A1 and A2A receptor binding activities, and in vitro metabolism by rat liver in order to search for orally active compounds. Most of the test compounds were potent adenosine A1 receptor antagonists with high A1 selectivity and the A1 affinity and A1 selectivity of carbonyl derivatives was particularly high. In particular, I was an extremely potent and selective adenosine A1 antagonist with high A1 selectivity (Ki=0.026 nM, A2A/A1=5400). In terms of metabolic stability, 2-oxopropyl, 2-hydroxypropyl, N-methylacetamide, 2-(piperidin-1-yl)ethyl and 1-methylpiperidin-4-yl (FR194921) derivatives were the most stable compounds of this series of analogs. Further in vivo evaluation indicated that several of the compounds, including FR194921 were detected in both plasma and brain after oral administration in rats. In particular, FR194921 displayed good plasma and brain concentrations. As a result, we could show that FR194921 is a good candidate for an orally active adenosine A1 receptor antagonist with high blood-brain barrier permeability and good bioavailability (Ki=6.6 nM, A2A/A1=820, BA=60.64.9% (32 mg/kg)).

IT 141060-39-1P 202646-80-8P, FR 194921
202646-91-1P 202646-92-2P 202646-94-4P
202646-96-6P 202646-98-8P 202646-99-9P
210879-61-1P 210879-63-3P 210879-64-4P
210879-67-7P 210879-68-8P 210879-69-9P
210879-71-3P 210880-05-0P 210880-07-2P
210880-09-4P 210880-11-8P 210880-20-9P
210880-21-0P 210880-23-2P 210880-25-4P
210880-27-6P 210880-28-7P 210880-29-8P
210880-31-2P 222722-65-8P 222722-71-6P
222722-94-3P 222722-96-5P 372492-23-4P
RL: BPR (Biological process); BSU (Biological study); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)


(synthesis of adenosine A1 receptor antagonists with high blood-brain barrier permeability)

RN 141060-39-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-(1-piperidinyl)ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 202646-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-91-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-92-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-propyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 202646-94-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-pentyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-96-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-(1-methylethyl)-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-98-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-(phenylmethyl)-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-99-9 CAPLUS
CN Piperidine, 1-acetyl-4-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 210879-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-63-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-64-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210879-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210879-68-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210879-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210879-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210880-05-0 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)



RN 210880-07-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210880-09-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210880-11-8 CAPLUS
CN 3-Pyrrolidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-20-9 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-21-0 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1,1-dimethylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-23-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-25-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-27-6 CAPLUS
CN Pyrrolidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS
CN Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 222722-65-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 222722-71-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-94-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-96-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 372492-23-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)


(synthesis of adenosine A1 receptor antagonists with high blood-brain barrier permeability)

RN 131185-06-3 CAPLUS


CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT	202646-90-0P	210880-36-7P	726182-36-1P	RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
RN	202646-90-0	CAPLUS		(synthesis of adenosine A ₁ receptor antagonists with high blood-brain barrier permeability)
CN	202646-90-0	CAPLUS		
	3(2H)-pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (9CI)	(CA INDEX NAME)		




RN	210880-36-7	CAPJUS
CN	1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI)	(CA INDEX NAME)




RN	726182-36-1	CAPLUS
CN	1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)	



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



RN	267235-56-3	CAPLUS
CN	Benzenesulfonamide, 4-{2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5- a]pyridin-3-yl}- (9CI) (CA INDEX NAME)	



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 47 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:581693 CAPLUS
 DOCUMENT NUMBER: 135:147439
 TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors for

INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 21 pp.


DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056555	A2	20010809	WO 2001-GB416	20010201
WO 2001056555	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MY, NZ, NL, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ZY	AZ, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MY, NZ, NL, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ZY		

RW:	GH, DM, KE, LS, MW, WZ, SD, SL, SZ, TZ, UG, ZW, XT, BE, CH, CY, DG, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BU, CF, CG, CI, CM, GA, GW, ML, MK, NE, SN, TD, TG	20010201
EP 1251839	A2 20021030 EP 2001-948935	20010201
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	20010201
JP 2003521511	1E, SI, LT, LV, FI, RO, MK, CY, AL, TR	20010201
US 2003013717	A1 200300116	20020725
PRIORITY APPLN. INFO.:		A 20000201
AB	The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of constipation.	W 20010201
IT	267235-56-3 267235-56-3D, derivs.	
RU:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(cyclolooxygenase-2 inhibitors for treatment of constipation)	
RN	267235-56-3 CAPUS	
CN	Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)	




RN	267235-56-3	CAPLUS
CN	Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)	



L5 ANSWER 48 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:517649 CAPLUS
DOCUMENT NUMBER: 135:107325
TITLE: Preparation of pyrazolopyridines as adenosine
antagonists and their use for treatment of various

INVENTOR(S): Akabane, Atsushi; Kuroda, Satoshi; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO. 2001192384
 KIND A
 DATE 20010717
 APPLICATION NO. JP 2000-378350
 DATE 20001213
 PRIORITY APPLN. INFO.: AU 1999-4622 A 19991213
 OTHER SOURCE(S): MARPAT 135:107325




AB Pyrazolopyridines I [R = lower alkenyl- or aryl-substituted lower alkyl (linked by O), Aryl; R1 = substituted oxadiazolyl, thiazolyl, oxazolyl, imidazolyl; A = lower alkylene] or their salts are prepared by N-substitution of I (R = H), cyclocondensation of I (R = AC(NH2):NOH; A = same as above) with R2COX2 (R2 = lower alkyl; X2 = leaving group), etc. Thus, 2.88 g I (R = H) was treated with NaH and allyl bromide at room temperature for 2 h in DMF to give 2.04 g I (R = allyl), which inhibited binding of [3H]DPCPX to A1 receptor, and [3H]CGS21680 to A2a receptor with Ki values of 0.04 and 2.69 nM, resp.

IT 141060-46-0P 350227-04-2P 350227-07-5P
 350227-09-7P 350227-11-1P 350227-13-3P
 350227-15-5P 350227-17-7P 350227-19-9P
 350227-21-3P 350227-22-4P 350227-24-6P
 350227-26-8P 350227-28-0P 350227-30-4P
 350227-32-6P 350227-34-8P 350227-36-0P
 350227-38-2P 350227-40-6P 350227-42-8P
 350227-44-0P 350227-46-2P 350227-48-4P
 350227-50-8P 350227-52-0P 350227-54-2P
 350227-56-4P 350227-58-6P 350227-59-7P
 350227-61-1P 350227-63-3P 350227-65-5P
 350227-67-7P 350227-69-9P 350227-71-3P
 350227-73-5P 350227-88-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); INF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES: (Uses)
 (Preparation of pyrazolopyridines as adenosine antagonists for treatment of various diseases)
 141060-46-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 350227-04-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 350227-07-5 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(3-(phenylmethoxy)propyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-09-7 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-11-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[(4-methyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-13-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(5-acetyl-4-methyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-15-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(4-phenyl-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-17-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(4-(3,4,5-trimethoxyphenyl)-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-19-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 350227-21-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4,5-dimethyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-22-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-24-6 CAPLUS
CN Piperidine, 1-[[2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]-4-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 350227-26-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 350227-28-0 CAPLUS
CN 4-Thiazolecarboxamide, N,N-dimethyl-2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 350227-30-4 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-(dimethylamino)ethyl]-2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 350227-32-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 350227-34-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[4-(hydroxymethyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-36-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[4-(4-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-38-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[4-(2-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-40-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[4-(3-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-42-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[4-(2,5-dimethoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-44-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-((2-phenylpyrazolo[1,5-a]pyridin-3-yl)methyl)-2-((4-(3-pyridinyl)-2-thiazolyl)methyl)- (9CI) (CA INDEX NAME)




RN 350227-46-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-(4-nitrophenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-48-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-ethyl-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-50-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-methylphenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-52-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-(4-chlorophenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-54-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-(2,4-dimethoxyphenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-56-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4,5-diphenyl-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-58-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-((4-(trifluoromethyl)-2-thiazolyl)methyl)- (9CI) (CA INDEX NAME)




RN 350227-59-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4-methyl-5-phenyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(5-propyl-1,2,4-oxadiazol-3-yl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-63-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-65-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4,5-dimethyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4,5-diphenyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4-phenyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-73-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4-phenyl-1H-imidazol-1-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-88-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-5-phenyl-1H-imidazol-2-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-06-3 141060-69-7 202647-16-3
 210880-36-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolopyridines as adenosine antagonists for treatment of
 various diseases)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA
 INDEX NAME)




RN 141060-69-7 CAPLUS
 CN 1(6H)-Pyridazineacetonitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)- (9CI) (CA INDEX NAME)




RN 202647-16-3 CAPLUS
 CN 1(6H)-Pyridazineethanethioamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)- (9CI) (CA INDEX NAME)




RN 210880-36-7 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 (9CI) (CA INDEX NAME)




IT 350227-76-8P 350227-79-1P 350227-81-5P
 350227-84-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolopyridines as adenosine antagonists for treatment of
 various diseases)
 RN 350227-76-8 CAPLUS
 CN 1(6H)-Pyridazineethanimidamide, N-hydroxy-6-oxo-3-(2-phenylpyrazolo[1,5-
 a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-79-1 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 , 1-methyl-2-oxopropyl ester (9CI) (CA INDEX NAME)



RN 350227-81-5 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 , 1,2-diphenylethyl ester (9CI) (CA INDEX NAME)




RN 350227-84-8 CAPLUS
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-oxo-2-phenylethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 49 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:371567 CAPLUS
DOCUMENT NUMBER: 135:5612
TITLE: Preparation of new pyrazolo terpyridines as remedies for inflammation, autoimmune diseases
INVENTOR(S): Yanamoto, Hirofumi; Takahashi, Fumie; Kato, Takeshi; Nakamura, Katsuya; Manabe, Koji
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001139575	A	20010522	JP 1999-323692	19991115
PRIORITY APPL. INFO.:			JP 1999-323692	19991115
OTHER SOURCE(S):			MARPAT 135:5612	

GI



I




II


AB The pyrazolo terpyridine or that salt which is cyclooxygenase - 2 (COX-II) inhibitors, those production methods, the medicine composition, and the person or

the animal which contain those inflammation condition, u painfully, prevention of the autoimmune disease and / or the method of treating is offered. Below-mentioned general formula (I) { in the formula, the R1 and the R2, the resp. hydrogen, the hydrogen, the low-grade alkyl group and the halogen et cetera, mean, R3 such as low-grade alkyl group and the cyclo (low grade) alkyl group resp. } So the chemical compound which is displayed or that salt.


IT 340321-35-9P 340321-41-7P 340321-70-2P
RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (preparation); USES (Uses)
(preparation of new pyrazolo terpyridines as remedies for inflammation autoimmune diseases)
RN 340321-35-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 340321-41-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 340321-70-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




IT 340322-61-4 340322-64-7 340322-66-9
340322-74-9 340322-75-0 340322-76-1
340322-80-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of new pyrazolo terpyridines as remedies for inflammation
autoimmune diseases)


RN 340322-61-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(4-methylphenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340322-64-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[4-(methylthio)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340322-66-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 340322-74-9 CAPLUS
CN 1H-Pyrrole, 2,5-dimethyl-1-[[4-[2-(4-(methylamino)phenyl)pyrazolo[1,5-
a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)






RN 340322-75-0 CAPLUS
CN 1H-Pyrrole, 2,5-dimethyl-1-[[4-[2-(4-(phenylmethoxy)phenyl)pyrazolo[1,5-
a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 340322-76-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-bromophenyl)-3-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 340322-80-7 CAPIUS
CN 1H-Pyrrrole, 1-[[[4-methylphenyl]ethynyl]sulfonyl]-3-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]]- (9CI) (CA INDEX NAME)




IT 291743-98-1P 340323-05-9P 340323-06-0P
340323-08-2P 340323-09-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of new pyrazolo terpyridines as remedies for inflammation autoimmune diseases)
RN 291743-98-1 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 340323-05-9 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 340323-06-0 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylthio)phenyl]-2-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 340323-08-2 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-cyclohexyl-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 340323-09-3 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-methoxyphenyl)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




IT 267235-61-0P 267235-62-1P 267235-87-0P
291743-97-0P 340321-37-1P 340321-38-2P
340321-39-3P 340321-40-6P 340321-42-8P
340321-43-9P 340321-44-0P 340321-45-1P

340321-46-2P 340321-47-3P 340321-49-5P
 340321-50-8P 340321-51-9P 340321-52-0P
 340321-53-1P 340321-55-3P 340321-56-4P
 340321-57-5P 340321-58-6P 340321-59-7P
 340321-60-0P 340321-61-1P 340321-62-2P
 340321-63-3P 340321-64-4P 340321-65-5P
 340321-66-6P 340321-67-7P 340321-68-8P
 340321-69-9P 340321-71-3P 340321-72-4P
 340321-73-5P 340321-74-6P 340321-75-7P
 340321-76-8P 340321-77-9P 340321-78-0P
 340321-79-1P 340321-80-4P 340321-81-5P
 340321-82-6P 340321-83-7P 340321-84-8P
 340321-85-9P 340321-86-0P 340321-87-1P
 340321-88-2P 340321-89-3P 340321-90-6P
 340321-91-7P 340321-92-8P 340321-93-9P
 340321-94-0P 340321-95-1P 340321-96-2P
 340321-97-3P 340321-98-4P 340321-99-5P
 340322-00-1P 340322-01-2P 340322-02-3P
 340322-03-4P 340322-04-5P 340322-05-6P
 340322-06-7P 340322-07-8P 340322-08-9P
 340322-09-0P 340322-10-3P 340322-11-4P
 340322-12-5P 340322-13-6P 340322-14-7P
 340322-15-8P 340322-16-9P 340322-17-0P
 340322-18-1P 340322-19-2P 340322-20-5P
 340322-21-6P 340322-22-7P 340322-24-9P
 340322-25-0P 340322-26-1P 340322-27-2P
 340322-28-3P 340322-30-7P 340322-31-8P
 340322-32-9P 340322-33-0P 340322-34-1P
 340322-35-2P 340322-38-5P 340322-39-6P
 340322-40-9P 340322-41-0P 340322-42-1P
 340322-43-2P 340322-44-3P 340322-45-4P
 340322-46-5P 340322-47-6P 340322-48-7P
 340322-49-8P 340322-50-1P 340322-51-2P
 340322-52-3P 340322-53-4P 340322-54-5P
 RN 267235-61-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-62-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 267235-87-0 CAPLUS


CN Pyrazolo[1,5-a]pyridine, 6-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 291743-97-0 CAPLUS
 CN Benzenesulfonamide, 4-(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 340321-37-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-cyclohexyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-38-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-39-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(3-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)


RN 340321-44-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-45-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)







RN 340321-46-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 340321-47-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(5-methyl-2-pyridinyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-49-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)







RN 340321-50-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(1-methylethyl)phenyl]-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-51-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 340321-52-0 CAPLUS
CN Benzenesulfonamide, 4-[2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340321-53-1 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340321-55-3 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-56-4 CAPLUS
CN Benzenesulfonamide, 4-(3-phenylpyrazolo[1,5-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 340321-57-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 340321-58-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-59-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-3-(4-(methanesulfonyl)phenyl)-
(9CI) (CA INDEX NAME)




RN 340321-60-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-methyl-3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-61-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-(4-(methanesulfonyl)phenyl)-2-
phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 340321-62-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-methanol, 3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-63-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 4-methyl-3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-64-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-(4-(methanesulfonyl)phenyl)-2-
phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 340321-65-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-methanol, 3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-66-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-chlorophenyl)-3-(4-(methanesulfonyl)phenyl)-
(9CI) (CA INDEX NAME)




RN	340321-67-7	CAPLUS
----	-------------	--------

Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




NRN 340321-68-8 CAPLUS

URN	340321-68-8	CAPLUS
CN	Pyrazolo[1,5-a]pyridine, 2-(2-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)	




URN 340321-69-9 CAPLUS

RN	340321-69-9	CAPLUS
CN	Benzenesulfonamide, 4-(2-cyclohexylpyrazolo[1,5-a]pyridin-3-yl)-(CA INDEX NAME)	(9CI)




NRN 340321-71-3 CAPLUS

340321-71-3	CAPLUS
Pyrazolo[1,5-a]pyridine, 3-(4-methoxyphenyl)-2-[4-(methylsulfonyl)phenyl]-	
(9CI)	(CA INDEX NAME)




NRN	340321-72-4	CAPLUS
-----	-------------	--------

RN	340321-72-4	CAPLUS
CN	Prazolo[1,5-a]pyridine, 2-{4-(methylsulfonyl)phenyl}-3-phenyl-	(CA
	INDEX NAME)	(9CI)




RN 340321-73-5 CAPLUS

BRN	340321-73-5	CAPLUS
CN		Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-
		(9CI) (CA INDEX NAME)




340321-74-6 CAPLUS

340321-74-6 CAPLUS
Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-{4-(methylsulfonyl)phenyl}-2-phenyl- (9CI) (CA INDEX NAME)




340321-75-7	CAPLUS
-------------	--------


340321-75-7	CAPLUS
Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)	




RN 340321-76-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-77-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-78-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-79-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-(methoxymethyl)-3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-80-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-81-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-82-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)



RN 340321-83-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-84-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-
(9CI) (CA INDEX NAME)

 $\text{HO}-\text{CH}_2$


RN 340321-85-9 CAPLUS

Pyrazolo[1,5-a]pyridine, 4-(4-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9c1) (CA INDEX NAME)

 CH_2F


RN 340321-86-0 CAPLUS

Pyrazolo[1,5-a]pyridine-7-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-87-1 CAPLUS

	CA 903	1- [4- [3- (4- (methylsulfonyl) phenyl) pyrazolo [1,5-a] pyridin-2-
Ethanone,	(CA INDEX NAME)	yl]phenyl]- (9CI)




RN 340321-88-2 CAPLUS

Pyrazolo[1,5-a]pyridine, 6-bromo-3-[4-(methylsulfonyl)phenyl]-2-phenyl-
(9CI) (CA INDEX NAME)



RN 340321-89-3 CAPLUS


Pyrazolo[1,5-a]pyridin-6-amine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

340321-90-6	CAPLUS
-------------	--------


340321-90-6 CAPLUS
Pyrazolo[1,5-a]pyridin-6-amine, N-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

340321-91-7 CAPLUS


Pyrazolo[1,5-a]pyridine, 7-(4-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




340321-92-8 CAPLUS

54021-32-0	ChEBI
Benzeneamine, 4-[-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]-	
(9CI) (CA INDEX NAME)	


2-yl]- (9CI) (CA INDEX NAME)




RN 340321-93-9 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[3-(4-(methylsulfonyl)phenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-94-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2,4-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)- (9CI) (CA INDEX NAME)




RN 340321-95-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(methoxymethoxy)phenyl]-3-(4-(methylsulfonyl)phenyl)- (9CI) (CA INDEX NAME)




RN 340321-96-2 CAPLUS
CN Benzenesulfonamide, 4-[3-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-




RN 340321-97-3 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-98-4 CAPLUS
CN Benzenesulfonamide, 4-[3-(2-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-99-5 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-methylphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-00-1 CAPLUS
CN Benzenesulfonamide, 4-[3-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]-
(9CI) (CA INDEX NAME)




RN 340322-01-2 CAPLUS
CN Benzenesulfonamide, 4-[3-[3-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-02-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 340322-03-4 CAPLUS
CN Benzenesulfonamide, 4-[2-(6-methyl-3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-04-5 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-05-6 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)



RN 340322-06-7 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-07-8 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-08-9 CAPLUS


CN Benzenesulfonamide, 4-[2-[4-(difluoromethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-09-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(trifluoromethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-10-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[3-chloro-4-methoxyphenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-11-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[3-fluoro-4-methoxyphenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-12-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[3-chloro-4-ethoxyphenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-13-6 CAPLUS
CN Benzenesulfonamide, 4-[2-(2,3-dihydro-1H-inden-5-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-14-7 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-15-8 CAPLUS
CN Benzamide, 4-[3-[(4-aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]-
(9CI) (CA INDEX NAME)




RN 340322-16-9 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-17-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[(methylsulfonyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-18-1 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-acetylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)





RN 340322-19-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-propoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-20-5 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-(2-chloroethoxy)phenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)






RN 340322-21-6 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)






RN 340322-22-7 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)






RN 340322-24-9 CAPLUS
CN Benzenesulfonamide, 4-[2-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-25-0 CAPLUS
CN Benzenesulfonamide, 4-[2-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-26-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[5-(trimethylsilyl)-3-isoxazolyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-27-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(5-ethoxy-3-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 340322-28-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-30-7 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-oxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-31-8 CAPLUS
CN Benzenesulfonamide, 4-[2-(5-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-32-9 CAPLUS
CN Benzenesulfonamide, 4-[2-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-33-0 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-amino-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-34-1 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-chloro-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-
yl]- (9CI) (CA INDEX NAME)




RN 340322-35-2 CAPLUS
CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-
yl]phenyl]- (9CI) (CA INDEX NAME)




RN 340322-38-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-[1-methylethenyl]phenyl]pyrazolo[1,5-a]pyridin-
3-yl]- (9CI) (CA INDEX NAME)




RN 340322-39-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(dimethylamino)phenyl]pyrazolo[1,5-a]pyridin-3-
yl]- (9CI) (CA INDEX NAME)




RN 340322-40-9 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)






RN 340322-41-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-[methyl(methylsulfonyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-42-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(2-propenyloxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-43-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(1-methyl-1H-pyrrol-3-yl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-44-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-cyanophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-45-4 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-ethenylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)






RN 340322-46-5 CAPLUS
CN Benzenesulfonamide, 4-[2-(6-chloro-3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-47-6 CAPLUS
CN Acetamide, N-[4-[3-(4-(aminosulfonyl)phenyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 340322-48-7 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)






RN 340322-49-8 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-(ethenyl)oxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 340322-50-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(1-azetidiny)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-51-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-furanyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 340322-52-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(methylamino)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069464	A1	20001123	WO 2000-JP3015	20000511
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RW, GU, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, A1	20020206	EP 2000-925617	20000511
EP 1177797	A1	20020206	EP 2000-925617	20000511
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	20040805	US 2003-716865	20031120
US 2004152639	A1	20040805	JP 1999-131108	A 19990512
PRIORITY APPL. INFO.:			WO 2000-JP3015	W 20000511
			US 2001-926469	B1 20011108
OTHER SOURCE(S):		MARPAT 134:533		
GI				





RN 340322-53-4 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-54-5 CAPLUS
 CN Benzenesulfonamide, 4-[2-(4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 50 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:824128 CAPLUS
 DOCUMENT NUMBER: 134:533
 TITLE: Novel use of adenosine ALA2a receptor dual antagonists
 INVENTOR(S): Matsuoka, Nobuya; Moriguchi, Akira; Tada, Miho; Mihara, Takuma
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: FIXXD2




III



II

AB Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine ALA2a receptor dual antagonists or salts thereof. Markush's structures of pyrazolopyridine derivs. (I), pyrazolopyrazine derivs. (II), and xanthine derivs. (III) were given.


IT 202646-79-5
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel use of adenosine ALA2a receptor dual antagonists in psychiatry)
 RN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 51 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:628138 CAPLUS
 DOCUMENT NUMBER: 133:222726
 TITLE: Preparation of pyrazolopyridines as selective inhibitors of COX-2
 INVENTOR(S): Campbell, Ian Baxter; Lambeth, Paul Francis; Naylor, Alan; Pegg, Neil Anthony
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032008	A1	20000308	WO 1999-EPI0263	19991222
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG			
EP 1157025	A1	20011128	EP 1999-968808	19991222
EP 1157025	B1	20040310		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002538157	T	20021112	JP 2000-602234	19991222
AT 261444	T	20040315	AT 1999-968808	19991222
ES 2216631	T3	20041016	ES 1999-968808	19991222
US 6498166	B1	20021224	US 2001-890925	20010830
PRIORITY APPLN. INFO:			GB 1999-4506	A 19990227
			GB 1999-20904	A 19990903
			WO 1999-EP10263	W 19991222
OTHER SOURCE(S):				
GI				




AB The title compds. [I; R0, R1 = H, halo, alkyl, etc.; R2 = halo, CN, CONR4R5, etc.; R3 = alkyl, NH2; R4, R5 = H, alkyl, (un)substituted Ph; NR4R5 = saturated 4-8 membered ring] which are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases, were prepared and formulated. E.g., a multi-step synthesis of I [R0 = 4-F; R1 = H; R2 = 6-CN; R3 = NH2] which showed IC50 of 21 nM against COX-2 vs. IC50 of 20,950 nM against COX-1, was given.
 IT 291743-84-5P 291743-85-6P 291743-86-7P
 291743-87-8P 291743-88-9P 291743-89-OP
 291743-90-3P 291743-91-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridines as selective inhibitors of COX-2)
 RN 291743-84-5 CAPLUS
 CN Benzenesulfonamide, 4-[6-cyano-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 291743-85-6 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 291743-86-7 CAPLUS
 CN Benzenesulfonamide, 4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 291743-87-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-[(4-methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 291743-88-9 CAPLUS
CN Benzenesulfonamide, 4-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 291743-89-0 CAPLUS
CN Benzenesulfonamide, 4-[6-chloro-2-(4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 291743-90-3 CAPLUS
CN Benzenesulfonamide, 4-[6-chloro-2-(3-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 291743-91-4 CAPLUS
CN Benzenesulfonamide, 4-(6-chloro-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 291743-97-0P 291743-98-1P 291743-99-2P
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as selective inhibitors of COX-2)
RN 291743-97-0 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 291743-98-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[(4-methylthio)phenyl]- (9CI) (CA INDEX NAME)

RN 204504-56-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 291743-99-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-[(4-methylthiophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 52 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:416645 CAPLUS
DOCUMENT NUMBER: 133:38215
TITLE: Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
US 6077842 A 20000620 US 1998-200376 19981124
PRIORITY APPL. INFO.: MARRPAT 133:38215
OTHER SOURCE(S):
AB A method is provided for inhibiting neoplasia, particularly cancerous and precancerous lesions, by exposing the affected cells to pyrazolopyridylpyridazinone derivs. Preparation of compds. of the invention is included.
IT 204504-56-3P
RL: BAC (Biological activity or effector, except 'adverse'); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrazolopyridylpyridazinone derivative preparation for inhibition of neoplastic cells)

REFERENCE COUNT: 164 THERE ARE 164 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 53 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:314697 CAPLUS
DOCUMENT NUMBER: 132:321858
TITLE: Preparation of pyrazolopyridines as selective COX-2 inhibitors
INVENTOR(S): Campbell, Ian Baxter; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2000026216 A1 20000511 WO 1999-EP8186 19991101
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CN, GM, GW, ML, MR, NE, SN, TD, TG
CA 2349567 A1 20000511 CA 1999-2349567 19991101
BR 9915011 A 20010807 BR 1999-15011 19991101
EP 1127058 A1 20010829 EP 1999-955897 19991101
EP 1127058 B1 20040901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
TR 200101208 T2 20011022 TR 2001-200101208 19991101
HU 200104204 A2 20020429 HU 2001-4204 19991101
JP 2002528547 T 20020903 JP 2000-579604 19991101
JP 3420751 B2 20030630
NZ 511349 A 20031031 NZ 1999-511349 19991101
AU 767464 B2 20031113 AU 2000-12667 19991101
AU 767464 B2 20040915 AT 1999-955897 19991101
ES 2228127 T3 20050401 ES 1999-955897 19991101
TW 342836 B 20030721 TW 1999-88119040 19991101
IN 2001K000463 A 20050311 IN 2001-KN463 20010124
ZA 2001003344 A 20020724 ZA 2001-3344 20010424
US 7223772 B1 20070529 US 2001-830836 20010501
NO 2001002156 A 20010702 NO 2001-2156 20010502
NO 318884 B1 20050518 GB 1998-24062 A 19981103
PRIORITY APPL. INFO.:

GB 1999-20909 A 19990903
WO 1999-EP8186 W 19991101

MARPAT 132:321858

OTHER SOURCE(S):
GI




I

AB The title compds. [I: R0, R1 = H, halo, alkyl, etc.; R2 = H, alkyl, alkyl substituted by one or more fluorine atoms, etc.; R3 = alkyl, NH2] which are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases, were prepared and formulated. E.g., a multi-step synthesis of I [R0 = 3-F; R1 = H; R2 = 6-CF3; R3 = NH2] which showed IC50 of 34 nM against COX-2, was given.


IT 267235-24-5P 267235-56-3P 267235-57-4P
267235-58-5P 267235-59-6P 267235-60-9P
267235-61-0P 267235-62-1P 267235-63-2P
267235-64-3P 267235-65-4P 267235-66-5P
267235-67-6P 267235-68-7P 267235-69-8P
267235-70-1P 267235-72-3P 267235-73-4P
267235-74-5P 267235-75-6P 267235-76-7P
267235-77-8P 267235-78-9P 267235-79-0P
267235-80-3P 267235-81-4P 267235-82-5P
267235-83-6P 267235-84-7P 267235-85-8P
267235-86-9P 267235-87-0P 267235-88-1P
267235-89-2P 267235-90-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines as selective COX-2 inhibitors)


RN 267235-24-5 CAPLUS
CN Acetamide, N-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-56-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-57-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 267235-58-5 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-59-6 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-60-9 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-[(4-fluorophenyl)-3-[(4-(methylsulfonyl)phenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)]-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-61-0 CAPIUS
CN Benzenesulfonamide, 4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-62-1 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-[(4-(methylsulfonyl)phenyl)-2-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)]-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-63-2 CAPIUS
CN Benzenesulfonamide, 4-[2-(4-methylphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-64-3 CAPIUS
CN Acetamide, N-[[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)]- (9CI) (CA INDEX NAME)



RN 267235-65-4 CAPIUS
CN Acetamide, N-[[[4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)]- (9CI) (CA INDEX NAME)




RN 267235-66-5 CAPIUS
CN Acetamide, N-[[[4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)]- (9CI) (CA INDEX NAME)




RN 267235-67-6 CAPIUS
CN Acetamide, N-[[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, sodium salt (9CI) (CA INDEX NAME)]- (9CI) (CA INDEX NAME)

CN Propanamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
a]pyridin-3-yl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 267235-72-3 CAPLUS

CN Benzamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
a]pyridin-3-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-73-4 CAPLUS

CN Butanoic acid, 4-[[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
a]pyridin-3-yl)phenyl]sulfonyl]amino]-4-oxo-, methyl ester (9CI) (CA
INDEX NAME)



RN 267235-74-5 CAPLUS


CN Butanoic acid, 4-[[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-



● Na


RN 267235-68-7 CAPLUS

CN Acetamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
a]pyridin-3-yl)phenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 267235-69-8 CAPLUS

CN Propanamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
a]pyridin-3-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-70-1 CAPLUS


a[pyridin-3-yl]phenyl]sulfonyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 267235-75-6 CAPIUS
CN Pentanamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-76-7 CAPIUS
CN Acetamide, 2-(acetyloxy)-N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-77-8 CAPIUS
CN Acetamide, 2-chloro-N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 267235-78-9 CAPIUS
CN Acetamide, 2-(diethylamino)-N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-79-0 CAPIUS
CN Carbamic acid, [[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 267235-80-3 CAPIUS
CN Carbamic acid, [[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


NAME)




RN 267235-81-4 CAPLUS
CN Benzenesulfonamide, 4-[(6-chloro-2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-82-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-chloro-2-(3-ethoxyphenyl)-3-[(4-(methylsulfonyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 267235-83-6 CAPLUS
CN Benzenesulfonamide, 4-[(6-methyl-2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-84-7 CAPLUS
CN Benzenesulfonamide, 4-[(2-(3-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-85-8 CAPLUS
CN Benzenesulfonamide, 4-[(2-(3-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-86-9 CAPLUS
CN Benzenesulfonamide, 4-[(2-(4-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-87-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-methyl-3-[4-(methanesulfonyl)phenyl]-2-phenyl-
(9CI) (CA INDEX NAME)




RN 267235-88-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-6-methyl-3-[4-(methanesulfonyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 267235-89-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-ethoxyphenyl)-6-methyl-3-[4-(methanesulfonyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 267235-90-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-ethoxyphenyl)-6-methyl-3-[4-(methanesulfonyl)phenyl]-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 8

8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 54 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:291038 CAPLUS
DOCUMENT NUMBER: 132:308348
TITLE: Preparation of pyridazinylopyrazolopyridines as

adenosine antagonists
INVENTOR(S): Akihane, Atsushi; Kuroda, Satoru; Itani, Hiromichi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024742	A1	20000504	WO 1999-JP5696	19991014
W: BR, CA, CN, JP, KR, US				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2002528453	T	20020903	JP 2000-578312	19991014
PRIORITY APPL. INFO.:			AU 1998-6721	A 19981023
			WO 1999-JP5696	W 19991014

OTHER SOURCE(S):
AB R1212R2 [Z1 = pyrazolo[1,5-a]pyridine-2,3-diyl; Z2 = 3-oxo-2,3-dihydropyridazine-6,2-diyl]; R1 = substituted Ph; R2 = H or alkyl] were prepared. Thus, 2-(MeO)C6H4I was alkylated by HC.tplbond.CSMe3 and the product deprotected to give HC.tplbond.CC6H4(OMe)-2 which was treated with EtMgBr/Ac2O to give MeOC.tplbond.CC6H4(OMe)-2. The latter was

cyclocondensed with 1-aminopyridinium iodide to give I (R1 = C6H4(OMe)-2, R2 = H). Data for biol. activity of I were given.

IT


265660-54-6P 265660-55-7P 265660-56-8P
265660-57-9P 265660-58-0P 265660-59-1P
265660-60-1P 265660-61-5P 265660-62-6P
265660-63-7P 265660-64-8P 265660-65-9P
265660-66-0P 265660-67-1P 265660-68-2P
265660-69-3P 265660-71-7P 265660-72-8P
265660-73-9P 265660-74-0P 265660-75-1P
265660-76-2P 265660-77-3P 265660-78-4P
265660-79-5P 265660-80-8P 265660-81-9P
265660-82-0P 265660-83-1P 265660-84-2P
265660-85-3P 265660-86-4P 265660-87-5P
265660-88-6P 265660-89-7P 265660-90-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridaziny/pyrazolopyridines as adenosine antagonists)


RN 265660-54-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-methyl- (9CI) (CA INDEX NAME)




RN 265660-55-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-56-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-57-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-methyl- (9CI) (CA INDEX NAME)




RN 265660-58-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-methyl- (9CI) (CA INDEX NAME)




RN 265660-59-1 CAPLUS


CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-60-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-61-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 265660-62-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-63-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-64-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-65-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-66-0 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-67-1 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-68-2 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
2-methyl- (9CI) (CA INDEX NAME)




RN 265660-69-3 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-71-7 CAPIUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-72-8 CAPIUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-73-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-74-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-
methyl- (9CI) (CA INDEX NAME)




RN 265660-75-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-
methylethyl)- (9CI) (CA INDEX NAME)




RN 265660-76-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-
3-yl]- (9CI) (CA INDEX NAME)




RN 265660-77-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-
a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-78-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-
methyl- (9CI) (CA INDEX NAME)




RN 265660-79-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(1-methylethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(propyloxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-81-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-82-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-83-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)





RN 265660-84-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-85-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 265660-88-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 265660-89-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 265660-90-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 265660-86-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 265660-87-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:125853 CAPLUS
DOCUMENT NUMBER: 132:245853

152-21000
DOCUMENT NUMBER:
TITLE: Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines

AUTHOR(S):
Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi;
Nishimura, Shintaro; Durkin, Kieran; Tenda, Yoshiyuki;
Sakane, Kazuo

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan

RESOURCE: Biorganic & Medicinal Chemistry (2000), 8(1), 55-64
CODEN: BNECEP; ISSN: 0968-0896

SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(1), 55-64

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER:
Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

A novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines was synthesized and evaluated for in vitro adenosine A₁ and A_{2A} receptor binding activities. Most of the cyclohexenyl derivs. (7a-e, 8a-g) were found to be potent adenosine A₁ receptor antagonists. In a series of analogs of FR166124 (38), aic. 7c, nitrile 7e and amide derivs. (7d, 8c, 8f) were found to be more potent A₁ antagonists with higher A_{2A}/A₁ selectivity than FR166124. Amongst them, 8r showed considerable water solubility (33.3 mg/mL), but lower than that of the sodium salt of FR166124 (> 200 mg/mL). Addnl., FR166124 had strong diuretic activity by both p.o. and iv administration in rats (min. ED=0.1 and 0.032 mg/kg, resp.).


IT 171050-45-6, FR166124 171051-35-7
and 0.002 mg/kg, resp.).

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(measure of reagent)
(Synthesis and structure-activity of novel 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


171050-45-6 CAPLUS

1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-(9CI) (CA INDEX NAME)



171051-35-7 CAPLUS

1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 171050-95-6P 171051-04-0P 171051-07-3P


171051-08-4P 171051-11-9P 171051-12-0P

171051-14-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (Synthesis and structure-activity of novel 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


171050-95-6	CAPLUS
-------------	--------

1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




171051-04-0 CAPLUS


Glycine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 171051-07-3 CAPLUS
 CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-08-4 CAPLUS
 CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171051-11-9 CAPLUS
 CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-12-0 CAPLUS
 CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 171051-14-2 CAPLUS


CN β-Alanine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 171050-85-4P 171050-87-6P 171050-88-7P
 171050-96-7P 171050-97-8P 171050-98-9P
 171050-99-0P 171051-01-7P 171051-02-8P
 171051-10-8P 171051-13-1P 171051-15-3P
 171051-19-7P 171051-22-2P 171051-23-3P
 171051-24-4P 171051-47-1P 171051-52-8P
 171051-55-1P 262358-35-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (Synthesis and structure-activity of novel 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


RN 171050-85-4 CAPLUS
 CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-87-6 CAPLUS
 CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171050-88-7 CAPLUS
 CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 171050-96-7 CAPLUS
CN 1-Cyclohexene-1-butanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-97-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171050-98-9 CAPLUS
CN Glycine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 171050-99-0 CAPLUS
CN p-Alanine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 171051-01-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-02-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-10-8 CAPLUS
CN 1-Cyclohexene-1-acetamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171051-13-1 CAPLUS
CN 1-Cyclohexene-1-acetamide, N-(2-hydroxyethyl)-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 262358-35-0 CAPLUS
CN Piperazine, 1-methyl-4-((2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl)-, monohydrochloride (9CI)
(CA INDEX NAME)




IT 171051-36-8 171051-40-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(Synthesis and structure-activity of novel 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)
RN 171051-36-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 171051-40-4 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 56 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:34554 CAPLUS
DOCUMENT NUMBER: 132:83673
TITLE: Combination of loop diuretics with adenosine A1-receptor antagonists for treatment of hypertension and related diseases
INVENTOR(S): Hropot, Max
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXMDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 970696	A1	20000112	EP 1998-108127	19980505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: EP 1998-108127 19980505
AB The invention relates to a pharmaceutical composition containing combination of a loop diuretic and an adenosine A1 receptor antagonist. This composition is useful for the treatment of and/or prophylaxis of hypertension, renal failure or disorders with increased proximal tubular reabsorption, e.g., congestive heart failure, liver cirrhosis or nephrotic syndrome. KW-3902 (30 g) was dissolved in a mixed solvent of EtOH (350 g) and CH2Cl2 (350 g), and Eudragit L 100 (90 g) was added to the solution. The resulting solution was sprayed on the mixture of furosemide (120 g) and lactose (760 g), and granulated at 60° with a fluidized bed granulator. After drying, the granules were sieved (24 mesh) and mixed uniformly and homogeneously with magnesium stearate in a blender. The resulting granules were filled into hard gelatin capsules. The capsules containing 5 mg KW-3902 and 20 mg of furosemide were obtained. Results of salidiuretic expts. show that KW-3902 at 0.01 and 0.1 mg/kg and furosemide at 10, 20 and 30 mg/kg body weight in male Wistar rats orally caused a significant increase in urine volume, sodium and chloride excretion as compared to the control. The combinations of KW-3902 at 0.1 mg/kg with furosemide at 10 mg/kg exerted significant additive or even synergistic effects with respect to urine volume, sodium and chloride excretion in the collection periods 1-4 h as compared with single compds.
IT 131185-37-0, FK-838
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of loop diuretics with adenosine A1-receptor antagonists for treatment of hypertension and related diseases)


RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinobutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 57 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 132:49958 CAPLUS
 DOCUMENT NUMBER: 132:49958
 TITLE: Preparation of pyrazolopyridine derivatives as adenosine antagonists
 INVENTOR(S): Akahane, Atsushi; Nishimura, Shintaro; Kuroda, Satoru; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967239	A1	19991229	WO 1998-JP2794	19980622
W: CA, CN, JP, KR, US				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.: MARPAT 132:49958				
OTHER SOURCE(S):				



AB The title compounds, I [R = alkanylalkyl, etc.] are prepared. These compounds are adenosine antagonists and useful as recognition augmenters, nootropic drugs, mental stimulants, analgesic agents, cardiac protective drugs, antidepressive drugs, cerebral vasodilators, tranquilizers, remedies for cardiac failure, cardiac tonics, hypotensive drugs, drugs for renal insufficiency, remedies for nephrotoxicity, renal protective agents, renal function improving drugs, diuretic agents, remedies for edema, antioesic drugs, antialsthatmatics, bronchodilators, remedies for apnea, remedies for gout, remedies for hyperuricemia, remedies for sudden infant death syndrome (SIDS), drugs for improving immunosuppression by adenosine, antidiabetic drugs, antitumor drugs, remedies for pancreatitis, remedies for Meniere syndrome, antianemic agents, remedies for thrombosis, remedies for heart infarction, remedies for embolism, remedies for arteriosclerosis obliterans, remedies for thrombotic phlebitis, remedies for brain

infarction, remedies for transient cerebral ischemia, remedies for angina pectoris, etc. In an in vitro test for adenosine A1 antagonism, 3-[2-(1-methyl-2-oxopropyl)-3-oxo-2,3-dihydropyridazine-6-yl]-2-phenylpyrazolo[1,5-a]pyridine at 3.2 x 10⁻⁷ M showed > 90% inhibition of binding of [3H]-N6-cyclohexyladenosine.

IT


210879-61-1P 210879-62-2P 210879-63-3P
 210879-64-4P 210879-65-5P 210879-66-6P
 210879-67-7P 210879-68-8P 210879-69-9P
 210879-70-2P 210879-71-3P 210879-72-4P
 210879-73-5P 210879-74-6P 210879-75-7P
 210879-76-8P 210879-77-9P 210879-78-0P
 210879-79-1P 210879-80-4P 210879-81-5P
 210879-82-6P 210879-83-7P 210879-84-8P
 210879-85-9P 210879-88-2P 210879-96-2P
 210879-99-5P 210880-03-8P 210880-04-9P
 210880-07-2P 210880-09-4P 210880-11-8P
 210880-13-0P 210880-14-1P 210880-15-2P
 210880-16-3P 210880-18-5P 210880-20-9P
 210880-23-2P 210880-25-4P 210880-27-6P
 210880-28-7P 210880-29-8P 210880-30-1P
 210880-31-2P 210880-33-4P 210880-34-5P
 210880-35-6P 252953-71-2P 252953-72-3P
 252953-73-4P 252953-74-5P 252953-75-6P
 252953-76-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolopyridine derivs. as adenosine antagonists)


RN 210879-61-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-62-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-63-3 CAPLUS


CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-64-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-65-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-acetyl-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-66-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-methyl-2-oxopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-68-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-70-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-72-4 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 7,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-73-5 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 7,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 210879-77-9 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 7,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 210879-75-7 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 7,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 210879-76-8 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 7,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester, (9CI) (CA INDEX NAME)

Double bond geometry as shown.







URN	210879-78-0	CAPLUS
CN	3(2H)-Pyridazinone, 2-(2-oxo-2-phenylethyl)-6-(2-phenylpyrazolo[1,5- a]pyridin-3-yl)- (9CI) (CA INDEX NAME)	




ERN	210879-79-1	CAPLUS
CN	Benzoic acid, 2-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]-, methyl ester (9CI)	(CA INDEX NAME)




210879-80-4 CAPLUS
Benzonitrile, 4-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




210879-81-5 CAPLUS
3(2H)-Pyridazinone, 2-[2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-6-(2-phenylpyrazolol[1,5-a]pyridin-3-yl)-(9CI) (CA INDEX NAME)




URN	210879-82-6	CAPLUS
3(2H)-Pyridazinone, 2-(2-[1,1'-biphenyl]-4-yl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI) <td></td> <td>(CA INDEX NAME)</td>		(CA INDEX NAME)




210879-83-7 CAPLUS
3(2H)-Pyridazinone, 2-[2-oxo-2-(3-pyridinyl)ethyl]-6-(2-phenylpyrazolo[1,5-
a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



210879-84-8 CAPIUS
3(2H)-pyridazinone, 2-(2-oxo-2-tricyclo[3.3.1.3,7]dec-1-ylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




210879-85-9 .CAPLUS
Glycine, N-[2,2-dimethyl-1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-
a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]-, methyl ester (9CI) (CA INDEX
NAME)




RN 210879-88-2 CAPLUS
CN 2-Piperidineacetic acid, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210879-96-2 CAPLUS
CN 2-Piperidineacetic acid, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210879-99-5 CAPLUS
CN Benzoic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-03-8 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, alpha,dimethyl-, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-04-9 CAPLUS
CN Benzoic acid, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 210880-07-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-09-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-11-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-13-0 CAPLUS
CN 1(6H)-Pyridazinebutanamide, N,N,α-tetramethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-14-1 CAPLUS
CN 1(6H)-Pyridazinepentanamide, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-15-2 CAPLUS
CN 1(6H)-Pyridazinepentanamide, N-methyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-16-3 CAPLUS
CN 1(6H)-Pyridazinepentanamide, N,N-dimethyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-18-5 CAPLUS
CN Piperidine, 1-[[1,4-dioxo-5-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl)- (9CI) (CA INDEX NAME)




RN 210880-20-9 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-23-2 CAPLUS


RN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-25-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-27-6 CAPLUS
CN Pyrrolidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-


pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-30-1 CAPLUS
CN Piperazine, 1-methyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS
CN Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-33-4 CAPLUS
CN 1(6H)-Pyridazinebutanamide, N,N-dimethyl-β, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-34-5 CAPLUS
CN Piperidine, 1-[[1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 210880-35-6 CAPLUS
CN 3-Pyrrolidinone, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 252953-71-2 CAPLUS
CN Benzeneacetic acid, α-[[1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}butyl]amino]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252953-72-3 CAPLUS
CN Glycine, N-[1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252953-73-4 CAPLUS

CN Benzeneacetic acid, α-[[1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}butyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252953-74-5 CAPLUS
CN 1(6H)-Pyridazinebutanenitrile, β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 252953-75-6 CAPLUS
CN 1(6H)-Pyridazinebutanenitrile, β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 252953-76-7 CAPLUS
CN Azetidine, 1-[[1,4-dioxo-5-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}pentyl]- (9CI) (CA INDEX NAME)




IT 131185-06-3 131185-08-5 210880-36-7.
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Preparation of pyrazolopyridine derivs. as adenosine antagonists)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 131185-08-5 CAPLUS
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-36-7 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 58 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:652945 CAPLUS
 DOCUMENT NUMBER: 132:49932
 TITLE: Process Improvements in the Production of a Novel Non-Xanthine Adenosine A1 Receptor Antagonist. A

AUTHOR(S):
 CORPORATE SOURCE:
 SOURCE:
 PUBLISHER:
 DOCUMENT TYPE:
 LANGUAGE:
 OTHER SOURCE(S):
 GI

"One-Pot" Horner-Emmons Isomerization Reaction
 Zanka, Atsuhiko; Itoh, Norihumi; Kuroda, Satoru
 Technological Development Laboratories, Fujisawa
 Pharmaceutical Co. Ltd., Osaka, 532-8514, Japan
 Organic Process Research & Development (1999), 3(6),
 394-399
 CODEN: OPRDFK; ISSN: 1083-6160
 American Chemical Society
 Journal
 English
 CASREACT 132:49932




I


AB Pilot plant scale synthesis of 2-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazin-6-one]-1-cyclohexen-1-yl] acetic acid (FR166124) (I) is described. The process involved efficient isomerization of regioisomers produced in a Horner-Emmons reaction and employed ester exchange and hydrolysis with NaOH in MeOH. Challenges encountered in the final purification stage to afford high quality drug substance in pure crystalline form are also described. Process improvements and optimization of each step permitted elimination of column chromatog., resulting in a straightforward, practical, and cost-effective synthesis of I. These methods were successfully scaled up in a pilot plant to give bulk drug suitable for pharmacol. and toxicol. evaluation.

IT 252765-35-8P 252765-36-9P 252765-37-0P
 RL: BYP (Byproduct); PREP (Preparation)
 (manuf of adenosine A1 receptor antagonist
 phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FR166124)
 via successive Horner-Emmons reaction, isomerization, and hydrolysis of
 phenylpyrazolopyridinylpyridazine)
 RN 252765-35-8 CAPLUS
 CN Cyclohexanol, 2-[[6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl]oxy]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 252765-36-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(sulfoxy)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 252765-37-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(methylthio)methoxy]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 171050-45-6P
RL: IMF (Industrial manufacture); PREP (Preparation)
(manuf of adenosine A1 receptor antagonist
phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FRI66124)
via successive Horner Emmons reaction, isomerization, and hydrolysis of
phenylpyrazolopyridinylpyridazone)
RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




IT 171050-40-1P 171050-43-4P 171051-34-6P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(manuf of adenosine A1 receptor antagonist
phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FRI66124)
via successive Horner Emmons reaction, isomerization, and hydrolysis of
phenylpyrazolopyridinylpyridazone)
RN 171050-40-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

RN 171050-40-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-43-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1R,2R)-2-hydroxycyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 131185-06-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(manuf of adenosine A1 receptor antagonist
phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FRI66124)
via successive Horner Emmons reaction, isomerization, and hydrolysis of
phenylpyrazolopyridinylpyridazone)
RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 171051-36-8P 171051-40-4P
RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(optimization of conditions for double bond isomerization of tert-Bu


RN 171051-36-8 CAPLUS
 CN Pyridazinylcyclohexanonecyclohexylmethylenecarboxylate)
 Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-
 pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA
 INDEX NAME)

Double bond geometry as shown.




RN 171051-40-4 CAPLUS
 CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-
 pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA
 INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 59 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:548679 CAPLUS
 DOCUMENT NUMBER: 131:299420
 TITLE: Synthesis of the water-soluble adenosine A1 receptor
 antagonist FR166124 through a novel sequential
 Horner-Emmons / isomerization reaction
 AUTHOR(S): Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi;
 Nishimura, Shintaro; Durkin, Kieran; Kinoshita,
 Takayoshi; Nakanishi, Isao; Sakane, Kazuo
 CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa
 Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
 SOURCE: Tetrahedron (1999), 55(34), 10351-10364
 CODEN: TETRAE; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:299420
 GI



AB An efficient synthesis of FR166124 I (R = H) was achieved through a novel
 sequential Horner-Emmons - isomerization reaction of cyclohexanone II with
 tert-Bu diethylphosphonacetate as the key process. E.g., cyclohexene
 oxide was treated with a phenylpyrazolopyridinylpyridazine in a
 toluene/water mixture in the presence of sodium hydroxide and
 triethylbenzylammonium chloride to give a cyclohexanol derivative in 80% yield
 which undergoes Swern oxidation with DMSO, oxalyl chloride, and triethylamine
 in methylene chloride to give II in 88% yield. E.g., II is added to a
 mixture of sodium hydride and tert-Bu diethylphosphonacetate in toluene at
 4° and allowed to warm to room temperature over 24h to give I (R = Me3C)
 in 80% yield, along with three isomers, formed by incomplete or undesired
 isomerization of the double bond, which were separated by chromatog.; addition


of F3CCO2H to a solution of I (R = Me3C) in methylene chloride provides I (R =
 H) (FR166124) in 75% yield. Extensive studies of the
 olefination/isomerization reaction indicated that temperature, base and
 conformation of the Horner-Emmons products were important factors in the
 isomerization reaction, leading to a proposed mechanism for this unusual
 Horner-Emmons reaction.

IT 131185-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of the adenosine A1 antagonist FR166124 with a novel
 Horner-Emmons olefination/isomerization as the key step)

RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA
 INDEX NAME)




IT 171050-40-1P 171051-34-6P 247110-27-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of the adenosine A1 antagonist FR166124 with a novel
 Horner-Emmons olefination/isomerization as the key step)


RN 171050-40-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-
 3-yl)- (9CI) (CA INDEX NAME)

CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-36-8 CAPLUS
CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2E) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 171051-40-4 CAPLUS
CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


I5 ANSWER 60 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:504267 CAPLUS
DOCUMENT NUMBER: 131:266565

TITLE: Discovery of FRI66124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist


AUTHOR(S): Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi; Nishimura, Shintaro; Durkin, Kieran; Kinoshita, Takayoshi; Tenda, Yoshiyuki; Sakane, Kazuo
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan



RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 247110-27-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 171050-45-6P, FRI66124
RL: SPN (Synthetic preparation); PREP (Preparation)
(Preparation of the adenosine A1 antagonist FRI66124 with a novel Horner-Emmons olefination/isomerization as the key step)


RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




IT 171051-35-7P 171051-36-8P 171051-40-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(the regio- and stereoselectivity, product analyses and energies of isomers formed in a novel Horner-Emmons olefination/isomerization reaction)

RN 171051-35-7 CAPLUS


SOURCE: Bioorganic & Medicinal Chemistry Letters (1999),
9(14), 1979-1984
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel 3-(2-cycloalkyl and cycloalkenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines were synthesized and evaluated for their adenosine A1 receptor binding activities. In this series, FR166124 was found to be the most potent and selective adenosine A1 receptor antagonist, and the double bond of the cyclohexenyl acetic acid group was essential for selectivity of A1 receptor binding. Furthermore, the solubility in water of the sodium salt of FR166124 was high.
IT 131185-37-0, FK838 171050-45-6, FR 166124
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
RN 131185-37-0 CAPLUS
CN 1-(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



IT 171050-53-6P 171050-59-2P 171050-80-9P
171050-81-0P
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
RN 171050-53-6 CAPLUS
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-59-2 CAPLUS
CN 1-Cycloheptene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-80-9 CAPLUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-81-0 CAPLUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 171051-03-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
RN 171051-03-9 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, sodium salt (9CI) (CA INDEX NAME)




● Na


IT 131185-06-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolo-[1,5-a]pyridine FRI66124 as adenosine A1 receptor antagonist)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 171050-40-1P 171050-41-2P 171050-49-0P
 171050-73-0P 171050-74-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolo-[1,5-a]pyridine FRI66124 as adenosine A1 receptor antagonist)
 RN 171050-40-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-41-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-49-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-73-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)
 Relative stereochemistry.



RN 171050-74-1 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)
 Relative stereochemistry.




IT 171051-72-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrazolo-[1,5-a]pyridine FRI66124 as adenosine A1 receptor antagonist)
 RN 171051-72-2 CAPLUS
 CN Cyclohexanone, 2-[[6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 61 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:206896 CAPLUS
 DOCUMENT NUMBER: 130:282079
 TITLE: Preparation of pyridazinylopyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them
 INVENTOR(S): Akabane, Akiyoshi; Kuroda, Satoshi; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11080157	A	19990326	JP 1997-252751	19970901
PRIORITY APPL. INFO.:			JP 1997-252751	19970901
OTHER SOURCE(S):			MARKPAT 130:282079	




AB The title compds. I [R1 = aryl; R2 = CH2CHMeOH, CH2CMe2OH, lower alkanoylaminoalkyl, N-alkanoyl-N-alkylaminoalkyl, lower alkenyloxy-carbonylaminoalkyl, 2-N,N-dialkylamino-2-methylpropyl, lower alkylaminoalkyl, aralkylaminoalkyl, N-alkyl-N-alkylaminoalkyl, perhydroazepinylalkyl, perhydroazocinylalkyl, lower alkylpiperidinylalkyl, 2-, or 3-pyridylalkyl, (un)substituted pyrazolylalkyl, (un)substituted imidazolylalkyl] (II) or their salts are prepared II or their salts are prepared, e.g. by treatment of I (R2 = H) or their salts with R2OH (R2 = amino-protected aralkylaminoalkyl, pyrazolylalkyl having protected amino, amino-protected imidazolylalkyl, amino-protected lower alkylaminoalkyl) or their salts. II are useful as recognition enhancers, antidiarrheal agents, psychostimulants, analgesics, cardioprotectants, antidepressants, cerebral circulation improvers, tranquilizers, antihypertensives, diuretics, bronchodilators, etc., 3-[2-(imidazol-4-yl)methyl]-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine hydrochloride (preparation given) at 10⁻⁷M showed >90% inhibition against ligand binding by

IT human A1 receptors.
 222722-75-0P 222722-77-2P 222722-79-4P
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyridazinylopyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them)
 RN 222722-75-0 CAPLUS
 CN Carbamic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 222722-77-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 222722-79-4 CAPLUS
 CN Acetamide, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)




IT 222722-39-6P 222722-40-9P 222722-41-0P
 222722-42-1P 222722-46-5P 222722-50-1P
 222722-52-3P 222722-55-6P 222722-58-9P
 222722-60-3P 222722-61-4P 222722-62-5P

222722-63-6P 222722-64-7P 222722-65-8P
 222722-66-9P 222722-67-0P 222722-69-2P
 222722-71-6P 222722-81-8P 222722-83-0P
 222722-85-2P 222722-87-4P 222722-89-6P
 222722-92-1P 222722-94-3P 222722-96-5P
 222722-98-7P 222723-65-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyridazinylopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them)

RN 222722-39-6 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1H-imidazol-2-ylmethyl)-6-(2-phenylpyrazolo[1,5-
 a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-40-9 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1H-imidazol-4-ylmethyl)-6-(2-phenylpyrazolo[1,5-
 a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-41-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[(2-(1H-imidazol-4-yl)ethyl)-6-(2-phenylpyrazolo[1,5-
 a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 222722-42-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[(2-(1H-imidazol-4-yl)ethyl)-6-(2-phenylpyrazolo[1,5-
 a]pyridin-3-yl)]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 222722-46-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[[1-(
 triphenylmethyl)-1H-imidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 222722-50-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1H-imidazol-2-ylmethyl)-6-(2-phenylpyrazolo[1,5-
 a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-52-3 CAPLUS
 CN 1H-Imidazole-1-acetic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-1(6H)-pyridazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 222722-55-6 CAPLUS
 CN 1H-Imidazole-1-acetic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 222722-58-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-1H-imidazol-2-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-60-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-61-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-62-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-63-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-1H-imidazol-5-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-64-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(5-amino-1H-pyrazol-1-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 222722-65-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-66-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-1H-imidazol-4-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-67-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 222722-69-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 222722-71-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 222722-81-8 CAPLUS
CN Acetamide, N-methyl-N-[2-[(2-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 222722-83-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-(dimethylamino)-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-85-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-methyl-2-[methyl(phenylmethyl)amino]propyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-87-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(methylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-89-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(phenylmethyl)amino]propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-92-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(methyl(phenylmethyl)amino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-94-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-96-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 222722-98-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1(2H)-azocinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222723-65-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-pyrazol-4-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 131185-06-3 210879-61-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyridazinylpyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them)
RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




L5 ANSWER 62 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:120305 CAPLUS
DOCUMENT NUMBER: 130:320362
TITLE: Discovery of 6-Oxo-3- (2-phenylpyrazolo[1,5-a]pyridin-3-yl)- 1(6H)-pyridazinebutanoic Acid (FK 838): A Novel Non-Xanthine Adenosine A1 Receptor Antagonist with Potent Diuretic Activity

AUTHOR(S): Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi; Kato, Takeshi; Kinoshita, Takayoshi; Kita, Yasuhiro; Kusunoki, Takahiro; Terai, Takao; Yoshida, Keizo; Shiokawa, Youichi
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Company Ltd., Yodogawa-ku Osaka, 532-8514, Japan
SOURCE: Journal of Medicinal Chemistry (1999), 42(5), 779-783.
CODEN: JMCWAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Based on an X-ray crystal structure of FK 453, the authors designed and synthesized a new series of pyrazolo[1,5-a]pyridines, in which heterocyclic groups were introduced instead of the acryloylamide of FK 453. 6-Oxo-3- (2-phenylpyrazolo[1,5-a]pyridin-3-yl)- 1(6H)-pyridazinebutanoic Acid (FK 838) displayed the most potent diuretic activity and was a potent and selective adenosine A1 receptor antagonist with good oral availability and solubility in water. FK 838 can be classified as the first of a new generation of adenosine A1 receptor antagonists, which are useful for the treatment of diseases such as hypertension and renal failure.

IT 131185-37-0, FK 838
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)
RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-06-3P 131185-30-3P 131185-31-4P


131185-32-5P 131754-91-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-30-3 CAPLUS
 CN 3(2H)-Pyridazinone, 2-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-31-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131754-91-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(3-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-04-1P 131185-05-2P 131185-08-5P
 131185-40-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)
 RN 131185-04-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 131185-05-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 131185-08-5 CAPLUS
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-40-5 CAPLUS
 CN 1(6H)-Pyridazinepentanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-02-9P 131185-07-4P 131185-28-9P
 131185-39-2P 223753-60-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (adenosine A1 receptor antagonist and diuretic activity of the
 pyrazolo-pyridine FK 838)
 RN 131185-02-9 CAPLUS
 CN 1(4H)-Pyridazinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 131185-07-4 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-28-9 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 131185-39-2 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 223753-60-4 CAPLUS
 CN 1(4H)-Pyridinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-,
 ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

I5 ANSWER 63 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:45448 CAPLUS
 DOCUMENT NUMBER: 130:246861

TITLE: Pyrazolopyridine derivatives act as competitive
 antagonists of brain adenosine A1 receptors:

[35S]GTPyS binding studies

Ito, Harunobu; Maemoto, Takuya; Akahane, Atsushi;
 Butcher, Steven P.; Oliverman, Henry J.; Finlayson,
 Keith

CORPORATE SOURCE:

Fujisawa Institute of Neuroscience, Japan
 European Journal of Pharmacology (1999), 365(2/3),
 309-315

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The effects of adenosine receptor ligands and three novel pyrazolopyridine
 derivs. on guanosine-5'-O-(3-[35S]thiotriphosphate ([35S]GTPyS)
 binding to rat cerebral cortical membranes were examined [35S]GTPyS
 binding was stimulated in a concentration dependent manner by several adenosine
 receptor agonists. The adenosine A2a receptor selective agonist,
 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS
 21680), was ineffective confirming specificity for adenosine A1 receptor
 activation. 2-Chloro-N6-cyclopentyladenosine (CCPA; 10-7 M)-stimulated
 [35S]GTPyS binding was inhibited by xanthine and pyrazolopyridine
 based adenosine receptor antagonists. The concentration-response curve for
 CCPA-stimulated [35S]GTPyS binding was shifted to the right with
 increasing concns. of antagonist without significant changes in maximal
 response. Schild analyses determined pKB values of 8.97, 8.88, 8.21, 8.16,
 7.79 and 7.65 for 8-cyclopentyl-1,3-dipropylxanthine (DPCPX),
 (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine
 ethanol (FK453), 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-
 pyridazinebutyric acid (FK838), 9-chloro-2-(2-furyl)[1,2,4]triazolo-
 [1,5-c]quinoxalin-5-amine (CGS 15943), 8-cyclopentyl-1,3-methylxanthine
 (CPT) and (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 acryloyl]-piperidin-2-yl acetic acid (FK352), resp. Schild slopes were

close to unity, confirming that these novel pyrazolopyridine derivs. act as competitive antagonists at rat brain adenosine A1 receptors. Also, [35S]GTPγS binding provides a convenient pharmacol. assay for the functional activity of adenosine A1 receptors in rat cortical membranes.

IT

131185-37-0, FK838
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(pyrazolopyridine derivs. act as competitive antagonists of brain adenosine A1 receptors in [35S]GTPγS binding studies in relation to effect of other ligands in rat cerebral cortical membranes)

RN 131185-37-0 CAPLUS
CN 1-(6H)-Pyridazinonebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 64 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

1998-635675 CAPLUS

ACCESSION NUMBER:

129:239894

TITLE:

Preventives and remedies for hyperphosphatemia

INVENTOR(S):

Nomura, Kazuhiko; Sasaki, Emiko; Nakazi, Kazumi; Kajiho, Tokunaki

Fujisawa Pharmaceutical Co., Ltd., Japan

PCT Int. Appl., 59 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841237	A1	19980924	WO 1998-JP933	19980305
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 972525	A1	20000119	EP 1998-905796	19980305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6303624	B1	20011016	US 1999-380617	19991104
PRIORITY APPLN. INFO.:			JP 1997-64034	A 19970318
			WO 1998-JP933	W 19980305

OTHER SOURCE(S):

MARPAT 129:239894

AB The invention relates to efficacious preventives and/or remedies for hyperphosphatemia or secondary accessory thyroid hyperfunction and concomitant symptoms thereof which contain adenosine antagonists as the active ingredient.


IT 131185-37-0 171050-45-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preventives and remedies for hyperphosphatemia)


RN 131185-37-0 CAPLUS

CN 1-(6H)-Pyridazinonebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-45-6 CAPLUS

CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

1998:499463 CAPLUS

ACCESSION NUMBER:

129:216575

TITLE:

Pilot-Scale Synthesis of a Novel Non-Xanthine

Adenosine A1 Receptor Antagonist. 1,3-Dipolar

Cycloaddition of Pyridine N-Imine to an Acetylene

Zanka, Atsuhiko; Hashimoto, Norio; Uematsu, Ryoichi;

Okamoto, Takumi

CORPORATE SOURCE:

Technological Development Laboratories, Fujisawa

Pharmaceutical Co. Ltd., Yodogawa-ku Osaka, 532, Japan

SOURCE:

Organic Process Research & Development (1998), 2(5),

320-324

CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Adenosine A1 receptor antagonist, FK838, has been synthesized in 44% overall yield by a five-step sequence which is operationally straightforward and readily carried out on a large scale. Investigations into the 1,3-dipolar cycloaddn. process that afforded a pyrazolo[1,5-a]pyridine derivative are also described. Process improvements and optimization of each step permitted elimination of column chromatog., resulting in a practical and cost-effective synthesis of FK838. These methods were successfully scaled up in a pharmaceutical pilot plant to give bulk drug used in clin. trials.


IT 131185-06-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(Pilot-scale preparation of FK838)

RN 131185-06-3 CAPLUS

CN 1-(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-37-OP, FK838
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (pilot-scale preparation of FK838)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 66 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:430761 CAPLUS
 DOCUMENT NUMBER: 129:144876
 TITLE: Pyrazolopyridines as adenosine antagonists and pharmaceuticals containing them
 INVENTOR(S): AkaBne, Atsushi; Nishimura, Shintaro; Kurota, Satoshi; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10182643	A	19980707	JP 1996-357706	19961226
PRIORITY APPLN. INFO.:			JP 1996-357706	19961226
OTHER SOURCE(S):			MARPAT 129:144876	




I


AB Pharmaceuticals contain pyrazolopyridines I [R = (substituted) lower alkanoyl(lower)alkyl, N-[(substituted) lower alkyl]carbamoyl(lower)alkyl, etc.] or their salts as adenosine, especially A1, antagonists with cognition-enhancing, analgesic, and locomotor-stimulant effects, and other pharmacol. actions. 3-[2-(1-Methyl-2-oxopropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine (preparation given) (at 3.2 + 10-7M) showed >90% inhibition of [3H]-N6-cyclohexyladenosine binding to rat A1 receptors.
 IT 210879-77-9P 210879-80-4P 210879-85-9P
 210880-03-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)
 RN 210879-77-9 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, α , α -dimethyl- β , β -dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 210879-80-4 CAPLUS
 CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210879-85-9 CAPLUS
 CN Glycine, N-[2,2-dimethyl-1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 210880-03-8 CAPLUS
CN 1(6H)-Pyridazinonebutanoic acid, α,α -dimethyl-, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 210879-61-1P 210879-62-2P 210879-63-3P
210879-64-4P 210879-65-5P 210879-66-6P
210879-67-7P 210879-68-8P 210879-69-9P
210879-70-2P 210879-71-3P 210879-72-4P
210879-73-5P 210879-74-6P 210879-75-7P
210879-76-8P 210879-78-0P 210879-79-1P
210879-81-3P 210879-82-6P 210879-83-7P
210879-84-8P 210879-87-1P 210879-88-2P
210879-91-7P 210879-94-0P 210879-96-2P
210879-99-5P 210880-04-9P 210880-05-0P
210880-07-2P 210880-09-4P 210880-11-8P
210880-13-0P 210880-14-1P 210880-15-2P
210880-16-3P 210880-18-5P 210880-20-9P
210880-21-0P 210880-23-2P 210880-25-4P
210880-27-6P 210880-28-7P 210880-29-8P
210880-30-1P 210880-31-2P 210880-32-3P
210880-33-4P 210880-34-5P 210880-35-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)
RN 210879-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-62-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-63-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-64-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-65-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-acetyl-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-66-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-methyl-2-oxopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-68-8 CAPLUS


CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-70-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-72-4 CAPLUS
CN 1(6H)-Pyridazinepentanoic acid, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-73-5 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 210879-74-6 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, α,α-dimethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 210879-75-7 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, α,α-diethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 210879-76-8 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, α-(ethoxymino)-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 210879-78-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-phenylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-79-1 CAPLUS
CN Benzoic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



RN	210879-81-5	CAPLUS
CN	3(2H)-Pyridazinone, 2-[2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-	(9CI) (CA INDEX NAME)


RN 210880-04-9 CAPIUS

CN Benzoic acid, 4-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-05-0 CAPIUS

CN 1(6H)-Pyridazineacetamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)





RN 210880-07-2 CAPIUS

CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-09-4 CAPIUS


CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-94-0 CAPIUS

CN Benzeneacetic acid, α-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210879-96-2 CAPIUS


CN 2-Piperidineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210879-99-5 CAPIUS

CN Benzoic acid, 2-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-11-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-13-0 CAPLUS
CN 1(6H)-Pyridazinebutanamide, N,N,α,α-tetramethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-14-1 CAPLUS
CN 1(6H)-Pyridazinepentanamide, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-15-2 CAPLUS
CN 1(6H)-Pyridazinepentanamide, N-methyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-16-3 CAPLUS
CN 1(6H)-Pyridazinepentanamide, N,N-dimethyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-18-5 CAPLUS
CN Piperidine, 1-[[1,4-dioxo-5-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl]- (9CI) (CA INDEX NAME)




RN 210880-20-9 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-21-0 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1,1-dimethylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-23-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-25-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-27-6 CAPLUS
CN Pyridazine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-30-1 CAPLUS
CN Piperazine, 1-methyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN	210880-31-2	CAPLUS
CN	Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI)	(CA INDEX NAME)




RN	210880-32-3	CAPLUS
CN	3-Azetidinol, 1-[1,4-dioxo-5-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl]- (9CI)	(CA INDEX NAME)




RN	210880-33-4	CAPLUS
CN	1(6H)-Pyridazinebutanamide, N,N-dimethyl- β , 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI)	(CA INDEX NAME)



210880-34-5	CAPLUS
Piperidine, 1-[1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl}butyl]- (9CI)	(CA INDEX NAME)




<p> RN 210880-35-6 CAPLUS CN 3-Pyrrolidinone, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME) </p>	<p> SMILES <chem>O=C1NCCC1C(=O)N2C=CC3=C(C=C2)N4C(=O)C=CC=C4N5C(=O)C=CC=C53</chem> </p>
--	--




IT 131185-06-3 131185-08-5 210880-36-7
 RU: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolopyridines as adenosine antagonists for
 pharmaceuticals)


Pharmaceuticals)	Index Name)
131185-06-3 CAPLUS	6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI)
3(2H)-Pyridazinone,	



RN	131185-08-5	CAPLUS
CN	1 (6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)	



210880-36-7	CAPLUS
1 (6H) - Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) -	
(9C1)	(CA INDEX NAME)



L5 ANSWER 67 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 1998:219808 CAPLUS
 128:230381
 TITLE: Preparation of pyrazolopyridazine derivatives
 as phosphodiesterase inhibitors

INVENTOR(S): Kouno, Yasushi; Ogata, Takenobu; Awano, Katsuya;
 Matsuzawa, Kayoko; Ito, Taro

PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
 PCT Int. Appl., 39 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814448	A1	19980409	WO 1997-JP3434	19970926
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RN:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2267103	A1	19980409	CA 1997-2267103	19970926
CA 2267103	C	20060530		
AU 9743213	A	19980424	AU 1997-43213	19970926
AU 733316	B2	20010510		
CN 1232463	A	19991020	CN 1997-198468	19970926
CN 1083841	B	20020501		
HU 9903018	A2	20000328	HU 1999-3018	19970926
EP 989129	A1	20000329	EP 1997-941255	19970926
EP 989129	B1	20021211		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
AT 229527	T	20021215	AT 1997-941255	19970926
ES 2187814	T3	20030616	ES 1997-941255	19970926
TW 494100	B	20020711	TW 1997-8611443	19971003
KR 2000048874	A	20000725	KR 1999-702894	19950402
US 6265577	B1	20010724	US 1999-269734	19950405
			JP 1996-283148	19961004
			WO 1997-JP3434	W 19970926

OTHER SOURCE(S): MARPAT 128:230381

GI



I




II

AB Novel pyrazolopyridazine deriva. (I: R1 = Cl-4 alkyl or C3-6 cycloalkyl; R2-R5 = H, Cl-4 alkyl, Ph, or alternatively R3 and R5 may be united to form a double bond) are prepared I possess phosphodiesterase inhibiting activity and have a selective potent bronchodilating effect on the respiratory tract. Thus, compound (II; preparation given) was refluxed with NH2NH2.H2O in EtOH to give I (R1 = R2 = Me, R3-R5 = H). One of I was tested and showed bronchodilating effect on the respiratory tract.

IT 204504-56-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridazine deriva. as phosphodiesterase inhibitors)

RN 204504-56-3 CAPLUS
 CN 3(2H)-Pyridazine, 6-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 68 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 1998:87731 CAPLUS
 128:154090
 DOCUMENT NUMBER: Preparation of pyrazolopyridine compounds as adenosine antagonists

TITLE: Akanane, Atsushi; Kuroda, Satoru; Itani, Hiromichi;

INVENTOR(S): Shimizu, Yasuyo
 Fujisawa Pharmaceutical Co., Ltd., Japan

PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 92 pp.

CODEN: F1XXD2

DOCUMENT TYPE:


Patent

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803507	A1	19980129	WO 1997-JP2493	19970717
W: AU, CA, CN, HU, IL, JP, KR, NO, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2260990	A1	19980129	CA 1997-2260990	19970717
AU 9734621	A	19980210	AU 1997-34621	19970717
AU 733034	B2	20010503		
EP 925299	A1	19980630	EP 1997-930832	19970717
EP 925299	B1	20020925		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1230186	A	19980929	CN 1997-197819	19970717
HU 9903527	A2	20000328	HU 1999-3527	19970717
JP 2000514821	T	20001107	JP 1998-506791	19970717
AT 224893	T	20021015	AT 1997-930832	19970717
ES 2179352	T3	20030116	ES 1997-930832	19970717
US 6124456	A	20000926	US 1999-147543	19990119
PRIORITY APPLN. INFO.:			AU 1996-1110	A 19960718
			WO 1997-JP2493	W 19970717
OTHER SOURCE(S):				
GI			MARPAT 128:154090	




AB The title compds. [I; R1 = aryl; R2 = lower alkyl (un)substituted with unsatd. 3 to 8-membered heteromonocyclic group, etc.] are prepared I are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular disease, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. Thus, 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (preparation given) was reacted with 4-chloro-1-methyl-piperidine.HCl in the presence of NaH to give I (R1 = Ph, R2 = Me), which was tested and showed adenosine antagonistic activity.

IT 202646-79-5P 202646-80-8P 202646-82-0P
202646-84-2P 202646-85-3P 202646-87-5P
202646-89-7P 202646-90-0P 202646-91-1P
202646-92-2P 202646-93-3P 202646-94-4P
202646-95-5P 202646-96-6P 202646-97-7P
202646-98-8P 202646-99-9P 202647-00-5P
202647-01-6P 202647-02-7P 202647-03-8P
202647-04-9P 202647-05-0P 202647-06-1P


202647-07-2P 202647-08-3P 202647-09-4P
202647-10-7P 202647-11-8P 202647-12-9P
202647-13-0P 202647-14-1P 202647-15-2P
202647-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
[preparation of pyrazolopyridine compds. as adenosine antagonists]
RN 202646-79-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 202646-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-82-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride. (9CI) (CA INDEX NAME)




● HCl

RN 202646-84-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 202646-85-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyrrolidinyl)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 202646-87-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202646-89-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyrrolidinyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202646-90-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 202646-91-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-92-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-propyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 202646-93-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-butyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-94-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-pentyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-95-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-hexyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-96-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-[1-(1-methylethyl)-4-piperidinyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-97-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-98-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[1-(phenylmethyl)-4-piperidinyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 202646-99-9 CAPLUS
CN Piperidine, 1-acetyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 202647-00-5 CAPLUS
CN Piperidinium, 1,1-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, iodide (9CI) (CA INDEX NAME)




RN 202647-01-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202647-02-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-azabicyclo[2.2.2]oct-3-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 202647-03-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-3-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-04-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-2-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-05-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(1-methyl-2-piperidinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-06-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(2-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 202647-07-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-4-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-08-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-(1-methyl-4-piperidinyl)ethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 202647-09-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 202647-10-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 202647-11-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-pyrrolidinylmethyl)-, (S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202647-12-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-hydroxy-4-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 202647-13-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4-hydroxy-4-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-14-1 CAPLUS
CN 4-Piperidinol, 1-acetyl-4-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 202647-15-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-methyl-4-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-23-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-2-pyrrolidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.



IT 141060-69-7
RL: RCT (Reactant); RACT (Reactant or reagent)
RL: (preparation of pyrazolopyridine compds. as adenosine antagonists)
RN 141060-69-7 CAPLUS
CN 1(6H)-Pyridazineacetonitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 202647-16-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
RL: (preparation of pyrazolopyridine compds. as adenosine antagonists)
RN 202647-16-3 CAPLUS
CN 1(6H)-Pyridazineethanethioamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 69 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:16460 CAPLUS
 DOCUMENT NUMBER: 128:24224
 TITLE: Efficient large-scale synthesis of 4-phenyl-3-butyne-2-one, a key intermediate for a novel potent adenosine antagonist
 AUTHOR(S): Zanka, Atsuhiko
 CORPORATE SOURCE: Technological Development Laboratories, Fujisawa Pharmaceutical Co. Ltd., Osaka, 532, Japan
 SOURCE: Organic Process Research & Development (1998), 2(1), 60-62
 CODEN: OPDFK; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Phenylacetylenic bromide Grignard reagent reacts with acetic anhydride under mild conditions to give 4-phenyl-3-butyne-2-one in high yield. This method was applicable to a large-scale synthesis, and optimized reaction conditions have been investigated.
 IT 131185-37-0P, FK 838
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (large-scale synthesis of phenylbutynone intermediate for)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 70 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:751670 CAPLUS
 DOCUMENT NUMBER: 128:97575
 TITLE: Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists
 AUTHOR(S): Maemoto, Takuya; Finlayson, Keith; Olverman, Henry J.; Akahane, Atsushi; Horton, Roger W.; Butcher, Steven P.
 CORPORATE SOURCE: Fujisawa Institute of Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ, UK
 SOURCE: British Journal of Pharmacology (1997), 122(6), 1202-1208
 CODEN: BJPCBM; ISSN: 0007-1188
 PUBLISHER: Stockton Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The pharmacol. profile of adenosine A1 receptors in human, guinea-pig, rat and mouse brain membranes was characterized in a radioligand binding assay by use of the receptor selective antagonist, [3H]-8-cyclopentyl-1,3-dipropylxanthine ([3H]-DPCPX). The affinity of [3H]-DPCPX binding sites in rat cortical and hippocampal membranes was similar. Binding site affinity was higher in rat cortical membranes than in membranes prepared from guinea-pig cortex and hippocampus, mouse cortex and human cortex.

PKD values (M) were 9.55, 9.44, 8.85, 8.94, 8.67, 9.39 and 8.67, resp. The binding site d. (Bmax) was lower in rat cortical membranes than in guinea-pig or human cortical membranes. The rank order of potency of seven adenosine receptor agonists was identical in each species. With the exception of 5'-N-ethylcarboxamidoadenosine (NECA), agonist affinity was 3.5-26.2 fold higher in rat cortical membranes than in human and guinea-pig brain membranes; affinity in rat and mouse brain membranes was similar. While NECA exhibited 9.3 fold higher affinity in rat compared to human cortical membranes, affinity in other species was comparable. The stable GTP analog, Gpp(NH)p (100 uM) reduced 2-chloro-N6-cyclopentyladenosine (CPA) affinity 7-13.9 fold, whereas the affinity of DPCPX was unaffected. The affinity of six xanthine-based adenosine receptor antagonists was 2.2-15.9 fold higher in rat cortical membranes compared with human or guinea-pig membranes. The rank order of potency was species-independent. In contrast, three pyrazolopyridine derivs., (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine ethanol (FK453), (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-piperidin-2-yl acetic acid (FK352) and 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutyric acid (FK838) exhibited similar affinity in human, guinea-pig, rat and mouse brain membranes. PKI values (M) for [3H]-DPCPX binding sites in human cortical membranes were 9.31, 7.52 and 7.92, resp. Drug affinity for adenosine A2A receptors was determined in a [3H]-2-[4-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine([3H]-CGS 21680) binding assay in rat striatal membranes. The pyrazolopyridine derivs., FK453, FK838 and FK352 exhibited pKi values (M) of 5.90, 5.92 and 4.31, resp., compared with pKi values of 9.31, 8.18 and 7.57 determined in the [3H]-DPCPX binding assay in rat cortical membranes. These novel pyrazolopyridine derivs. therefore represent high affinity, adenosine A1 receptor selective drugs that, in contrast to xanthine based antagonists, exhibit similar affinity for [3H]-DPCPX binding sites in human, rat, mouse and guinea-pig brain membranes.
 IT 131185-37-0, FK838
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (species differences in human and laboratory animal brain adenosine A1 receptor pharmacol. revealed by use of xanthine and pyrazolopyridine based antagonists)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 71 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:717919 CAPLUS
 DOCUMENT NUMBER: 128:10318
 TITLE: Preventives and remedies for ischemic intestinal lesion and ileus
 INVENTOR(S): Kadowaki, Makoto; Tomoi, Masaaki
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Kadowaki, Makoto; Tomoi, Masaaki
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXAD2
 DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740047	A1	19971030	WO 1997-JP1417	19970424
W: AU, CA, CN, JP, KR, US				
RA: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9724056	A	19971112	AU 1997-24056	19970424
EP 900796	A1	19980310	EP 1997-919667	19970424
EP 900796	B1	20041215		
R: CH, DE, ES, FR, GB, IT, LI				
US 6214843	B1	20010410	US 1999-147169	19990127
PRIORITY APPLN. INFO.:			JP 1996-105020	A 19960425
			WO 1997-JP1417	W 19970424
OTHER SOURCE(S):		MARPAT 128:10318		




R5-C=N-R4

I II


AB Preventives and/or remedies for ischemic intestinal lesions and/or ileus which contain as the active ingredient pyrazolo[1,5-a]pyridine compounds. Represented by general formula (I) or salts thereof wherein R1 represents lower alkyl, etc.; R2 represents a group represented by general formula (II), etc. (wherein R4 represents protected amino, etc.; and R5 represents hydrogen, etc.); and R3 represents hydrogen, etc. The effects of I on intestinal transport and contractility were tested in rat models.

IT 131185-37-0 171050-45-6
RL: BMC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



LS ANSWER 72 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:58055 CAPLUS

DOCUMENT NUMBER: 127:262667

TITLE: Preparation of pyrazolo[1,5-a]pyridine derivatives as

adenosine antagonists and their pharmaceutical uses

Kuroda, Satoshi; Itani, Hiromichi; Akabane, Atsushi

Fujisawa Pharmaceutical Co., Ltd., Japan

Jpn. Kokai Tokkyo Koho, 17 pp.

SOURCE: CODEN: JPKXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09216883	A	19970819	JP 1996-24146	19960209
PRIORITY APPLN. INFO.:			JP 1996-24146	19960209
OTHER SOURCE(S):		MARPAT 127:262667		




AB The deriva. I [R1 = aryl; R2 = oxodihydropyridazinyl Q [R3 = H, lower alkyl, acyl-lower alkyl, acyl-lower alkanoyl-lower alkyl, (un)substituted heterocyclyl, (un)substituted lower alkyl; R4 = H, acyl, cyano, heterocyclyl, lower hydroxyalkyl, (unprotected) amino; R5 = H, lower alkyl; R4 and/or R5 = substituent], pyridazinyl QI [R6 = halo, lower alkoxy, (un)substituted arylamino; R7 = acyl, lower hydroxyalkyl] or their pharmaceutically acceptable salts are claimed. Also claimed are pharmaceuticals containing I or their salts and carriers. I show cognition-enhancing, analgesic, antidepressant, vasodilating, diuretic, cardiotonic, renal circulation-increasing, lipolysis-promoting, antidiabetic, insulin secretion-promoting, platelet aggregation-inhibiting effects, etc., and are especially useful as cardiac infarction inhibitors, antihypertensives, renal failure inhibitors, and diuretics. 3-Propionyl-2-phenylpyrazolo[1,5-a]pyridine (0.50 g), prepared by acylation of 2-phenylpyrazolo[1,5-a]pyridine with (EtCO)2O, was successively treated with CO(CO2Et)2 at 100° for 65 h then with H2NNH2.H2O at 125° for 8 h to give 0.42 g 3-[4-(2-isopropylidenehydrazino)carbonyl-1,5-methyl-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine.

IT 195826-94-9P 195826-95-0P 195826-96-1P
195826-97-2P 195826-98-3P 195826-99-4P


195827-00-0P 195827-01-1P 195827-02-2P
 195827-03-3P 195827-04-4P 195827-05-5P
 195827-07-7P 195827-08-8P 195827-09-9P
 195827-10-2P 195827-12-4P 195827-13-5P
 195827-14-6P 195827-15-7P 195827-16-8P
 195827-17-9P 195827-18-0P 195827-19-1P
 195827-20-4P 195827-21-5P 195827-22-6P
 195827-23-7P 195827-24-8P 195827-25-9P
 195827-26-0P 195827-27-1P 195827-28-2P
 195827-29-3P 195827-30-6P 195827-31-7P
 195827-32-8P 195827-33-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of pyrazolo[1,5-a]pyridine derivs. as adenosine antagonists and their pharmaceutical uses)


RN 195826-94-9 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-5-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)




RN 195826-95-0 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-5-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195826-96-1 CAPLUS
 CN 3(2H)-Pyridazinone, 5-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195826-97-2 CAPLUS
 CN 3(2H)-Pyridazinone, 5-methyl-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195826-98-3 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, hydrazide (9CI) (CA INDEX NAME)




RN 195826-99-4 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-00-0 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 195827-01-1 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 195827-02-2 CAPLUS
CN Glycine, N-[(2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-03-3 CAPLUS
CN Glycine, N-[(2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 195827-04-4 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-05-5 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-07-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 195827-08-8 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-09-9 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-10-2 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-12-4 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-13-5 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 195827-14-6 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-15-7 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-16-8 CAPLUS


CN 1(6H)-Pyridazinepentanoic acid, 5-(ethoxycarbonyl)-γ, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 195827-17-9 CAPLUS
CN 1(16H) 3'-Bipyridazine]-5-carboxylic acid, 1', 4', 5', 6'-tetrahydro-6, 6'-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)




RN 195827-18-0 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-[(4-methoxyphenyl)methyl]-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-19-1 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-[(4-methoxyphenyl)methyl]-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 195827-20-4 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-chloro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 195827-21-5 CAPLUS
CN 4-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-[(3,4,5-trimethoxyphenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-22-6 CAPLUS
CN 4-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 195827-23-7 CAPLUS


CN 4-Pyridazinecarboxylic acid, 3-ethoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-24-8 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 195827-25-9 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-chloro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 195827-26-0 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 195827-27-1 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-28-2 CAPLUS
CN 4-Pyridazinemethanol, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-29-3 CAPLUS
CN 3(2H)-Pyridazinone, 4-(hydroxymethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-30-6 CAPLUS
CN 3(2H)-Pyridazinone, 4-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

1997:262220 CAPLUS
126:272373

Pyrazolopyridine derivatives for prevention and treatment of constipation and allergic intestinal diseases

INVENTOR(S): Takeda, Masahiro; Ishe, Masayuki; Kadowaki, Makoto;
Horiati, Haruo; Tomoi, Masaaki
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JFXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09059157	A	19970304	JP 1995-208815	19950816
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			JP 1995-208815	19950816
			MAEPAT 126:272373	



I

AB Pyrazolopyridine derivs. [I: R1 = allyl, heterocyclic; R2 = protected amino, amido-carboxyl, cyano, -C(R5) =NR4, -R-R6, unsatd. heterocyclic; R3 = H, halogen, low alkyl, low alkoxy; R4 = protected amino, OH; R5 = H, low alkyl; R6 = amino; A = low fatty carboxylate] are claimed for prevention and treatment of constipation and allergic intestinal diseases. I can be formulated into oral and parenteral dosage forms. I (3-[2-(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine) given orally promoted defecation in normal and constipated mice.


IT 131185-37-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pyrazolopyridine derivs. for prevention and treatment of constipation and allergic intestinal diseases)

RN 131185-37-0 CAPLUS


CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




L5 ANSWER 74 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN




RN 195827-31-7 CAPLUS
CN 3(2H)-Pyridazinone, 4-(2-hydroxyethyl)-2-[(3-hydroxyphenyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-32-8 CAPLUS
CN Carbanic acid, [2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 195827-33-9 CAPLUS
CN 3(2H)-Pyridazinone, 4-amino-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 73 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

1996-521818 CAPLUS
125:191894

Effects of selective adenosine A1 receptor antagonism
on glomerular microcirculation and tubuloglomerular
feedback

AUTHOR(S):
CORPORATE SOURCE:
SOURCE:

Han, Wen-Hua
Department of Internal Medicine (I), Kanazawa
University, Kanazawa, 920, Japan
Kanazawa Daigaku Juzen Igakai Zasshi (1996), 105(2),
239-248

CODEN: JUZIAG; ISSN: 0022-7226

Juzen Igakai

PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

Journal

Japanese


AB Renal clearance and micropuncture studies were carried out in anesthetized Sprague-Dawley rats to examine the effects of a selective adenosine A1 receptor antagonist, FK 838 on the glomerular microcirculation and tubuloglomerular feedback (TGF) mechanism. A low dose (1 µg/min/kg) and a high dose (10 µg/min/kg) infusion of FK 838 increased urine volume by 2.2 and 3.8 times and fractional excretion of sodium by 25 and 59 times, resp. While the mean blood pressure and renal plasma flow remained unaltered. The glomerular filtration rate showed a transient minimal increase during the high dose infusion. TGF responsiveness was estimated by measuring changes in the early proximal flow rate (EPFR) when the loop of Henle was perfused orthogradely with Ringer's solution at 40 nL/min. Loop perfusion decreased EPFR by 46.8% from 31.5 to 17.1 nL/min/g kidney weight. The reduction of EPFR in response to loop perfusion was 31.9% at the low and 9.8% at the high dose of FK 838 infusion, showing a suppression of TGF response. To determine the proximal tubule transport of FK 838, probenecid (100 mg/kg + 30 mg/h/kg) was administered i.v. before infusing the high dose of FK 838. The plasma concentration of FK 838 was increased by 2.8-apprx.3.4-fold and natriuresis was enhanced by probenecid, although its urinary excretion was unaltered. EPFR reduction was 6.1% after probenecid and comparable with the high dose of FK 838 alone. The effect of FK 838 from the tubular lumen was also studied by perfusing FK 838 (10-7, 10-6, and 10-5 M) in Ringer's solution into the loop at 40 nL/min. TGF-mediated reduction of EPFR was decreased to 34.8, 21.8 and 6.8%, resp. in a dose dependent manner. In conclusion, FK 838 induces marked natriuresis and diuresis through the direct tubular effect. Intravascular and intratubular FK 838, after gaining access to the juxtaglomerular apparatus, blocks the sensing mechanism of macula densa cells and antagonizes afferent arteriolar vasoconstriction induced by endogenous adenosine, and thus inhibits TGF. This study demonstrates a crucial role of A1 receptor activation by endogenous adenosine in the control of glomerular microcirculation and tubular sodium handling.

IT 131185-37-0, FK 838

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(adenosine A1 receptor antagonism effect on glomerular microcirculation and tubuloglomerular feedback in rats)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 75 OF 88
ACCESSION NUMBER:
DOCUMENT NUMBER:

1996:440609 CAPLUS
125:86637

Preparation of novel pyrazolopyridine derivatives as
adenosine antagonists

Shiohara, Yoichi; Akaha, Atsushi; Katayama, Hirohito;
Mitsunaga, Takafumi
Futisawa Pharmaceutical Co, Japan
Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JFXXAF

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

1

Japanese

Patent

CODEN: JFXXAF

Jpn. Kokai Tokkyo Koho, 9 pp.

Futisawa Pharmaceutical Co, Japan

Shiohara, Yoichi; Akaha, Atsushi; Katayama, Hirohito;

adenosine antagonists

Preparation of novel pyrazolopyridine derivatives as

125:86637

1996:440609 CAPLUS

PATENT NO.

JP 0809976

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

GI

KIND

A

DATE

19960416

APPLICATION NO.

JP 1994-237543

DATE

19940930

MARKET

125:86637

JP 1994-237543

JP 1994-237543

JP 1994-237543


JP 1994-237543

JP 1994-237543

JP 1994-237543

JP 1994-237543

JP 1994-237543



AB

Pyrazolopyridine compds. I [R1 = aryl; R2 = acylalkyl, N-monoalkylcarbamoylalkyl, substituted aralkyl] and their pharmaceutically acceptable salts as adenosine antagonists are prepared. Thus, 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was treated with NaH, then reacted with Et 8-bromooctanoate to give 3-(2-(7-ethoxycarbonyloctyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (II). II was then hydrolyzed to give 3-(2-(7-carboxyheptyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine, 10-8 M solution of which showed 96.7% adenosine antagonism in guinea pig.

IT

131185-08-5P 178878-89-2P 178878-90-5P

178878-91-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(intermediate for adenosine antagonistic dihydropyridazinylpyrazolopyri

dine deriva.)


131185-08-5 CAPLUS

1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-


yl)- (9CI) (CA INDEX NAME)

RN


CN




RN 178878-89-2 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 178878-90-5 CAPLUS
CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 178878-91-6 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 131185-06-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of adenosine antagonistic dihydropyridazinylpyrazolopyridine derivs.)
RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 178878-84-7P 178878-85-8P 178878-86-9P
178878-87-0P 178878-88-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridine derivs. as adenosine antagonist)
RN 178878-84-7 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 178878-85-8 CAPLUS
CN Benzamide, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 178878-86-9 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 178878-87-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-phenylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of adenosine subtype-1 receptor antagonist (FK-838) on salt-induced hypertension in Dahl salt-sensitive rats in relation to diuretic activity and kidney protection and effect on renin-angiotensin system)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9C1) (CA INDEX NAME)



L5 ANSWER 77 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:54563 CAPLUS

DOCUMENT NUMBER: 124:164769

TITLE: A new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats

AUTHOR(S):

Uehara, Yoshio; Numabe, Atsushi; Hirawa, Nobuhito; Kawabata, Yukari; Nagoshi, Hiroshi; Kaneko, Hiroshi; Gomi, Tomoko; Goto, Atsuo; Toyooka, Teruhiko; Omata, Masao

CORPORATE SOURCE: Dep. Medicine, Univ. Tokyo, Tokyo, Japan

SOURCE: American Journal of Hypertension (1995), 8(12, Pt. 1), 1189-99

CODEN: AJHVE6; ISSN: 0895-7061

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors investigated the effects of the adenosine type-1 receptor antagonist FK-838 on salt-induced hypertension in Dahl-Sea salt-sensitive (Dahl S) rats. Dahl S rats fed a high-salt (4% NaCl) diet for 4 wk were treated with FK-838 or hydrochlorothiazide for 4 wk and alterations in kidney function and morphol. changes were assessed. FK-838 attenuated the development of hypertension in Dahl S rats, and caused a decrease in aortic weight in a dose-dependent fashion. The adenosine antagonist did not produce any detectable metabolic disturbance. The blood pressure reduction by FK-838 was associated with attenuation of glomerular and arterial injury in the kidney. The renal protective effect of FK-838 treatment was associated with a reduction of plasma renin activity and plasma aldosterone concentration

In

contrast, the thiazide diuretic, which produced almost the same blood pressure reduction as FK-838, did not attenuate renal damage. These data indicate that adenosine A1 receptor antagonism reduces salt-induced hypertension and the consequent renal injuries.

IT 131185-37-0, FK 838

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(a new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9C1) (CA INDEX NAME)

RN 178878-88-1 CAPLUS

CN 1(6H)-Pyridazinepropanamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9C1) (CA INDEX NAME)



L5 ANSWER 76 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:227703 CAPLUS

DOCUMENT NUMBER: 124:306972

TITLE: The effects of adenosine subtype-1 receptor antagonist (FK-838) on salt-induced hypertension in Dahl salt-sensitive rats

AUTHOR(S):

Kaneko, Hiroshi; Numabe, Atsushi; Doumoto, Maho; Uehara, Yoshio; Yagi, Shigeru Sch. Med., Dokkyo Univ., Japan

CORPORATE SOURCE: Dokkyo Igakai Zaasshi (1995), 10(2), 235-44

SOURCE: CODEN: DIZAE6; ISSN: 0911-5900

PUBLISHER: Dokkyo Igakai

DOCUMENT TYPE: Journal


LANGUAGE: Japanese

AB The authors investigated the effects of an adenosine type-1 (A1) receptor antagonist (FK-838) on salt-induced hypertension in Dahl-Sea salt-sensitive (Dahl S) rats. Alterations in kidney function and morphol. changes were assessed in Dahl S rats treated for 4-wk with FK-838 (1.0 mg/kg, 10.6 mg/kg) or hydrochlorothiazide (HCTZ, 9.7 mg/kg), a thiazide diuretic. All prolonged treatments decreased systolic blood pressure in Dahl S rats fed a high-salt (2% NaCl) diet. There was a trend toward increased urinary excretion and fractional excretion of sodium with FK-838 treatment. The blood pressure reduction by FK-838 was associated with the partial resolution of glomerular and arterial injury in the kidney. The renal protective effect of FK-838 treatment was associated with the reduction

of


plasma renin activity and plasma aldosterone concentration. In contrast, HCTZ which produced almost the same blood pressure reduction as FK-838, did not attenuate renal damage. These data indicate that A1 receptor antagonism ameliorates salt-induced hypertension and the consequent renal injury. The protective effects of FK-838 may be mediated in part by a decrease in the activity of the renin-angiotensin system.

IT 131185-37-0, FK-838



L5 ANSWER 78 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:960198 CAPLUS
 DOCUMENT NUMBER: 124:8834
 TITLE: Preparation of (oxopyridazinyl)pyrazolopyridines as
 adenosine antagonists
 INVENTOR(S): Akahane, Atsushi; Nishimura, Shintaro; Itani,
 Hiromichi; Durkin, Kieran P. M.
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Pct Int. Appl., 167 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518128	A1	19950706	WO 1994-JP2230	19941226
W: AU, CA, CN, FI, HU, JP, KR, NO, RU, US				
CA 2180253	A1	19950706	GB, IE, IT, LU, MC, NL, PT, SE	19941226
AU 9512817	A	19950717	CA 1994-2180253	19941226
AU 694157	B2	19980716	AU 1995-12817	19941226
EP 737193	A1	19961016	EP 1995-903969	19941226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1139928	A	19970108	CN 1994-194724	19941226
HU 76280	A2	19970728	HU 1996-1789	19941226
JP 09507485	T	19970729	JP 1995-517911	19941226
ZA 9410409	B2	20041006	ZA 1994-10409	19941229
IL 112193	A	20001031	IL 1994-112193	19941229
BR 9500905	A	19951024	BR 1995-905	19950306
IN 1995M00292	A	20050225	IN 1995-M0292	19950310
US 5773530	A	19980630	US 1996-663119	19960913
US 6355640	B1	20020312	US 1998-72696	19980506
PRIORITY APPLN. INFO.:			GB 1993-26524	19931229
			GB 1994-4323	A 19940304
			WO 1994-JP2230	W 19941226
			US 1996-663119	A1 19960913
OTHER SOURCE(S):				
GI			MARPAT 124:8834	




AB Title compds. [I; R1 = aryl; R2 = (un)substituted cycloalkyl] were prepared
 Thus, I (R1 = Ph, R2 = H) was alkylated by 2-chlorocyclohexanone and the
 product condensed with (EtO)2P(O)CH2CO2Et to give, after saponification, title
 compound II and the exo-unsatd. product. II gave reduction of serum creatinine
 from 3.60 (control) to 1.10mg/dL i.v. in rats experiencing
 cisplatin-induced renal failure.
 IT 171050-39-8P 171050-40-1P 171050-41-2P
 171050-42-3P 171050-43-4P 171050-44-5P
 171050-45-6P 171050-46-7P 171050-47-8P
 171050-48-9P 171050-49-0P 171050-50-3P
 171050-51-4P 171050-52-5P 171050-53-6P
 171050-54-7P 171050-55-8P 171050-56-9P
 171050-57-0P 171050-58-1P 171050-59-2P
 171050-60-5P 171050-61-6P 171050-62-7P
 171050-63-8P 171050-64-9P 171050-65-0P
 171050-66-1P 171050-67-2P 171050-68-3P
 171050-69-4P 171050-70-7P 171050-71-8P
 171050-72-9P 171050-73-0P 171050-74-1P
 171050-75-2P 171050-76-3P 171050-77-4P
 171050-78-5P 171050-79-6P 171050-80-9P
 171050-81-0P 171050-82-1P 171050-83-2P
 171050-84-3P 171050-85-4P 171050-86-5P
 171050-87-6P 171050-88-7P 171050-89-8P
 171050-90-1P 171050-91-2P 171050-92-3P
 171050-93-4P 171050-94-5P 171050-95-6P
 171050-96-7P 171050-97-8P 171050-98-9P
 171050-99-0P 171051-00-6P 171051-01-7P
 171051-02-8P 171051-03-9P 171051-04-0P
 171051-05-1P 171051-06-2P 171051-07-3P
 171051-08-4P 171051-09-5P 171051-10-8P
 171051-11-9P 171051-12-0P 171051-13-1P
 171051-14-2P 171051-15-3P 171051-16-4P
 171051-17-5P 171051-18-6P 171051-19-7P
 171051-20-0P 171051-21-1P 171051-22-2P
 171051-23-3P 171051-24-4P 171051-25-5P
 171051-26-6P 171051-27-7P 171051-28-8P
 171051-29-9P 171051-30-2P 171051-31-3P
 171051-32-4P 171051-33-5P 171051-34-6P
 171051-35-7P 171051-36-8P 171051-37-9P
 171051-38-0P 171051-39-1P 171051-40-4P
 171051-41-5P 171051-42-6P 171051-43-7P
 171051-44-8P 171051-45-9P 171051-46-0P
 171051-47-1P 171051-48-2P 171051-49-3P
 171051-50-6P 171051-51-7P 171051-52-8P
 171051-53-9P 171051-54-0P 171051-55-1P
 171051-56-2P 171051-57-3P 171051-58-4P
 171051-59-5P 171051-60-8P 171051-61-9P
 171051-62-0P 171051-63-1P
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study): PREP (Preparation): USES (Uses)

(Preparation of (oxypyridazinyl)pyrazolopyridines as adenosine antagonists)


RN 171050-39-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-cyclohexyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)



RN 171050-40-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-41-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-42-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-43-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-((1R,2R)-2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171050-44-5 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-46-7 CAPLUS
CN Cyclohexanecarboxylic acid, 3-hydroxy-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, [1S-(1α,3β,4α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171050-47-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxycycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-48-9 CAPLUS
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-49-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-50-3 CAPLUS
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171050-51-4 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclopentylidene]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171050-52-5 CAPLUS
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171050-53-6 CAPLUS
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-54-7 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclopentylidene]- (9CI) (CA INDEX NAME)




RN 171050-55-8 CAPLUS
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-56-9 CAPLUS
CN Cyclohexanecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-57-0 CAPLUS
CN Cyclohexanecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171050-58-1 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cycloheptylidene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171050-59-2 CAPLUS
CN 1-Cycloheptene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171050-60-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171050-61-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1,4-dioxaspiro[4.5]dec-8-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-62-7 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-63-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-3-pyrrolidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-64-9 CAPLUS
CN 1,3-Cyclohexanedione, 2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 171050-65-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 171050-66-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-67-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 171050-68-3 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-2,4-dioxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 171050-69-4 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 3,6-dihydro-2,6-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 171050-70-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1,2,3,4-tetrahydro-2-hydroxy-6-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 171050-71-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171050-72-9 CAPLUS
CN Cyclopentaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-73-0 CAPLUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-74-1 CAPLUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-75-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-76-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylcyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 171050-77-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(octahydro-2-oxo-7-benzofuran-1-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-78-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171050-79-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 171050-80-9 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-


1(6H)-pyridazinyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-81-0 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-82-1 CAPLUS
CN Cyclopentanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-83-2 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-84-3 CAPLUS


CN 1-Pyrrolidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-85-4 CAPLUS
CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-86-5 CAPLUS
CN Glycine, N-[1-oxo-4-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 171050-87-6 CAPLUS
CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-88-7 CAPLUS
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 171050-89-8 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)
Relative stereochemistry.



RN 171050-90-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)
Relative stereochemistry.




RN 171050-91-2 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 3,6-dihydro-2,6-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 171050-92-3 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-2,4-dioxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 171050-93-4 CAPLUS
CN Cyclohexanecarboxylic acid, 1-hydroxy-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-94-5 CAPLUS
CN Acetic acid, [4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)



RN 171050-95-6 CAPLUS
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-96-7 CAPLUS
CN 1-Cyclohexene-1-butanolic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-97-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171050-98-9 CAPLUS
CN Glycine, N-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-99-0 CAPLUS
CN β-Alanine, N-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171051-00-6 CAPLUS
CN Acetic acid, [[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]amino]oxy]- (9CI) (CA INDEX NAME)




RN 171051-01-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-02-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-03-9 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, sodium salt (9CI) (CA INDEX NAME)




● Na


RN 171051-04-0 CAPLUS
CN Glycine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-05-1 CAPLUS
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 171051-06-2 CAPLUS
CN 1-Cyclohexene-1-butanolic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 171051-07-3 CAPLUS
CN Glycine, N-methyl-N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-08-4 CAPLUS
CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




SRN	171051-09-5	CAPLUS
CN	1-Cyclohexene-1-butanamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI)	(CA INDEX NAME)




171051-10-8	CAPLUS
1-Cyclohexene-1-acetamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5- alpyridin-3-yl)-1(6H)-pyridazinyl]- (9Ci) (CA INDEX NAME)	




Index Name	171051-11-9	CAPLUS
β-Alanine, N-methyl-N'-[2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(5H)-pyridazinyl)-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI)		




INDEX NAME	CA
171051-12-0 CAPLUS	
Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl amino]-, methyl ester (9CI) (CA	




RN	171051-13-1	CAPLUS	(CA INDEX
CN	1-Cyclohexene-1-acetamide, N-(2-hydroxyethyl)-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI)		




171051-14-2 CAPLUS
β-Alanine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




171051-15-3 CAPLUS
1-Cyclohexene-1-acetamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-
a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




171051-16-4	CAPLUS
1-cyclohexene-1-butamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5- alpyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)	




RN	171051-17-5	CAPLUS
CN	1-Cyclohexene-1-butanamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI)	(CA INDEX NAME)




NRN	NAME	CA INDEX
171051-18-6	CAPLUS	
CN	Glycine, N-[1-oxo-4-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]butyl]-, ethyl ester (9CI)	




URN	171051-19-7	CAPLUS
CN	Thiomorpholine, 4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI)	(CA INDEX NAME)




NRN	171051-20-0	CAPLUS
CN	Pipetazine, 1-methyl-4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)	




NRN	INDEX	NAME
171051-21-1	CAPLUS	Piperazine, 1-([2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl)-4-(triphenylmethyl)-



URN	171051-22-2	CAPLUS
CN	Morpholine, 4-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]- (9CI)	(CA INDEX NAME)




RN	171051-23-3	CAPLUS
CN	Pyrrolidine, 1-[[2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl)-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)	




NRN 171051-24-4 CAPLUS


CN Piperidine, 1-([2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl)- (9CI) (CA INDEX NAME)




RN 171051-25-5 CAPLUS
CN 4-Piperidinamine, N-methyl-1-([2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl)- (9CI) (CA INDEX NAME)




RN 171051-26-6 CAPLUS
CN Hydrazinecarboxamide, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)




RN 171051-27-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydrazonocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-28-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(hydroxyimino)cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-29-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(methoxyimino)cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-30-2 CAPLUS
CN Acetic acid, [[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]amino]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-31-3 CAPLUS
CN Hydroxylamine-O-sulfonic acid, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)




RN 171051-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methylenecyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-33-5 CAPLUS
CN Acetic acid, [4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, ethyl ester (9CI) (CA INDEX NAME)



RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-35-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-36-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-37-9 CAPLUS
CN Acetonitrile, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-38-0 CAPLUS
CN Acetonitrile, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-39-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(5,6-dihydro-4,4,6-trimethyl-4H-1,3-oxazin-2-yl)methylene]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


3-yl)- (9CI) (CA INDEX NAME)




RN 171051-44-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-45-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171051-46-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-(2-hydroxyethyl)-1-cyclohexen-1-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-40-4 CAPLUS
CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-41-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-phenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-42-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-methoxyphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-43-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methoxyphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN	171051-56-2	CAPLUS
CN	3(2H)-Pyridazinone, 2-(4-oxo-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI)	(CA INDEX NAME)




RN	171051-57-3	CAPLUS
CN	3(2H)-Pyridazinone, 2-(3-oxo-4-piperidiny1)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI)	(CA INDEX NAME)




RN	171051-58-4	CAPLUS
CN	1-Pyrrolidineacetic acid, 2-oxo-3-[6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)	




RN	171051-59-5	CAPLUS
CN	1-Piperidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)	




RN	171051-60-8	CAPLUS
CN	Acetic acid, [[5,6,7,8-tetrahydro-5-oxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5- alpyridin-3-yl]-1(6H)-pyridazinyl]-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)	



RN	171051-61-9	CAPLUS
CN	Acetic acid, [[5,6,7,8-tetrahydro-5-oxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5- a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-naphthalenyl]oxy)-(9CI) (CA INDEX NAME)	




RN	171051-62-0	CAPLUS
CN	Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)	




RN	171051-63-1	CAPLUS
CN	Cyclohexanecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)	

CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylethynyl)-3-pyridazinyl]-
(9CI) (CA INDEX NAME)




RN 171051-73-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-hydroxy-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 171051-74-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-hydroxy-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 79 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:652344 CAPLUS

DOCUMENT NUMBER: 123:55871

TITLE: Preparation of pyrazolopyridine derivatives as allergy

INVENTOR(S): inhibitors

PATENT ASSIGNEE(S): Ogata, Takenobu; Amada, Junichiro; Ohashi, Mitsuo;

SOURCE: Matsuzawa, Kayoko

DOCUMENT TYPE: Kyorin Seiyaku KK, Japan

LANGUAGE: Jpn. Kokai Tokkyo Koho, 6 pp.


FAMILY ACC. NUM. COUNT: CODEN: JKXXAF

PATENT INFORMATION: Patent Japanese 1

PATENT NO. KIND DATE APPLICATION NO. DATE

JP 0703769 A 19950203 JP 1993-203566 19930726

PRIORITY APPLN. INFO.: JP 1993-203566 19930726




IT 171051-72-2P

RL: BVP (Byproduct); PREP (Preparation)

(preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)

RN 171051-72-2 CAPLUS

CN Cyclonexanone, 2-[(6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl)oxy]- (9CI) (CA INDEX NAME)




IT 131185-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)

RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-57-4P 171051-64-2P 171051-73-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)


RN 131185-57-4 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 3-(6-chloro-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 171051-64-2 CAPLUS

OTHER SOURCE(S):
GI MARPAT 123:55871




II


AB The title compds. I (R = H, alkyl, etc.; m = 0 - 2; n = 0 or 1) are prepared against anaphylactic airway constriction in guinea pigs.

IT 164391-26-8p 164391-27-9p
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolopyridine derivs. as allergy inhibitors)

RN 164391-26-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-cyclopropyl-3-(3,6-dihydro-2H-thiopyran-4-yl)-(9CI) (CA INDEX NAME)




RN 164391-27-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-cyclopentyl-3-(3,6-dihydro-2H-thiopyran-4-yl)-(9CI) (CA INDEX NAME)



L5 ANSWER 80 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:117558 CAPLUS
DOCUMENT NUMBER: 122:123153
TITLE: Pyrazolopyridine derivatives for prevention and treatment of Meniere's disease
INVENTOR(S): Robaato, Gelburieru Feterora
PATENT ASSIGNEE(S): Air Products and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent


LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06192092	A	19940712	JP 1993-247703	19931004
PRIORITY APPLN. INFO.: OTHER SOURCE(S): AB Pyrazolopyridine derivs. such as (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(2-hydroxyethyl)piperidine are therapeutics for prevention and treatment of Meniere's disease. IT 131185-08-5 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrazolopyridine derivs. for prevention and treatment of Meniere's disease) RN 131185-08-5 CAPLUS CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI) (CA INDEX NAME)			GB 1992-20894	A 19921005



L5 ANSWER 81 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:435602 CAPLUS
DOCUMENT NUMBER: 121:35602
TITLE: Preparation of pyrazolopyridines as intermediates for pharmaceutical dihydropyridazopyrazolopyridines
INVENTOR(S): Nakamura, Hitoshi; Kawakami, Ryoichi; Yamazaki, Hiroshi; Hashimoto, Norio; Taki, Isao
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06009631	A	19940118	JP 1993-120928	19930423
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			JP 1992-107289	A1 19920427
			CASREACT 121:35602; MARPAT 121:35602	



AB Pyrazolopyridines I (R1 = lower alkyl; R2, R3 = H, substituting group; X-


= anion) are prepared by treatment of R2C6H4C.tpi bond.CCOR1 (R1, R2 = same as above) with aminopyridines II (R3, X- = same as above). Treatment of 5.00 g I (R1 = Me, R2 = H) with 11.55 g II (R3 = H, X- = iodide) and K2CO3 in DMF at 33-37° for 1 h gave 6.66 g I (R1 = Me, R2 = R3 = H).

IT 131185-06-3P 131185-07-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation and reaction of)


RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 131185-07-4 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




IT 131185-08-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Preparation of, acetylphenylpyrazolopyridine as intermediate for)

RN 131185-08-5 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 82 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1994:153722 CAPLUS

DOCUMENT NUMBER:

120:153722

TITLE:

Pyrazolopyridine compounds for the treatment of anemia

INVENTOR(S):

Kohno, Yutaka; Nagatomi, Itsuo; Hanaoka, Kaori

PATENT ASSIGNEE(S):

Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 61 pp.

CODEN: PIXXD2

PATENT

DOCUMENT TYPE:

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325205	A1	19931223	WO 1993-JP762	19930607
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 644762	A1	19950329	EP 1993-913487	19930607
EP 644762	B1	19971217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08500338	T	19960116	JP 1993-501330	19930607
AT 161178	T	19980115	AT 1993-913487	19930607
JP 5265084	B2	20020325	JP 1994-501330	19930607
US 5643938	A	19970701	US 1994-338539	19941208
			GB 1992-12264	A 19920610
			GB 1992-15794	A 19920724
			WO 1993-JP762	W 19930607
PRIORITY APPL. INFO.:				
			MARPAT 120:153722	

OTHER SOURCE(S):

GI



AB Pyrazolopyridine compds. [I; R1=lower alkyl, R2= Q (R4= protected amino, R5=H), R3=H] or salt thereof are useful for the prevention and treatment of anemia. Monkeys were injected with 1.25% saline solution and treatment with phenylhydrazine.HCl on days 1 and 3 followed by oral administration of 3.2 mg 3-[(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]2-phenylpyrazolo[1,5-a]pyridine/kg twice a day for 5 days. The hematocrit value and erythropoietin level on day 5 was 24 and 272.2 resp., as compared to 19% and 250.8 mIU/mL for controls.


IT 131185-37-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Preparation of, for treatment of anemia)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 83 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1992:605214 CAPLUS

DOCUMENT NUMBER:

117:205214

TITLE:

Preparation and use of adenosine antagonists for the

prevention and treatment of pancreatitis and ulcer

Shiokawa, Youichi; Akahane, Atsushi; Katayama,

INVENTOR(S):

Hirohito; Mitsuunaga, Takafumi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 45 pp.
 CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 497258	A2	19920805	EP 1992-101308	19920128
EP 497258	A3	19931013		
EP 497258	B1	20020102		
	R:	AT, BE, CH, DE, DK, FR, IT, LI, LU, NL, SE		
US 5155114	A	19921013	US 1991-713460	19910614
CA 2060138	A1	19920730	CA 1992-2060138	19920128
AT 211384	T	20020115	AT 1992-101308	19920128
JP 05058913	A	19930309	JP 1992-13506	19920129
			US 1991-648320	A 19910129
			US 1991-715460	A 19910614
			PH 1991-42760	A 19910709
			GB 1989-1423	A 19890123
			US 1990-466929	A2 19900118
			US 1990-626009	B2 19900118

PRIORITY APPL. INFO.: MARPAT 117:205214

OTHER SOURCE(S):
 AB Adenosine antagonists are disclosed for preparation of medicaments for prevention and/or treatment of pancreatitis and/or ulcers. Preparation of a large number of pyrazolopyridine derivative adenosine antagonists is included. The trans isomer of (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acetyl]-2-(carboxymethyl)piperidine (I) (preparation given) inhibited gastric ulcer induced by N6-cyclohexyladenosine by 99.8%. I also inhibited (as reflected by serum amylase level reduction) N6-cyclohexyladenosine-induced pancreatitis.

IT 131185-06-3P 131185-32-5P 141060-80-2P

141060-81-3P 141060-82-4P 143881-06-5P


RL: RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation and reaction of, for adenosine antagonist preparation for ulcer and

pancreatitis treatment)


RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-80-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 141060-81-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-(4-(acetyloxy)butyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-82-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-(4-hydroxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 143881-06-5 CAPLUS


CN 3(2H)-Pyridazinone, 2-(5-bromopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 141060-38-0P 141060-39-1P 141060-40-4P
 141060-41-5P 141060-42-6P 141060-43-7P
 141060-44-8P 141060-45-9P 141060-46-0P
 141060-48-2P 141060-49-3P 141060-50-6P
 141060-51-7P 141060-52-8P 141060-53-9P
 141060-54-0P 141060-55-1P 141060-56-2P
 141060-57-3P 141060-58-4P 141060-59-5P
 141060-60-8P 141060-61-9P 141072-32-4P
 143881-04-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as adenosine antagonist for ulcer and pancreatitis treatment)

RN 141060-38-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[2-(4-morpholinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-42-6 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)


● HCl

RN 141060-39-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-40-4 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[2-(dimethylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-41-5 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[3-(dimethylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-42-6 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 141060-43-7 CAPLUS
 CN 1(6H)-Pyridazinepropanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-44-8 CAPLUS
 CN 1(6H)-Pyridazinebutanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 141060-50-6 CAPLUS
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 141060-51-7 CAPLUS
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 141060-52-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-53-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


RN 141060-45-9 CAPLUS
CN 1(6H)-Pyridazinone, 2-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-46-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-48-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)




RN 141060-49-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)






● HCl

RN 141060-54-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[4-(dimethylamino)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-55-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[4-(2-hydroxyethyl)-1-piperazinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 141060-56-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[4-(2-methoxyphenyl)-1-piperazinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-, (9CI) (CA INDEX NAME)




RN 141060-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 141060-58-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[3-(1H-tetrazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




RN 141060-59-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[4-(1H-tetrazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 141060-60-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 141060-62-0 CAPLUS
CN 1(6H)-Pyridazinehexanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-63-1 CAPLUS
CN 1(6H)-Pyridazineheptanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 141060-64-2 CAPLUS
CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-65-3 CAPLUS
CN 1(6H)-Pyridazineonanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-66-4 CAPLUS
CN 1(6H)-Pyridazinedecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 141060-61-9 CAPLUS
CN 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 141072-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 143881-04-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2,3-dihydro-2-oxo-5-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 141060-62-0P 141060-63-1P 141060-64-2P
141060-65-3P 141060-66-4P 141060-67-5P
141060-68-6P 141060-69-7P 141060-70-0P
141060-71-1P 141060-72-2P 141060-73-3P
141060-74-4P 141060-75-5P 141060-76-6P
141060-77-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for adenosine antagonist for ulcer and pancreatitis treatment)


RN 141060-67-5 CAPLUS
CN 1(6H)-Pyridazinone, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)





RN 141060-68-6 CAPLUS
CN 1(6H)-Pyridazinetridentanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-69-7 CAPLUS
CN 1(6H)-Pyridazineacetone, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-70-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 141060-71-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[5-(1H-tetrazol-5-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 141060-72-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)




RN 141060-73-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[7-(1H-tetrazol-5-yl)heptyl]- (9CI) (CA INDEX NAME)




RN 141060-74-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[8-(1H-tetrazol-5-yl)octyl]- (9CI) (CA INDEX NAME)




RN 141060-75-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[9-(1H-tetrazol-5-yl)nonyl]- (9CI) (CA INDEX NAME)



RN 141060-76-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[10-(1H-tetrazol-5-yl)decyl]- (9CI) (CA INDEX NAME)




RN 141060-77-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[12-(1H-tetrazol-5-yl)dodecyl]- (9CI) (CA INDEX NAME)




IT 141060-83-5P 141060-84-6P 141060-85-7P
141060-86-8P 141060-87-9P 141060-88-OP
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for adenosine antagonist preparation for ulcer and pancreatitis treatment)


RN 141060-83-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(6-bromohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-84-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(7-bromoheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-85-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(8-bromooctyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-86-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(9-bromononyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-87-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(10-bromodecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-88-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(12-bromododecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-80-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 141060-81-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[4-(acetyloxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)]




RN 141060-82-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-hydroxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-83-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(6-bromohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 141060-84-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(7-bromoheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-85-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(8-bromooctyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-86-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(9-bromononyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 141060-87-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(10-bromodecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-88-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(12-bromododecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 141060-38-0P 141060-39-1P 141060-40-4P
141060-41-5P 141060-42-6P 141060-43-7P
141060-44-8P 141060-45-9P 141060-46-0P
141060-47-1P 141060-48-2P 141060-49-3P
141060-50-6P 141060-51-7P 141060-52-8P
141060-53-9P 141060-54-0P 141060-55-1P
141060-56-2P 141060-57-3P 141060-58-4P
141060-59-5P 141060-60-8P 141060-61-9P
141060-62-0P 141060-63-1P 141060-64-2P
141060-65-3P 141060-66-4P 141060-67-5P
141060-68-6P 141060-69-7P 141060-70-0P
141060-71-1P 141060-72-2P 141060-73-3P
141060-74-4P 141060-75-5P 141060-76-6P
141060-77-7P 141072-32-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine antagonist)

RN 141060-38-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(4-morpholinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-39-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-40-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(dimethylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-41-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[3-(dimethylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-42-6 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 141060-43-7 CAPLUS


CN 1(6H)-Pyridazinepropanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-44-8 CAPLUS
CN 1(6H)-Pyridazinebutanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-45-9 CAPLUS
CN 1(6H)-Pyridazinepentanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-46-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-oxo-5-oxazolidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-48-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)




RN 141060-49-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-50-6 CAPLUS
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 141060-51-7 CAPLUS
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 141060-52-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-[(2-hydroxy-3-(1-naphthalenyloxy)propylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 141060-53-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-[(2-hydroxy-3-(1-naphthalenyloxy)propylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




● HCl

RN 141060-54-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-[(2-hydroxy-3-(1-naphthalenyloxy)propylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




● HCl

RN 141060-55-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-[(2-hydroxy-3-(1-naphthalenyloxy)propylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




● 2 HCl


RN 141060-56-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-[(2-methoxyphenyl)-1-piperazinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 141060-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(2-(1H-tetrazol-5-yl)ethyl)- (9CI) (CA INDEX NAME)




RN 141060-58-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(2-(1H-tetrazol-5-yl)propyl)- (9CI) (CA INDEX NAME)




RN 141060-59-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[4-(1H-tetrazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 141060-60-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-61-9 CAPLUS
CN 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 141060-62-0 CAPLUS
CN 1(6H)-Pyridazinehexanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-63-1 CAPLUS
CN 1(6H)-Pyridazineheptanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-64-2 CAPLUS
CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-65-3 CAPLUS
CN 1(6H)-Pyridazinedecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-66-4 CAPLUS
CN 1(6H)-Pyridazinedecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-67-5 CAPLUS
CN 1(6H)-Pyridazineundecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-68-6 CAPLUS
CN 1(6H)-Pyridazinetridecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-69-7 CAPLUS
CN 1(6H)-Pyridazineacetoneitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-70-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 141060-71-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[5-(1H-tetrazol-5-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 141060-72-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)




RN 141060-73-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[7-(1H-tetrazol-5-yl)heptyl]- (9CI) (CA INDEX NAME)




RN 141060-74-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[8-(1H-tetrazol-5-yl)octyl]- (9CI) (CA INDEX NAME)




RN 141060-75-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[9-(1H-tetrazol-5-yl)nonyl]- (9CI) (CA INDEX NAME)




RN 141060-76-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[10-(1H-tetrazol-5-yl)decyl]- (9CI) (CA INDEX NAME)



RN 141060-77-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[12-(1H-tetrazol-5-yl)dodecyl]- (9CI) (CA INDEX NAME)



RN 141072-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 85 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN .
ACCESSION NUMBER: 1991-62080 CAPLUS
DOCUMENT NUMBER: 114:62080
TITLE: Preparation of 3-heterocyclyl- α -phenylpyrazolo[1,5-a]pyridines as adenosine antagonists
INVENTOR(S): Shiohara, Youichi; Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 86 pp.
CODEN: EPXDXW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 379979	A1	19900801	EP 1990-101042	19900119
EP 379979	B1	19970319		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL

ZA	9000200	A	19901031	ZA	1990-200	19900111
IL	93050	A	19950526	IL	990-93050	19900114
US	4985444	A	19910115	US	1990-466929	19900118
FI	96205	B	19960215	FI	1990-307	19900119
FI	96205	C	19960527			
AT	150462	T	19970415	AT	1990-101042	19900119
ES	2098229	T3	19970501	ES	1990-101042	19900119
CA	2008263	A1	19900723	CA	1990-2008263	19900122
CA	2008263	C	20000314			
NO	9000306	A	19900724	NO	1990-306	19900122
NO	176356	B	19941212			
NO	176356	C	19950322			
JP	02243689	A	19900927	JP	1990-12995	19900122
JP	07094454	B	19951011			
HU	53368	A2	19901028	HU	1990-228	19900122
RU	2007403	C1	19940215	RU	1990-4742944	19900122
KR	159502	B1	19981201	KR	1990-690	19900122
AU	9048696	A	19900726	AU	1990-48696	19900123
AU	628913	B2	19920924			
CN	1044656	A	19900815	CN	1990-100900	19900123
CN	1031570	B	19960417			
JP	08081465	A	19960326	JP	1995-64422	19950323

PRIORITY APPL. INFO.: CASREACT 114:62080; MARPAT 114:62080
OTHER SOURCE(S): GB 1989-1423 A 19890123
GI



II


AB The title compds. [I; R1 = aryl; R2 = (substituted) unsatd. heterocyclyl], were prepared. Thus, 3-acetyl-2-phenylpyrazolo[1,5-a]pyridine and glyoxylic acid hydrate were stirred 205 h at 100° to give a product which was refluxed with N2H4 in aqueous NH3 to give 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine. The latter was stirred 2 days with Br(CH2)3CO2Et and triton B in CHCl3 and the product was saponified to give title compound II. II had an ED50 of ~.31 mg/kg orally in rats for diuretic activity.

IT 131185-02-9P 131185-03-0P 131185-04-1P
131185-05-2P 131185-06-3P 131185-07-4P
131185-08-5P 131185-09-6P 131185-10-9P
131185-11-0P 131185-12-1P 131185-13-2P
131185-14-3P 131185-15-4P 131185-16-5P
131185-17-6P 131185-18-7P 131185-19-8P
131185-20-1P 131185-21-2P 131185-22-3P
131185-23-4P 131185-24-5P 131185-25-6P
131185-26-7P 131185-27-8P 131185-28-9P
131185-29-0P 131185-30-3P 131185-31-4P
131185-32-5P 131185-33-6P 131185-34-7P
131185-35-8P 131185-36-9P 131185-37-0P
131185-38-1P 131185-39-2P 131185-40-5P
131185-41-6P 131185-42-7P 131185-43-8P
131185-44-9P 131185-45-0P 131185-46-1P


131185-47-2P 131185-48-3P 131185-49-4P
 131185-50-7P 131185-51-8P 131185-52-9P
 131185-53-0P 131185-54-1P 131185-55-2P
 131185-56-3P 131185-57-4P 131185-58-5P
 131185-59-6P 131185-60-9P 131185-61-0P
 131185-62-1P 131185-63-2P 131185-64-3P
 131185-65-4P 131185-66-5P 131185-67-6P
 131185-68-7P 131185-69-8P 131185-70-1P
 131185-71-2P 131185-72-3P 131185-73-4P
 131185-74-5P 131185-75-6P 131185-76-7P
 131185-77-8P 131754-91-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of, as adenosine antagonists)


RN 131185-02-9 CAPLUS
 CN 1(4H)-Pyridazinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-03-0 CAPLUS
 CN 1(6H)-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-04-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 131185-05-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-07-4 CAPLUS
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-08-5 CAPLUS
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-09-6 CAPLUS
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




RN 131185-10-9 CAPLUS
CN 1(4H)-Pyridinecarboxylic acid, 3-chloro-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-11-0 CAPLUS
CN 1(4H)-Pyridinecarboxylic acid, 3-acetyl-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-12-1 CAPLUS
CN 1(4H)-Pyridinecarboxylic acid, 3-cyano-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-13-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methyl-4-pyridazinyl)-2-phenyl- (CA INDEX NAME) (9CI) (CA)




RN 131185-14-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(5-methyl-4-pyridazinyl)-2-phenyl- (CA INDEX NAME) (9CI) (CA)




RN 131185-15-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 131185-16-5 CAPLUS
CN 2(1H)-Pyridinone, 5,6-dihydro-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-17-6 CAPLUS
CN 2-Pyrimidinamine, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-18-7 CAPLUS
CN 2(1H)-Pyridinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


INDEX NAME)




RN 131185-19-8 CAPLUS
CN 3H-Pyrazolo[1,5-a]pyridine, 4,5-dihydro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 131185-20-1 CAPLUS
CN 3H-Pyrazolo[1,5-a]pyridine, 1,2-dihydro-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 131185-21-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methylimidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-
2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-22-3 CAPLUS
CN 3-Pyridinecarbonitrile, 1,2-dihydro-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-23-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-24-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(1-methyl-1H-pyrazol-4-yl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-25-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 131185-26-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methyl-5-pyrimidinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-27-8 CAPLUS
CN 2-Pyrimidinamine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-28-9 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-29-0 CAPLUS
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-30-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-31-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-33-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-ethoxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-34-7 CAPLUS
CN 1H-Pyrazole-1-propanoic acid, 5-hydroxy-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-35-8 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 5,6-dihydro-2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-36-9 CAPLUS
CN 1(4H)-Pyridazinepropanoic acid, 5,6-dihydro-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (9CI) (CA INDEX NAME)




RN 131185-38-1 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




• Na


RN 131185-39-2 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 131185-40-5 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (9CI) (CA INDEX NAME)




RN 131185-41-6 CAPLUS
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




• Na


RN 131185-42-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,2-dihydro-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 131185-43-8 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 5,6-dihydro-2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-44-9 CAPLUS
CN 1(4H)-Pyridazinepropanoic acid, 5,6-dihydro-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




RN 131185-45-0 CAPLUS
CN 1H-Pyrazole-1-propanoic acid, 5-hydroxy-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


● Na




RN 131185-46-1 CAPLUS
CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-47-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-chloro-4-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-48-3 CAPLUS
CN Ethanone, 1-(4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 131185-49-4 CAPLUS
CN 3-Pyridinecarbonitrile, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-50-7 CAPLUS
CN 1(6H)-Pyridazinepropanamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-51-8 CAPLUS
CN 1(6H)-Pyridazinepropanamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-52-9 CAPLUS
CN Piperidine, 1-(1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)propyl- (9CI) (CA INDEX NAME)




RN 131185-53-0 CAPLUS
CN 2(1H)-Pyrimidinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-54-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-55-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-chloro-4-pyridinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-56-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-chloro-4-pyrimidinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-57-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-chloro-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-58-5 CAPLUS
CN 3-Pyridazinamine, N,N-dimethyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-59-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methoxy-4-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-60-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methoxy-4-pyridinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-61-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methoxy-4-pyrimidinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-62-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 131185-63-2 CAPLUS
CN 3(2H)-Pyridazinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-64-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methyl-4-pyridazinyl)-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131185-65-4 CAPLUS
CN 3-Pyridazineethanol, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-α-(trichloromethyl)- (9CI) (CA INDEX NAME)




RN 131185-66-5 CAPLUS
CN 2-Propenoic acid, 3-(4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-

pyridazinyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 131185-67-6 CAPLUS
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-68-7 CAPLUS
CN 1(2H)-Pyrimidinepropanoic acid, 2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-69-8 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-70-1 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-carboxy-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, α-methyl ester (9CI) (CA INDEX NAME)




RN 131185-71-2 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-cyano-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-72-3 CAPLUS
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-73-4 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-74-5 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-carboxy-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-75-6 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-cyano-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-76-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,2-dihydro-1-methyl-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-77-8 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 131754-91-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




L5 ANSWER 86 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989-95084 CAPLUS
 DOCUMENT NUMBER: 110:95084
 TITLE: Preparation of new nitrogen-bridged heterocycles. 18. Facile formations of 3-arylpyrazolo[1,5-a]pyridines and 1-arylindolizines
 Kakehi, Akikazu; Ito, Suketaka; Kinoshita, Naosumi; Abaka, Yukio
 AUTHOR(S): Fac. Eng., Shinshu Univ., Nagano, 380, Japan
 Buletin of the Chemical Society of Japan (1988), 61(6), 2055-61
 CORPORATE SOURCE: CODEN: BCSJAG; ISSN: 0009-2673
 SOURCE: Journal
 DOCUMENT TYPE: English
 LANGUAGE: CASREACT 110:95084
 OTHER SOURCE(S): GI




AB The base treatment of [(benzylthio)methyleneamino]pyridinium I (X = N; R, R1 = H, Me; R2 = Ph, substituted Ph, R3 = SMe, Ph, OEt, NEt2) and [(benzylthio)vinyl]pyridinium bromides I (X = CR4; R, R1 = H, Me; R2 = Ph, substituted Ph, R3 = SMe, R4 = CO2Et, cyano, COPh), possessing an electron-withdrawing substituent such as a nitro or cyano group in the presence or absence of a dehydrogenating agent afforded 3-arylpyrazolo[1,5-a]pyridines II (X = N) and 1-arylindolizines II (X = CR4) resp. in moderate to good yields, while the reactions of the parent pyridinium salts and those having an electron-releasing group did not produce any significant products. The mode of the reaction, a ring contraction-desulfurization, is the same as that observed in related monocyclic species.
 IT 119093-32-2P 119093-39-9P 119093-44-6P
 119093-50-4P
 RL: SPN (Synthetic preparation); PREP (Preparation of)


RN 119093-32-2 CAPLUS
 CN Benzonitrile, 2-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 119093-39-9 CAPLUS
 CN Benzonitrile, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 119093-44-6 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(2-nitrophenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 119093-50-4 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(4-nitrophenyl)-2-phenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 87 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1973:71992 CAPLUS
 DOCUMENT NUMBER: 78:71992
 TITLE: Reactive intermediates. XXI. Thermal decarboxylation of 2,6-diazatricyclo[5.2.1.0.2,6]deca-4,8-diene-3,10-diones to pyrazolo[1,5-a]pyridines
 Rees, C. W.; Yelland, M.
 AUTHOR(S): Chem. Dep., Univ. Leicester, Leicester, UK
 CORPORATE SOURCE: Journal of the Chemical Society, Perkin Transactions
 SOURCE: 1: Organic and Bio-Organic Chemistry (1972-1999) (1973), (3), 221-5
 CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 78:7192
 GI For diagram(s), see printed CA issue.
 AB Oxidation of pyrazolin-5-ones (I; R = H, Ph, or CH₂Ph) in the presence of tetracyclone gave the corresponding adducts (II), which on heating lost CO₂ and rearranged to the pyrazolo[1,5-a]pyridines (III).
 IT 22889-10-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 22889-10-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, hexaphenyl- (8CI, 9CI) (CA INDEX NAME)



L5 ANSWER 88 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1969:422062 CAPLUS
 DOCUMENT NUMBER: 71:22062
 TITLE: A novel heterocyclic rearrangement. Extrusion of carbon dioxide from non-adjacent carbonyl groups
 AUTHOR(S): Rees, Charles W.; Yelland, M.
 CORPORATE SOURCE: Univ. Leicester, Leicester, UK
 SOURCE: Journal of the Chemical Society [Section] D: Chemical Communications (1969), (8), 377-8
 CODEN: CCJDAO; ISSN: 0577-6171

DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA issue.
 AB Oxidation of 4-substituted-3-phenyl-2-pyrazolin-5-ones with Pb(OAc)₄ in CH₂Cl₂ containing tetraphenylcyclopentadienone (I) gave good yields of the Diels-Alder adducts (II). Thermolyses of I at 210°/1 mm. 16 hrs. caused extrusion of CO₂ and formation of 30-45% III. The proposed mechanism for this unusual rearrangement involved N-C bond fission (1st part of stepwise retro-Diels-Alder) to give a zwitterion, formation of a lactone produced by attack of the pyrazolone O at the cyclopentenone carbonyl group, and subsequent loss of CO₂ with formation of III. The thermolyses also produced 35-40% I, the stable product of the normal retro-Diels-Alder reaction.
 IT 22889-10-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 22889-10-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, hexaphenyl- (8CI, 9CI) (CA INDEX NAME)



=>
 =>
 =>
 => d his
 (FILE 'HOME' ENTERED AT 11:12:37 ON 21 JUN 2007)
 FILE 'REGISTRY' ENTERED AT 11:12:46 ON 21 JUN 2007
 STRUCTURE UPLOADED
 L1 2214 S L1 FULL
 L2 0 S L2 FULL
 L3
 L4
 L5 FILE 'CAPLUS' ENTERED AT 11:14:28 ON 21 JUN 2007
 88 S L3 FULL
 => log y
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SINCE FILE ENTRY 511.23
 SINCE FILE ENTRY -68.64
 TOTAL SESSION 856.09
 TOTAL SESSION -68.64
 STN INTERNATIONAL LOGOFF AT 12:14:58 ON 21 JUN 2007